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A leverse transcription polymerase chain reaction (RT-PCR) digoxigenin enzyme linked
immunosorbent assay (DIG ELISA) specific for guinea pig IGF-I mRNA was developed to
quantify the expression of IGF-I. B-actin mRNA was also quantified by a similar procedure
as internal reference. Relative abundance of IGF-I mRNA is expressed as the ratio of IGF-I to
p-actin cDNA products of RT-PCR. Both IGF-I and B-actin mRNA DIG ELISAs were
validated by comparison with their analysis by conventional nonisotopic PCR measured by
densitometlic analysis of ds cDNA of predicted size resolved by agarose gel electlophoresis
and stained with ethidium bromide. The two methods compare favourably fol both IGF-I and
p-actin. IGF-I and B-actin mRNA were then routinely measured by PCR DIG-ELISA
because of its superior throughput, sensitivity and reproducibility. IGF-I and IGF-II proteins
in blood were measuled by radioimmunoassay after size exclusion HPLC of plasma atp}ì2.5.
IGFBPs in plasma were measured by western ligand blot analysis.
The lelative abundance of IGF-I mRNA in liver, was found to be increased by pregnancy in
ad.libitum fed guinea pigs. Plegnancy also increased plasma IGF-I concentrations in ad
libituru fed guinea pigs. Reducing feed intake by 30Vo before and throughout pregnancy
abolished this effect of pregnancy on both IGF-I mRNA in liver and IGF-I protein in plasma.
Plasma IGF-II was unaffected by pregnancy but was reduced by undernutrition in both
pr:egnant and nonpregnant animals. Plasma IGFBP-3 concentration ìwas unaffected by
pregnancy but was reduced by undernutrition regardless ofpregnancy status. Pregnancy
increased plasma IGFBP-1 levels in feed restricted but not in ad libitumfed animals.
Undelnutrition decreased plasma IGFBP-1 concentration in nonpregnant guinea pigs but
increased it in pregnant animals. Pregnancy increased plasma IGFBP-2 concentration in
nutritionally restricted animals only. Feed restriction increased concentrations of IGFBP-2 in
plasma fi'om plegnant animals only. Pregnancy increased plasma IGFBP-4 concentration in
both ad libitum fed and nutritionally restricted animals. Nutrition had no effect on plasma
IGFBP-4levels.
Plasma IGF-I (y) was positively correlated (r2 = 0.68, p<0.002)) to the relative abundance of
hepatic IGF-I mRNA (x), y = 105 + 65x - L4x2 when animals from all four treatments wele
combined. Because 68Vo of the variation in plasma IGF-I can be accounted for by vatiation in
the lelative abundance of IGF-I mRNA this strongly indicates that liver is the major source of
endocline IGF-I in guinea pigs. Overall therefore, approximately two-thirds of the IGF-I in
blood of guinea pigs appears to come from liver.
X
Pregnancy increased hepatic IGF-I mRNA abundance 6-fold but increased plasma IGF-I
concentration only 3-fold \n ad libitum fed guinea pigs. This suggests that pregnancy
increased both IGF-I synthesis and clearance of endocrine IGF-I. An alternate explanation
could be that translation of IGF-I mRNA is saturable resulting in accumulation of
untlanslated IGF-I mRNA in liver at high levels of IGF-I expression.
In pregnant animals the relative abundance of hepatic IGF-I mRNA was positively correlated
with maternal body weight (r2 = O'6I,p = 0.01), weight gain during pregnancy (r2= 0'69'
p<0.01) and uterine weight (r2 = 0.62,p = 0.01), consisting of uterus, fetuses and placentae.
Maternal hepatic IGF-I mRNA abundance was also positively correlated with fetal weight (r2
= 0.64,p<0.01) and placental weight (r2 = 0.55, p = 0.03). These positive associations
indicate that IGF-I originating from maternal liver has endocrine actions on the mother,
placenta and fetus.
Covariate analyses revealed that the number of fetuses per dam (rz = 0.4, p<0.02), total fetal
weight (r2 = 0.72,p<0.001) and total placental weight (r2 = 0.63, p<0.001) were dependent on
maternal plasma IGF-I concentrations but not any other measurements of the maternal IGF
axis. Covariate analyses that included interactions between measurements of IGF endocrine
components tevealed that the ratio of the concentrations of IGF-I to those of IGFBP-2 in
plasma of pregnant animals was a stronger positive determinant of uterine weight (r2 = O'52,
p<0.01), fetal weight (r2 - 0.52, p<0.01) and placental weight (r2 = 0.52, p<0.01) than for any
other measure of pregnancy phenotype. These associations suggest that IGFBP-2 may inhibit
the growth promoting endocrine actions of IGF-I on the mother and conceptus.
Co¡rpar-ison between the concentrations of individual components of the IGF system and the
ratio of the concentrations of IGFs/IGFBPs identified independent covariates of specific
tissue weights. In pregnant guinea pigs the ratio [IGF-I]/[IGFBP-2] was positively correlated
with weights of some maternal tissues as well as those of the fetuses and placentae. The same
ratio [IGF-I]/IIGFBP-21 was found to be a correlate of weight of the gastrointestinal tract but
this was negative. This suggests molecular complexes formed between IGF-I and IGFBP-2
has different biological roles at different tissue sites. The ratio [IGF-I]/[IGFBP-1] was also
correlated with weights of tissues in pregnant guinea pigs but these are different from those
found with [IGF-I]/IIGFBP-21. All of these ratios that correlate with weights of maternal
tissues, fetuses, placentae contain tIGF-Il and none contain [IGF-II]. This suggests
pregnancy shifts somatic growth of the mother and conceptus from IGF-II dependence to
IGF-I dependence. All of the associations between concentrations of the ratios of
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concentrations of IGF endocrine and tissue weights in pregnancy appear to be IGF-I
dependent. However, IGFBP-3 was identified as an independent covariate of selected tissues
in the pregnant guinea pig suggesting IGFBP-3 may also have some lGF-independent actions.
In the nonpregnant animals IGFBP-3 concentration is a correlate of the weights of different
tissues to that seen in pregnancy suggesting pregnancy factors may differentially regulate the
site of action, synthesis and/or turnover of IGFBP-3. In summary, pregnancy shifts the
dependence of somatic growth on the IGF endocrine axis from IGF-II to IGF-I dependence.
In the nonpregnant guinea pig all ratios between concentrations of IGFs and IGFBPs that
wele coÍrelated with tissue or organ weights contained [IGF-II]. The ratio UGF-III/UGFBP-
2l was found to be positively correlated with weights of almost all tissues studied. Therefore
in this species IGF-II is the major IGF endocrine determinant of somatic growth unlike the
situation in nonpregnant rats where IGF-I is the main endocrjne IGF correlate of somatic.
In conclusion, liver has been identified as the major source of endocrine IGF-I in pregnancy
in guinea pigs. Pregnancy increases hepatic abundance of IGF-I mRNA and circulating levels
of IGF-I protein. These effects are dependent on maternal nutrition. Associations between
maternal hepatic IGF-I mRNA abundance, plasma IGF-I concentration and pregnancy
phenotype indicate that maternal endocrine IGF-I of hepatic origin is important in regulating







This thesis contains no material which has been accepted for the award of any other degree or
diploma in any university or other tertiary institution and to the best of my knowledge and
belief, contains no material previously published or written by another person, except where
due reference has been made in text. I give my consent to this copy of my thesis, when






I would like to thank my supervisor Dr. Phil Owens for his guidance, encouragement and
belief in my ability to pursue these studies.
I would like to thank Professor Jeffrey Robinson for allowing me to perform these studies in
the Department of Obstetrics and Gynaecology
I would also like to thank the many staff and students in the Department of Obstetrics and
Gynaecology for their support, advice, and the help given. I especially would like to thank
Associate Professor Dave Kennaway for his tireless support throughout my studies, which
was much appreciated. I would very much like to thank Dr Karen Kind and Dr Claile Roberts
for.reading my thesis and their encouragement and endless motivational chats.
I would like to acknowledge all the people involved with the collection of biological samples
from the animals used in this study these include, Karen Kind, Claire Roberts and Annica
Sohlstrom.
Finally I would like to thank Kym, Peta and Kristine for their patience, encouragement and
support throughtout my studies.
XIV
LIST OF FIGURES
Figure 1.1 Structure of the human IGF-I gene and the
different IGF-I mRNAs


















Figure 2.3 Schematic of PCR ELISA procedure for
the quantitation of Dig labelled PCR products
Schematic representation of the partial guinea pig IGF-I
gene and rat B-actin gene.
Schematic diagram of digoxigenin labelling of amplified
PCR products
Agarose gel electrophoresis of total RNA
Agarose gel electrophoresis of RT-PCR products
Agarose gel electrophoresis of adipose fat RT-PCR products
Proposed organisation of the guinea pig IGF-I cDNA and
the partial nucleotide sequence of the amplified fragment





Figure 2.8 Sequence alignment of rat cytoplasmic, guinea pig liver and
heart B-actin
Figure 2.9 RT-PCR amplification profile of guinea pig liver IGF-I
quantitated by agarose gel electrophoresis, ethidium
bromide staining and transillumination with UV light
RT-PCR amplification profile of guinea pig liver B-actin
quantitated by agarose gel electrophoresis, ethidium
bromide staining and transillumination with UV light
Variability of RT-PCR amplification of guinea pig liver
IGF-I and the coefficient of variation associated with
replicates run on the same gel and measured by densitometry.
Effect of concentration of digoxigenin-dNTP and liver cDNA




Figure 2.L3 The efficiency of amplification of IGF-I and p-actin, measured
by PCR Dig-ELISA 2-4t
XV
Figule 3.1 Schematic representation of nutritional treatments of pregnant
and nonpregnant guinea pigs
Figure 3.2 Flow chart representing the processing of all liver samples from
RNA extraction to RTPCR and DIG ELISA for the quantitation
of IGF-I mRNA and B-actin mRNA.
Figure 3.3 Relationship between pregnant uterine weight and fetal and
placental weights.
Figure 3.4 Effect of pregnancy and nutrition on plasma IGF-I
in guinea pigs.
Figure 3.5 Effect of pregnancy and nutrition and on plasma IGF-II
in guinea pigs.
Figure 3.6 Effect of pregnancy and nutrition on plasma IGFBPs
in guinea pigs.
Figure 3.7 Agarose gel electrophoresis of total RNA from a representative
number of guinea pig livers.
Figure 3.8 RNA yield from guinea pig livers
Figure 3.9 Repeatability of Dig-ELISA RTPCR measurements of
guinea pig hepatic RNA
Figure 3.10 Relative abundance of hepatic IGF-I mRNA.
Figure 3.lL Correlation between plasma IGF-I concentration and relative
abundance of hepatic IGF-I mRNA.
Figure 3.L3 Correlations between uterine components and the ratio of the
concentrations of IGF-I and IGFBP-2 in plasma from pregnant
guinea pigs.
Figure 3.L4 Theoretical model showing the two possible relationships
between the ratio of the concentration of IGFs to IGFBPs
and tissue weights.
Figure 4.1 Proposed IGFBP-I and IGFBP-2 IGF dependent
and IGFBP-3 independent actions in pregnancy..
Figure 3.12 Effect of nutrition on the relationships between uterine weight,


















Insulin-like binding protein specific proteases
Table 1.2 Growth hormone and nutritional responsiveness
of the leader exons
Table 1.3 Growth, survival and birth weight characteristics of knockout
mice with single or multiple gene deletions of the IGF system
Table 1.4 Effect of pregnancy on maternal endocrine IGF-I system.
Table 2.L Criteria for design and use of primers
Table2.2 Oligonucleotides primers designed for amplification of
guinea pig cDNA by PCR
Table 2.3 Biotinylated oligonucleotides that bind streptavidin coated
ELISA plates for the immobilisation of Dig-labelled PCR
products
Table2.4 Specificity of capture oligonucleotide for respective
Dig-labelled PCR amplicon.
Table 3.1 Effect of pregnancy and nutrition on maternal phenotype.
Table 3.2 Effect of pregnancy and feed availability on maternal
tissue weights.
Table 3.3 Effect of pregnancy and feed availability on maternal
tissue weights.
Table 3.4 Effect of nutrition on fetal and placental weights at day
60 of pregnancy.
Table 3.5 Effects of pregnancy and feed availability on IGF
endocrine variables.
Table 3.6 Effects of pregnancy and feed availability on the ratio of the
concentration of IGFs to IGFBPs.
Table 3.7 Effects of pregnancy and feed availability on the relative
abundance of IGF-I mRNA.
Table 3.8 Associations between plasma IGF-I and abundance
of hepatic IGF-I mRNA.
1'able 3.9 Associations between the relative abundance of hepatic
IGF-I mRNA with body phenotype.
Associations between relative abundance of hepatic





















Table 3.1L Associations between the relative abundance of hepatic
IGF-I mRNA and weights of tissues. 3-46
Table 3.12 Associations between plasma IGF-I and adult body
phenotype. 3-41
Table 3.13 Associations between plasma IGF-I and adult tissue weights. 3-48
Table 3.14 Associations between plasma IGF-I and adult tissue weights. 3-49
Table 3.15 Relationship between plasma IGF-II and adult body phenotype. 3-51
Table 3.16 Relationship between plasma IGF-II and adult body composition. 3-52
Table 3.L7 Relationship between plasma IGF-II and adult tissue weights. 3-53
Table 3.18 Summary of endocrine IGF variables as independent covariates
identified as predictors ofbody phenotype in pregnant,
nonpregnant, ad libitum fed and feed restricted guinea pigs.
Table 3.19 Summary of endocrine IGF variables as independent covariates
identified as predictors of tissue weights in pregnant and
nonpregnant guinea pigs.
Table 3.20 Summary of endocrine IGF variables as independent covariates
identified as predictors of tissue weights in ad libitunt fed and
feed restricted guinea pigs.
Table 3.2L Summary of independent covariates identified as predictors of
body phenotype in pregnant and nonpregnant guinea pigs.
A combination of eight independent variables the ratio of IGF-I,
-II to IGFBP-I, -2, -3, -4 were included in the analysis.
Table3.22 Summary of independent covariates identified as predictors of
tissue weights in the pregnant and nonpregnant guinea pig.
Table 3.23 Summary of independent covariates identified as predictors of
body phenotype in ad libitum fed and underfed guinea pigs.
Table 3.24 Summary of independent covariates identified as predictors of
tissue weights in ad libitum fed and underfed guinea pigs.
Table 3.25 Associations between hepatic IGF-I mRNA, maternal endocrine
IGF axis and fetal and placental weights.
Table 3.26 Associations between the ratio of plasma IGFs to plasma IGFBPs
and maternal and fetal tissues.
Identification of independent covariates as predictors of
fetal and placental weights (dependent variables) and IGF-I













Table 3.28 Summary of predictors of fetal and placental tissue weights
(dependent variable) using the ratios of plasma IGFs to plasma
IGFBPs as independent variables.
Table 3.29 Identification of independent covariate as predictors of fetal
and placental weight in ad libitum fed and feed restricted
pregnant guinea pigs.
Table 4.1 Covariates of tissue weights in pregnant guinea pigs






























































insulin-like growth factor binding proteins 1-6













































reverse transcription polymerase chain reaction
sodium docedyl sulfate
standard error of the mean
thymine










PUBLICATIONS ARISING FROM THE RESEARCH IN THIS THESIS
Abstracts
Pat Grant, Claire Roberts, Julie Owens and Phil Owens. (2000) Pregnancy changes the
relationship between plasma concentrations of IGF-I and hepatic abundance of IGF-I mRNA.
ICE 2000 Satellite Symposium. " Endocrinology and Development" P6.
Grant P.4., Kind K.L., Roberts C.T., Owens J.A. and Owens P.C. (2001) Relationships
between hepatic expression of insulin-like growth factor-I (IGF-I) and the IGF endocrine
system are affected by nutrition and pregnancy. Proceedings of the Endocrine Society of
Australia. 44, Abstract 421 .
Grant P.4., Kind K.L., Roberts C.T., Owens J.A. and Owens P.C. (2002) Insulin-like growth
factor binding proteins in pregnancy directs actions of endocrine IGF-L Proceedings of the
Australian Society for Medical Research, South Australian Division, Abstract O18.
xxlt
OTHER PUBLICATIONS BY THE CANDIDATE
Roberts, C., Kind, KL., Earl, RA., Grant, PA., Robinson, JS., Sohlstrom, A., Owens, pC., and
Owens, JA. (2002). Circulating insulin-like growth factor (IGF) -I and IGF binding proteins -
1 and -3 and placental development in the guinea pig. Placenla in press.
Roberts, C. T., A. Sohlstrom, K.L. Kind, P. A. Grant, R. A. Earl, J. S. Robinson, T. y.
Khong, P. C. Owens, and J. A. Owens. Altered placental structure induced by maternal food
restriction in guinea pigs: a lole for circulating IGF-II and IGFBP-2 in the mother? Placenta
22:571-82,2001.
Gatfold, K. L., J. A. owens, R. G. Campbell, J. M. Boyce, P. A. Grant, M. J. De Blasio, and
P. C. Owens. Treatment of underfed pigs with GH throughout the second quarter of
pregnancy increases fetal growth. J Endocrinol 166 227-34,2000.
Sohlstrom, 4., A. Katsman, K. L. Kind, P. A. Grant, P. c. owens, J. s. Robinson, and J. A.
Owens. Effects of acute and chronic food restriction on the insulin-like growth factor axis in
the guinea pig.J Endocrinol I5l: I07-I4,1998.
Gajanandana, o., K. L'vine, P. A. Grant, G. L. Francis, s. E. Knowles, J. wrin, J. c. wallace,
and P. C. Owens. Measurement of an analog of insulin-like growth factor-I in blood plasma
using a novel enzyme-linked immunosorbent assay. J htdocrinol156:401-I4,1998
Gatford, K. L., K. J. Quinn, P. E.'Walton, P. A. Grant, B. J. Hosking, A. R. Egan, and P. C.
Owens. Ontogenic and nutritional changes in circulating insulin-like growth factor (IGF)-I,
IGF-II and IGF-binding proteins in growing ewe and ram lambs. J Endocrinol I55: 47-54,
1991.
xxlll
Ogawa, E., B. H. Breier, M. K. Bauer, B.'W. Gallaher, P. A. Grant, P. E. Walton, J. A.
Owens, and P. D. Gluckman. Pretreatment with bovine growth hormone is as effective as
treatment during metabolic stress to reduce catabolism in fasted lambs. Endocrinotogy 137:
1242-8, tgg6.
Gatfold, K. L., T. P. Fletcher,I. J. Clarke, P. C. Owens, K. J. Quinn, P. E. Walton, p. A.
Glant, B. J. Hosking, A. R. Egan, and E. N. Ponnampalam. Sexual dimorphism of circulating
somatotropin, insulin-like growth factor I and II, insulin-like growth factor binding proteins,
ancl insulin: relationships to growth rate and carcass characteristics in glowing lambs. J Anint
Sci74: l3l4-25,1996.
Maclennan, A. H., P. Grant, and G. Bryant-Greenwood. hRLX-1.In vitro response of human
and pig myometrium. J Reprod Med 40:103-6,1995.
Kind, K. L., J. A. Owens, J. S. Robinson, K. J. Quinn, P. A. Grant, P. E. V/alton, R. S.
Gilmoul, and P. C. Owens. Effect of restriction of placental growth on expression of IGFs in
fetal sheep: relationship to fetal growth, circulating IGFs and binding proteins. J Endocrinol
146:23-34,1995.
Carr', J. M., J. A. Owens, P. A. Grant, P. E.'Walton, P. C. Owens, and J. C. Wallace.
Cilculating insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs) and tissue
mRNA levels of IGFBP-2 and IGFBP-4 in the ovine fetus. -/ Endocrinol 145 545-51 , 1995
Calr, J. M., P. A. Grant, G. L. Francis, J. A. Owens, J. C. V/allace, and P. E. Walton. Isolation
and characterization of ovine IGFBP-4: protein purification and cDNA sequence. J Mot
Encl c¡crinol 13 : 2I9 -36, 1994.
XXIV
Bolthwick GM., Grant. P., and Maclennan AH. Relaxin Levels in the Human: an indicator of
target, storage and production sites. In'. Progress in Relaxin Research The Proceedings of the
Second International Congres s, 1994.
Maclennan, A. H., and P. Grant. Human relaxin. In vitro response of human and pig
myometlium. J Reprod Med 36: 630-4, 199I.
Maclennan, A. H., P. Grant, and A. C. Borthwick. Relaxin and relaxin c-peptide levels in
hunran reproductive tissues. Reprod Fertil Dev 3: 571-83,I99I.
Maclennan, A. H., P. Grant, D. Ness, and A. Down. Effect of porcine relaxin and
progesterone on rat, pig and human myometrial activity in vitro. J Reprod Med 3l: 43-9,
I 986.
Maclennan, A. H., R. C. Green, P. Grant, and R. Nicolson. Ripening of the human cervix and
induction of labor with intracervical purified porcine relaxin. Obstet Gynecol68: 598-601,
1986.
Maclennan, A. H., J. F. Kerin, C. Kirby, P. Grant, G. M. Warnes, L. W. Cox, G. Bryant-
Gleenwood, and F. Greenwood. The effect of porcine relaxin vaginally applied at human






Fetal growth and development and hence phenotype at birth are determined by interactions
between the fetal genome, the placenta, the intrauterine environment, maternal adaptation to
pregnancy, maternal factors including size, age and nutritional status before and during
pregnancy and the transfer by the placenta of oxygen and nutrients to the growing conceptus.
The potential growth trajectory of the fetus is determined by its genome, but other factors
interact with the fetal genome to produce the actual growth trajectory. For example, the size
of the fetus is heavily dependent on the delivery of glucose and oxygen to the fetus. Maternal
undernutrition and/or impaired placental function reduce the delivery to the fetus of essential
substrates resulting in intrauterine growth retardation (ruGR). ruGR is associated with
increased rates of mortality and morbidity for the fetus as well as the newborn infant. It has
also been shown that babies who are small at birth have increased risk of adult diseases such
as diabetes, hypertension and heart disease (Barker, 1994). This has been suggested to be a
result of permanent intrauterine programming. During embryonic and fetal life cells in
different organs and systems replicate and differentiate at different stages of development. It
is proposed that during these processes cells are most sensitive to permanent programming of
patterns of organ structure, physiology and metabolism (Barker,1994). These can predispose
the individual to impaired function in adult life resulting in an increased risk of diseases. This
is known as the fetal origins of adult diseases hypothesis, also known as the "Barker
hypothesis'.
The placenta is the organ that delivers essential substrates to the fetus and provides signalling
pathways between the mother and fetus. Weights of the human placenta and baby at birth
have been shown to be positively correlated with the concentrations of insulin-like growth
factor-I (IGF-I) in maternal plasma (Caufriez et al., 1994;Mclntyre et al., 2000). The placental
trophoblast is important in controlling maternal metabolism @vain Brion, 1994). The
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placental syncytiotrophoblast synthesises steroids, peptides, polypeptide hormones and
cytokines that are normally produced by, or under the control of, the hypothalamus and
pituitary in non-pregnant individuals (Petragliaet al., 1996). Mechanisms that regulate the
partitioning of nutrients between maternal tissues and the conceptus are poorly understood'
However, peptides such as placental lactogen and placental growth hormone variant, which
possess a high degree of amino acid sequence homology with pituitary growth hormone,
impart many of their effects through the insulin-like growth factor system (Talamantes, 1988)
The in vitro cellular actions and in vivo phannacological actions of IGFs include stimulation
of cellular proliferation and differentiation, increasing uptake of amino acids, glucose uptake,
inhibition of lipolysis and increasing synthesis of DNA, RNA and protein.
1.1 Physiological response to pregnancy
In many species pregnancy involves major anatomical, physiological and metabolic changes
essential for both maternal and conceptus survival. Maternal adaptation to pregnancy
involves increased adipose deposition early in pregnancy to ensure adequate energy reserve
for successful lactation as well as enlargement of breast tissue for milk production. The
maternal cardiovascular system expands and organs including the thyroid, kidney, liver,
pancreas and pituitary increase in size (Metcalfe, 1988). Increased energy requirements of
maternal tissues as well as those of the conceptus, result in the need for appropriate
partitioning of nutrients to ensure fetal survival. Mechanisms regulating maternal or fetal
supply of glucose, amino acids and/or free fatty acids appear to be controlled by the placenta.
Many of the physiological changes that occur in the mother are responses to placental
production of steroids, peptides, polypeptide hormones and cytokines (Petraglia et al.,
1996;Robertson et al., 1994).
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1.1.1 Regulation of substrate partitioning between the mother, placenta and fetus.
Endocrine alterations
The placenta synthesises many hormones including progesterone, estrogen, placental lactogen
(PL), placental growth hormone variant, human chorionic gonadotrophin, leptin,
adrenocorticotrophin (ACTH), thyrotrophin-releasing hormone, luteinizing hormone-
releasing hormone, corticotropin-releasing hormone (CRH) and somatostatin (Petraglia et al.,
1996;Stables, 1999;Yen, 1991). Some of these have direct actions on cells and others act
indirectly through mediators such as insulin, glucocorticoids and IGFs (Evain Brion,
1994;Owens, 1991).
Pregnancy in the human is characterised by elevated blood concentrations of insulin, insulin
resistance in peripheral tissues (Butte, 2000), high fasting glucose and amino acid levels in
blood. Progesterone and estrogen have been demonstrated to induce insulin secretion by
hypertrophy of the pancreatic islets of Langerhans in humans and animals (Cunningham,
lgg3). However, these hormones have different effects on maternal glucose status. Estradiol
treatment significantly lowers glucose levels, whereas progesterone decreases tissue
sensitivity to insulin and does not alter glucose levels (Yen, 1991).
Cortisol, PL and placental growth hormone antagonise the peripheral actions of insulin which
promotes lipolysis, thereby increasing free fatty acid availability and increases protein
breakdown in muscles consequently increasing amino-acid availability, thus providing
alternate substrates to glucose for fetal and maternal tissues (Yen, 1991). Corticoid
stimulation of lipolysis occurs only when insulin is insufficient to promote lipogenesis'
Although cortisol binding globulin (CBG) transcortin increases with pregnancy there is still a
Chapter 1-4
Placental hormones and growthfaclors in pregnancy
The placenta produces many hormones, steroids and cytokines that are either secreted by or
regulated by the maternal hypothalamus and pituitary in non-pregnancy. Growth hormone for
example, which is normally secreted by the pituitary into systemic blood in a pulsatile manner,
is replaced by other somatogenic hormones including placental growth hormone that is
secreted continuously into the maternal circulation in increasing amounts as pregnancy
progresses (Caufriez et al., 1990;Evain-Brion, 1999). In addition the placenta produces PL
and prolactin, both of which have a high degree of amino acid sequence similarity with
pituitary derived growth hormone (Handwerger and Freemark, 2000) and it is suggested that
these hormones, like GH, impart their actions directly and indirectly through the IGF system.
Human and rhesus monkey placental syncytiotrophoblasts synthesize placental growth
hormone, which has a high affinity for hepatic membrane GH receptors (Evain Brion, t994).
Maternal plasma levels of placental growth hormone correlate significantly with those of IGF-
I in human pregnancy. In mothers with growth restricted fetuses low blood levels of both
IGF-I and placental growth hormone are found at28 and 36 weeks of pregnancy (Mclntyre et
al., 2000). Maternal levels of free GH, total GH and IGF-I in blood are positively correlated
with birth weight (Mclntyre et al., 2000) and maternal glycemia. Pregnant mothers with
noninsulin-dependent diabetes mellitus (NIDDM) have elevated plasma levels of GH-binding
protein (GHBP) whereas in those with insulin-dependent diabetes mellitus (IDDM), GIIBP
was decreased at both 28 and36 weeks of gestation while free placental GH was increased at
36 weeks.
Maternal plasma concentrations of IGF-I are not related to plasma levels of PL (Caufriez et
a|.,I994;Evain-Brion,1999). However,Iwashita et al (1992) observed a positive correlation
between maternal plasma IGF-I and hPL levels. They also found that levels of PL in cord
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blood at birth positively correlated ',vith fetal blood levels of IGF-I and IGF-tr at 33 weeks of
gestation (Lassarre et al., 1991). These authors proposed that PL regulates fetal IGFs through
fetal PL receptors prior to the expression of GH receptors, which first occurs postnatally.
Identification of the major site of synthesis and the mechanism that increases plasma IGF-I in
pregnancy would allow greater understanding of the maternal adaptive mechanisms that
sustain fetal growth. This may identify therapeutics for the prevention and or treatment of
ruGR by manipulating the maternal IGF axis to alter maternal metabolism and partitioning of
nutrients thus ultimately promoting fetal growth.
1.2 Insulin-like growth factors
Identification of growth faclors
In the early 1950's in vitro actions of serum were identified as three separate biological
activities, sulfation factor activity (SFA) related to longitudinal bone growth (Salmon and
Daughaday, 1957), non-suppressible insulinlike activity (NSILA) which has the same
biological actions as insulin, but cannot be suppressed by insulin antibodies (Froesch et al.,
1966), and multiplication-stimulating activity (MSA) which is the component of serum that
promotes cell proliferation (Dulak and Temin,1973).
By the late 1940's and early 1950's it was known that GH from the pituitary gland promoted
the longitudinal growth of bones and that this was associated with synthesis of chondroitin
sulphate by chrondrocytes. In 1957 Salmon and Daughaday discovered that stimulation of the
uptake of sulfate into cartilage in vitro was only achieved in the presence of normal rat serum
and not with serum from hypophysectomized (pituitary deficient) rats. The addition of growth
hormone to media containing cartllage and hypophysectomized rat serum could not stimulate
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sulfate uptake. However, serum from hypophysectomized rats who had been treated with GH
restored this effect. They proposed that GH stimulated the secretion into blood of a factor that
promoted chondroitin-sulphate synthesis by chrondrocytes. This has been referred to as the
somatomedin hypothesis. The bone growth promoting mediators of GH (also known as
somatotropin) were collectively referred to as somatomedins (Daughaday, 1999).
In 1978 Rinderknecht and Humbel purified and chemically characterised NSILA from human
plasma, which consisted of two similar biologically active forms, which they named IGF-I and
IGF-tr because of their structural similarity to pro-insulin and their mitogenic effects on
cultured mammalian cells (Daughaday and Rotwein, 1989;Rotwein, 1991;Sara and Hall,
1990). Subsequent assessment of their biological activities revealed GH promoted production
of IGF-I. The somatomedins were then renamed IGFs. IGF-I was identical to somatomedin
C, while MSA isolated from conditioned medium of cultured rat liver cells was identified to
be rat IGF-tr (Dulak and Temin,1973).
The human IGF-I cDNA sequence appeared 5 years later (Jansen et al., 1983). Organisation
and structure of the IGF-I gene has been published for many species including human (de
Pagter Holthuizen et al., 1986;Rotwein et al., 1986), rat (Shimatsu and Rotwein, 1987), mouse
(Bell et al., 1986), chicken (Kajimoto and Rotwein, 1991) and guinea pig (Bell et al., 1990).
1.2.L Insulin-like growth factor-I
The insulin family includes insulin, relaxin, nerve growth factor, IGF-I and IGF-tr. Human
IGF-I is a basic 70 amino acid polypeptide with a molecular weight of I ,646 daltons and IGF-
tr is a slightly acidic 67 amino acid polypeptide having a molecular weight of 7 ,41I daltons.
IGF-I and IGF-tr are single chain polypeptides having 707o homology with each other and
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approximately 50Vo homology with proinsulin (Froesch and Zapf,L981;Rinderknecht and
Humbel, 1978). Both IGFs have A and B domains (named after the A and B chains of
insulin) joined by three disulphide bridges similar to proinsulin. However, IGFs and pro-
insulin have unique connecting C-peptides (Froesch andZapf ,1985). The IGFs have a short
D extension peptide at the carboxy-terminus of the A domain which is not present in either
pro-insulin or insulin (Sara and Hall, 1990).
I.2.l.l IGF-I gene
The human IGF-I gene is mapped to the long arm of chromosome 12 (12q22-q24.1). The
IGF-I gene extends over 50 kb (chicken) to 80 kb (rat) of chromosomal DNA. The structure
of the human and rat (Hoyt et al., 1992) IGF-I gene consists of 6 exons and 5 introns (Figure
1.1). Exons 1 and 2 contain 5' untranslated sequences and the NH2-terminus of the signal
peptide, exons 3 and 4 encode the remainder of the signal peptide and the mature IGF-I
polypeptide, while exons 5 and 6 encode for COOH-terminal regions of the alternative E
domains of the prohormone (Rotwein, I99I).
Multiple forms of IGF-I mRNA transcripts occur as a result of several mechanisms (Figure
1.1). These include usage of different promoters and transcription start sites leading to
distinct 5' untranslated regions and different NHz-terminal coding domains, alternate splicing
of exon 5 and 6 for the production of transcripts that encode peptides with distinct carboxyl-
termini, known as IGF-Ia and IGF-Ib prohormones, differences in the 3' untranslated region

































Figure L.1 Structure of the human IGF-I gene and the different IGF'I mRNAs
Boxes represent exons and the coding regions are black and the non-coding are white. Solid back lines represent
introns. Polyadenylation sites are indicated by arrows, the promoter regions by the letter P, and bent affows
indicate transcription initiation sites. Dashed lines indicate alternate splicing of exons 5 and 6 producing
alternate carboxy-terminal Ea and Eb domains and alternate splicing of exon I and2 producing different leader
peptides. IGF-I mRNAs transcribed from exon 1 and exon 2 are also known as class 1 and class 2 transcripts
respectively. (adapted from Rotwein 199I, 1999)
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gene also contains a cAMP responsive element. Initiation of IGF-I transcription by cyclic
AMP has been shown to involve protein kinase A (PKA) (Thomas et al., L996). Parathyroid
hormone, parathyroid hormone-related hormone and prostaglandin Ez induce IGF-I expression
by this pathway whereas l7p-estradiol suppresses c-AMP induced transcription of IGF-I.
Glucocorticoids, such as cortisol, decrease transcription of P1 but the exact responsive
elements have not been identified. Growth hormone binding to the growth hormone receptor
activates a cascade of transduction pathways, but the exact elements responsible for IGF-I
induction have not been unravelled. (Holthuizen,1999)'
Human cell lines SK-N-MC (human neuroepithelioma) and OVCAR-3 (human ovarian
carcinoma) expressing IGF-I mRNA have been shown to have different levels of activity at
promoters P1 and P2.InOVCAR cells P2 is four times more active than Pl. In SK-N-MC
cells Pl is three times more active than P2. Arecent study has identified two GATA
elements, GATA-A and GATA-B, in promoter Pl of exon 1 of cultured SK-N-MC, OVCAR-
3 and C6 cells (Wang and Adamo, 2000). Mutation of GATA-A resulted in stimulation of
promoter P1 activity in SK-N-MC cells while mutation of GATA-B inhibited this activity'
However, little or no effect \ryas apparent on promoter activity in the other cell lines tested.
This suggests that there is cell specific regulation of IGF-I gene promoter usage (Jansen et al',
tgg2). Examples above show that the synthesis of IGF-I mRNA is intricately managed by
each cell type through interactions with both tissue specific and ubiquitously expressed
transcription factors. These appear to act both independently and in combination.
Dietary protein restriction has been shown to affect the transcription of several genes by
alteration of the abundance and activity of a number of liver transcription factors (Marten et
a1.,1996). Some of these include hepatocyte nuclear factors (HNF)-l, -3 and -4 as well as the
CCAAT/enhancer-binding protein (CÆBP) family. The ubiquitous transcription factor Sp1
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increased DNA binding activity, whereas nuclear factor 1 (NFl) DNA binding activity was
unaltered by dietary protein deprivation (Marten et al., 1996). Smaller NFl-like proteins were
decreased by protein deprivation and their DNA binding activity reduced. IGF-I regulatory
binding sites for liver transcription factors have been identified in the promoter region of exon
1 and nutritional protein restriction alters the abundance and activity of liver transcription
factors HNF-I, CÆBP, Sp1 and NFl. This suggests this may be a mechanism through which
protein restriction regulates IGF-I gene transcription. IGF-I gene expression in cultured ovine
hepatocytes r,vas increased by the synergistic action of GH and the concentration of amino
acids in the cultured media (Wheelhouse et al., 1999). The expression of liver transcription
factor CCAAT/enhancer-binding protein Ê (CÆBPB) isoforms, liver-enriched activating
protein (LAP) and liver-enriched inhibitory protein (LIP) were differentially affected by
dietary protein restriction (Wheelhouse et al., 1999). Dietary protein restriction decreased the
ratio of LAP to LIP suggesting that more of the liver-enriched inhibitory protein binds the
CCAAT/enhancer sequence in the IGF-I promoter thus inhibiting IGF-I gene expression.
Insulin also has been shown to regulate IGF-I gene expression in cultured rat hepatocytes,
H4m, cells and CHO-IR cells by an insulin-responsive binding protein (IRBP) that interacts
with an AT-rich site in the V region (footprinted sequence) in the IGF-I gene (Kaytor et al.,
2001). The level of IRBP and interaction with the AT-rich site increases with concentrations
of insulin. Therefore IGF-I gene expression is increased by insulin through insulin-response
nuclear factors.
The nucleotide sequences of the multiple transcription initiation sites in the IGF-I gene are
highly conserved between mammalian species (Hall et al.,1992;Jansen et al., 1991;Kajimoto
and Rotwein, 1991;Ohlsen et aL.,1993). Transcription initiation sites commonly require a
GC-rich promoter that contains a TATA box. Mammalian IGF-I gene promoters do not
contain TATA elements and are not GC rich. These promoters within the genes are not
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constitutively active but are regulated by cellular differentiation and development (Smale and
Baltimore, 1989).
1.2.1.2 IGF-I polypeptide
IGF-I peptide contains a NHz-terminal B domain of 29 amino acids, a C domain of 12
residues an A domain of 2l amino acids and a COOH- terminal D domain of 8 residues.
There is77Vo amino acid sequence identity between mammalian and non-mafiìmalian species
The main variations are found in the C domain with minor variations in the D domain.
Amino acids in the A and B domain have been shown by mutagenesis to be important for
binding to the IGF type-I receptor and to IGF binding proteins (IGFBPs) 1 and 3 (Rotwein,
1991). There are 3 amino acid differences between the rat and human, a proline for aspartic
acid at position 820, an isoleucine for serine at position C35 and threonine for alanine at
position D67. The mouse IGF-I amino acid sequence, identified from a cDNA mouse liver
library (Bell et al., 1986), has one more substitution than the rat, an alanine for serine at
position D69. The cow, pig and guinea pig mature IGF-I polypeptides are identical to human
IGF-I (Bell et al., l990;Daughaday and Rotwein, 1989). Jansen et al (1983) discovered that
IGF-I is synthesised as precursor proteins with different C termini in the E domain. In
addition two IGF-I cDNAs (IGF-IEa and IGF-IEb) have been identified in the human
(Rotwein et al., 1986), (Conover et al., 1993), rat (Lowe et al., 19SS) and mouse (Bell et al',
1936) derived by alternate promoter usage from a single gene.
Alternate splicing of the IGF-I transcripts also produces precursor proteins with different
COOH-termini (E region). IGF-IEa in mammalian species has a common 16 amino acid
region in the E domain with only one substitution and a fairly highly conserved Ea domain.
However in non-mammalian vertebrates both Ea and Eb domains are more variable. The Eb
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region in IGF-IEb is longer and has a greater degree of amino acid substitution between
species than found in the Ea region of IGF-IEa (Rotwein, 1991) in both mammalian and non-
mammalian species. A major difference between IGF-IEa and IGF-IEb in the rat is due to the
insertion of 52 nucleotides in the cDNA encoding the E domain of the IGF-IEb prohormone,
yet the length of IGF-IEb protein only differs from that of IGF-IEa by 6 amino acids.
Alternate splicing of exon 4 (52 base insert) in the rat and mouse changes the amino acid
reading frame of IGF-IEb introducing a termination codon in exon 5, which thus accounts for
the small difference in length. Two alternate IGF-I mRNA forms are also produced in
humans, but by a different mechanism from that which occurs in rats. In the human IGF-IEa
and IGF-IEb mRNA are products of mutually exclusive splicing of either exon 4 or 5 to exon
3 (Foyt, 1991). In the human splicing of exon 3 to exon 4 encodes IGF-IEb precursor of 77
amino acids. Different mechanisms of altemate splicing between species produces diversity
in the E domain of IGF-I.
Another difference between IGF-IEa and IGF-IEb mRNAs is the length of the 3' untranslated
regions due to variable polyadenylation (Lund et al., 1939). Using rabbit reticulocyte lysate as
an in vitro cell free translation system the half life of the large IGF-I transcript (7.0 - 7.5 kb)
was shown to be much shorter than the smaller (0.9 - 1.2 kb) IGF-I mRNAs (Hepler et a1',
1990). Zhang et aI (1998) showed amino acid deprivation of cultured rat hepatocytes
produced rapid degradation of the 7.5 kb, 1.6 kb and 0.7 - 1.0 kb IGF-I mRNA transcripts.
This suggests that in tissues where the 7.0 - 7.5 kb species dominates IGF-I mRNA may be
highly unstable, resulting in a decline in translatable message to encode for the mature protein.
Two potential glycosylation sites have been identified in the E region of rat IGF-IEa
prohormone. Insertion of the 52bp exon 4 produces rat IGF-IEb with no glycosylation sites at
all. The rabbit reticulocyte in vitro translation system was used to demonstrate that either one
or both of the predicted glycosylation sites can be used to produce three glycosylation forms
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of rat IGF-IEa prohormone. Three forms were identified and incubation with N-glycanase F
converted these to a single form as seen by PAGE and autoradiography (Bach et al., 1990).
Different glycosylated forms of IGF-Ia may differ in stability, bioactivity, secondary structure
and intracellular protein transport. Both precursors appear to give rise to the same mature
secreted IGF-I protein, however differences in biological function have been postulated for
different forms of IGF-Ia and IGF-Ib.
L.2.2 Insulin-like growth factor-Il
1.2.2.1IGF-II gene
The human IGF-tr gene is mapped to chromosome 1lp15.5 and is 3'to the insulin gene and
less than 200 kb 5'to the H19 gene (Rotwein, 1999). These linked genes are mapped to
chromosomeT inthe mouse (Rotwein and Hall, 1990) and chromosome 1 in the rat (Rechler,
1991). The human IGF-tr gene contains 10 exons and 9 introns. The polypeptide coding
region extends over 3 exons (exon 8 to 10 in humans and exons 4 to 6 in rodents). Human
exon 8 (rat exon 4) codes for the 24 amino acid signal peptide and the mature IGF-tr peptide
and human exon 9 (rat exon 5) encodes the first 11 residues of the E domain. The remaining
E domain and the 3'untranslated region is encoded by human exon 10 (rat exon 6) (Rotwein,
1991;Rotwein, 1999). Multiple RNA transcripts are produced from the IGF-tr gene. This is
due in part to differential use of four promoters (Pl, P2,P3, P4) in human IGF-tr and three
(PL,P},P3) for rodent IGF-tr. In addition to these variable transcription initiation sites,
variable RNA polyadenylation occurs in exon 10 for human and exon 6 for rodents. These
mechanisms interact to produce numerous transcripts whose physiological significance has yet
to be determined. In humans IGF-tr is expressed in many fetal and adult tissues whereas rat
IGF-tr is abundantly expressed in embryonic and fetal tissues, with no significant expression
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in adults except for in the brain and spinal cord (Rechler, 1991). Expression from promoters
P3 and P4 has been shown in fetal and non-hepatic adult tissues. In human adult liver P2,P3
and P4 are inactive. Pl directs initiation of transcription of IGF-tr postnatally (van Dijk et al.,
1991). In rats, IGF-tr gene promoters Pl, P2 andP3 are silenced in liver after weaning'
1.2.2.2 IGF-II polypeptide
IGF-tr is a67 amino acid single chain polypeptide similar to IGF-I and pro-insulin in
structural organisation with an amino-terminal B domain of 28 amino acids, C domain of 12
amino acids, an A domai n of 2l amino acids, followed by a 6 residue carboxy-terminal D
region (NH2-B-C-A-D-COOH) @aughaday and Rotwein, 1989;Rechler, 1991;Rotwein,
ßgg). The amino acid sequences of IGF-tr from many mammalian and several non-
mammalian vertebrates have been determined. Variant forms of IGF-tr have also been
identified in the human and rat and have altered affinity for the type-I IGF-I receptor
compared with native IGF-tr. However the significance of these variants has yet to be
determined. Replacement of leucine for tyrosine 27 in the B domain reduces the affinity of
IGF-tr for the IGF type-I receptor. IGF-tr is synthesised as a precursor protein with 88 or 89
amino acid carboxy-terminal E domain, which unlike IGF-I is invariant. Some human
tumours secrete large forms of pro-and prepro- IGF-tr possessing the E domain which produce
hypoglycaemia (Rotwein, 1 99 1 ;Rotwein, 1999),
L.3 Insulin-like growth factor receptors
The mitogenic actions of both IGF-I and IGF-tr are mediated by the type I IGF receptor,
insulin receptors and hybrid type I IGF /Insulin receptors. Type I IGF receptor is similar in
structure and has a greater than 507o amino acid sequence homology with the insulin receptor
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Type I IGF receptor is encoded by a single gene spanning 100 kb of DNA. The type I IGF
receptor is a heterodimer consisting of apair of an alpha and beta subunits linked by
disulphide bonds. The alpha subunit is extracellular and contains a cysteine rich domain that
is responsible for the binding of IGF-I, IGF-tr and insulin. The beta subunit is comprised of a
hydrophobic transmembrane domain, a juxtamembrane domain, intracytoplasmic tyrosine
kinase enzyme domain with an ATP binding site, and a carboxy-terminal domain. Typically
type I IGF receptor binds to IGF-I with higher affinity than IGF-tr and binds insulin with 500
to 1000 times lower affinity (De Meyts, 1994).
There is a fourth receptor which essentially only binds IGF-tr and does not share any sequence
homology with the type I IGF or insulin receptor (Kiess, 1999). The type tr IGF receptor is a
single chain glycoprotein comprised of 2,264 amino acids of extracellular domain, 23 amino
acids of transmembrane domain and 164 amino acids of intracellular domain. It is also known
as the cation-independent mannose-6-phosphate receptor (CIM6PR). The extracellular
domain binds the ligands and the intracellular domain regulates movement within cellular
compartments. It has no established catalytic activity in response to IGF-tr binding. The
CIM6PR clears IGF-tr from cells and recycles lysosomal enzymes glycosylated with mannose-
6-phosphate. IGF-tr receptor knockout mice fail to clear circulating and tissue IGF-tr
resulting in the development of organ overgrowth due to mitogenic actions of IGF-tr on type I
IGF receptors (DErcole, 1999). Direct signalling of IGF-tr through the CIM6PR has been
observed (Nissley, 1999), however, the mechanism is unclear.
In many cell lines and tissues expressing the type I IGF and insulin receptors, hybrid receptors
may form. The hybrid receptors bind IGF-I with similar affinity to that of the type I IGF
receptor. The type I IGF /insulin hybrid receptor forms by the dimerization between type I
IGF receptor alpha,/beta subunit hetero-monomer and an insulin receptor alpha/beta subunit.
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Type I IGF/insulin hybrid receptors were purified from human placenta (Kasuya et al., 1993)
and their abundance is increased in placenta from hyperinsulinaemic women with gestational
hypertension, compared with placentas from normal pregnant women with gestational
hypertension (Valensise et al., 1996). In obese humans, plasma levels of IGF-I and insulin
correlate respectively with the abundance of type I IGF receptor and insulin receptor in
skeletal muscle, which then determines the abundance of hybrid receptors in this tissue
(Federici et al., 1998). Circulating levels of insulin and IGF-I and ratio of the abundance of
type I IGF receptor/insulin receptor has been proposed as a mechanism determining the
abundance ofhybrid receptors. It has been suggested that hybrid receptors provide an
alternate signalling pathway for IGF-I but the relative numbers and ratio may be important in
conveying unique biological functions.
1.3.1 Regulation of type-I IGF receptor abundance
IGF-I receptor abundance is developmentally regulated in most tissues. The abundance of the
type I IGF receptor in rat liver progressively decreases, while expression of hepatic IGF-I
mRNA and plasma IGF-I peptide increase with postnatal age. The type I IGF receptor appears
as early as the eight-cell stage prior to implantation in the mouse embryo. IGF-I and insulin
are not expressed until after implantation, however, IGF-tr protein has been detected as early
as the two-cell stage, suggesting IGF-tr action may be mediated by the type I IGF receptor
early in mouse embryonic development. Platelet-derived Growth Factor and basic Fibroblast
Growth Factor increase the abundance of type I IGF receptor in cultured human fibroblasts
(Werner, l99l). Treatment with estrogens or with follicle stimulating hormone increases the
level of type I IGF receptor mRNA in vivo in ovaries and in vitro in cultured granulosa cells
(Werner, 1991). Fasting increases the abundance of the type I IGF receptor by 1.6 to 2.5 fold
in a number of rat tissues including lung, testes, kidney, stomach and heart (Lowe et al.,
1e8e).
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1.3.2 Type I IGF receptor Intracellular signalling
Binding of IGF-I to the cysteine rich domain of the extracellular cr-subunit of the IGF type I
receptor initiates a sequence of signalling events commencing with autophosphorylation of the
receptor B-subunit. This permits the binding of other intracellular proteins, which are
subsequently tyrosine phosphorylated. IGF-I can initiate at least two cascades of intracellular
proteins one of which activates the MEK, MAP kinases that ultimately can initiate cellular
proliferation. Secondly, IGF-I activation of the type I IGF receptor has been shown to
stimulate the phosphatidylinositol 3-kinase (Pl3-kinase) which leads to the promotion of
glucose transport, carbohydrate metabolism and antiapoptosis (Kato et aL.,1993;Kulik et al.,
1997;Thomson et al., 7997)
1.4 Insulin-like growth factor binding proteins
1.4.1 ClassifTcation
The IGFs circulate bound with high affinity to carrier proteins known as insulin-like growth
factor binding proteins (IGFBPs), of which 6 have been identified. These are referred to as
IGFBP-1 to -6 (Figure I.2). This class of proteins has been recently enlarged to include
IGFBP-related proteins-1 to -5 (IGFBP-rp) and collectively are referred to as the IGFBP
superfamily (Hwa et a1., 1999). IGFBP-I to -6 share a structural similarity of a high number
of cysteines (16-20), which are clustered at the amino-terminus and the carboxy-terminus. It
has been proposed that these two terminal domains provide the tertiary site for high affinity
binding of IGF-I and IGF-tr. IGFBP-rp-1 to -5 and the IGFBPs, have identical amino-terminal
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domains and different carboxy-terminal domains that explains their low affinity binding for
IGFs (Hwa et al., 1999).
Figure 1.2 Circulating molecular complexes of IGFs to IGF-binding proteins
Adapted from (TVetterau et a1.,1999).
IGFBP-I IGFBP-2 IGFBP-3 IGFB4 IGFBP-s IGFBP-6
I IGF
Acid labile subunit
l.4.l.l Actions of insulin-like growth factor binding proteins
IGFBPs act to transport the IGFs to tissues, modulate their bioavailability and bioactivity,
control clearançe of IGF-I and IGF-II and regulate the amount of each IGF presented to their
receptors. IGF independent actions of IGFBPs have also been reported (Baxter,
2000;Wetterau et a1.,1999). IGFBPs are expressed by many cell types and occur in most
biological fluids. IGFBP-3 is the major binding protein in blood that circulates as a 150 kDa
complex consisting of either IGF-I or IGF-II with IGFBP-3 and an acid labile subunit (ALS)
This 150 kDa complex accountsfor -75%o of the IGF-I and II in blood in adult humans. The
remainder of the IGFs are complexed to the other binding proteins IGFBP-I, 2,4,5, and 6.
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The fraction of free IGF-I and IGF-tr reported varies considerably, ranging from undetectable
to I9%o for IGF-I and IVo for IGF-tr (Frystyk et al., 1994).
Human IGFBP-I has a molecular weight of 25.3 kDa and the cDNA encodes for a259 amino
acid precursor with a 25 amino acid prepeptide and a234 amino acid mature protein with an
arginine-glycine-aspartic acid (RGD) sequence near the end of the carboxy terminus. This
sequence binds to cell surface integrin receptors. IGFBP-I binds to the o5p1 integrin in
porcine aortic cells (Jones et al., 1995). On a nonreducing SDS-PAGE gel human IGFBP-1
migrates between 25 and 31 kDa (Ooi and Boisclair, 1999). IGFBP-1 has equal affinity for
IGF-I and tr and is posttranslationally phosphorylated, altering its charge and causing a
conformational change, which increases its affinity for IGF-L Phosphorylation of IGFBP-1
does not affect IGF-tr affinity. IGFBP-1 associated with integrin receptors indicates IGFBP-1
may deliver IGF-I to specific target cells. Phosphorylation also appears to protect IGFBP-1
from proteolysis. In pregnancy nonphosphorylated forms are susceptible to protease actions,
which lower IGFBP-1 affinity for IGF-I and thereby increase IGF bioavailability (Clemmons,
1991;Gibson et al., 2001;Westwood et al., 1997).
IGFBP-I is developmentally regulated in fetal rats. IGFBP-I mRNA has been identified in
the liver of fetal rats in mid gestation, while its expression appeared in nonhepatic tissues
(stomach, heart, lung and kidneys) at lower levels late in gestation. The human fetal liver also
expresses IGFBP-I (Ooi and Boisclair, 1999). In human adults the liver and decidua from late
pregnancy are major sites of IGFBP-1 synthesis. The protein is found in serum, lymph, CSF
and in very large amounts in amniotic fluid. IGFBP-I was initially purified from human
amniotic fluid and/or human decidua. Serum IGFBP-I levels are regulated by insulin and
corticosteroids. Feeding reduces plasma IGFBP-1 and fasting increases circulating levels.
IGFBP-1 is a glucoregulator (Baxter, 1995). Insulin suppresses serum IGFBP-1 through a
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PEPCK-like response sequence in the promoter region of IGFBP-1 gene (Otsrien, 2001).
IGF-I stimulated glucose uptake is inhibited by IGFBP-I in vivo. IGFBP-1 is elevated in a
number of catabolic disorders including malnutrition, poorly controlled diabetes, and
intrauterine growth retardation (Collett Solberg and Cohen,1996).
Rat IGFBP-2 was originally purified from BRL-34 cell conditioned media and is a32lÐa
protein with a RGD sequence at the C-terminal end similar to IGFBP-I. Binding to the
integrin receptor cr5pl has been demonstrated using Ewing sarcoma cells (Strain 4673) only
when IGFBP-2 is bound to IGF-I or IGF-tr (Rauschnabel et al., 1999). IGFBP-2 binds
heparin and heparin sulphate that are components of cell surface proteoglycans and the
extracellular matrix. Bovine IGFBP-2 was purified from the MDBK cell line and revealed
877o amino acid sequence homology with the rat IGFBP-2. The IGFBP-2 protein migrates at
34 kDa on a non-reducing SDS-PAGE gel. IGFBP-2 is not glycosylated or phosphorylated,
but fragments have been identified in serum of newborn fasted pigs and in follicular fluid
suggestive of protease activity. In the fetal rat IGFBP-2 is expressed in high levels during
early embryonic life and expression declines after birth. Circulating levels of IGFBP-2
increase with prolonged fasting, protein restriction, hypophysectomy (rat), GH deficiency
(human), diabetes and intravenous infusion of IGF-I (Clemmons, 1991;Thissen et al., 1994).
IGFBP-3 protein was originally purified from human plasma, and is 264 amino acids long.
The protein is N-glycosylated and circulates in serum in the glycosylated form with a
molecular weight of 40-45 kDa as determined by nonreducing SDS-PAGE. Biological
activity of IGFBP-3 is unaffected by the degree of glycosylation but susceptibility to
proteolysis may be altered. Phosphorylated IGFBP-3 is secreted from human skin fibroblasts
(Coverley and Baxter, 1995). Phosphorylation of IGFBP-3 by casein kinase 2 does not alter
the binding affinity for either IGF-I or tr but protects IGFBP-3 from degradation by plasmin
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and cysteine proteases. Phosphorylated IGFBP-3 has reduced affinity for the ALS complex
and cell surfaces (Coverley et al., 2000). IGFBP-3 contains a cell-surface recognition site
(heparin-binding domain) which allows IGF-independent binding to bovine endothelial cells
and other studies have proposed an IGFBP-3 receptor in breast cancer cells. Further evidence
suggests that type V receptor for transforming growth factor-B (TGF-P) may be an IGFBP-3
receptor in mink lung cells (Baxter, 2000;Booth et al., 2002). Serum levels of IGFBP-3 are
age dependent, increasing from birth, peaking at puberty and declining thereafter in the
human.
IGFBP-3 is expressed in mouse embryonic tissue at day 18 but is detected slightly earlier in
the rat embryo at day 14. In the adult rat the liver, kidney, uterus, placenta, ovary, stomach
and heart abundantly express IGFBP-3. Circulating levels of IGFBP-3 are increased by
growth hormone, IGF-I, adolescence, acromegaly and are reduced by undernutrition, diabetes,
dexamethasone and hypopituitarism (Clemmons, 1991). IGFBP-3 both inhibits and
potentiates IGF actions. IGFBP-3 inhibited IGF-I stimulated proliferation of immortalized
human chondrocytes (Matsumoto et al., 2000). IGFBP-I (10 Urg/l to 250 ¡rgll) inhibited IGF-I
(0.1 pg/l) and -tr (1 pg/l) but not insulin (5 pgll) stimulated glucose consumption in mouse
Balb/c3T3 fibroblasts. IGFBP-I at concentrations of 1 ¡rgll to 50 pgll inhibited IGF-I to a
greater extent than IGF-tr. In comparison IGFBP-3 at290 pgll inhibitedS0To and607o of
IGF-I and IGF-tr stimulated glucose consumption in mouse Balb/c3T3 fibroblasts respectively
although IGFBP-3 had a greater inhibitory effect on IGF-tr than IGF-I (Okajima et al., 1993).
Preincubation of BALB/c3T3 fibroblasts with IGFBP-3 followed by coincubation with IGF-I
and IGFBP-3 potentiated this inhibitory effect 5O-fold. However other studies have reported
IGFBP-3 stimulation of IGF-I mitogenic activity (Cortizo and Gagliardino, 1995). This
suggests that IGFBP-3 has multiple actions that are tissue and cell dependent.
Chapter I-24
The existence of proteases for IGFBPs (see also L4.L.2) was first identified when
discrepancies between the estimation of IGFBP-3 in pregnant serum by western ligand blots
and radioimmunoassays were reported (Davenport et al., I990;Gargosky et al., 1990b). Other
studies reported IGFBP-3 to be proteolytically modified in severe illness, malnutrition,
malignancy, diabetes, and in the maternal serum of complicated pregnancies. Many studies
have examined the effect of IGFBP-3 proteolysis in pregnancy showing that fragments have a
reduced affinity for iodo-IGF-I and iodo-IGF-tr which suggests greater availability of IGFs to
target tissues (Suikkari and Baxter, L992). IGFBP-3 has also been suggested to inhibit
IGFBP-4 proteolysis. Conditioned media of human dermal fibroblasts cultured with
increasing concentrations of IGF-I (5, 50 and 100 nglml) resulted in proteolysis of IGFBP-4.
The addition of excess IGFBP-3 was able to block IGF induced proteolysis of IGFBP4
(Donnelly and Holly, L996). The mechanism underlying the inhibition of IGFBP-4
proteolysis possibly involves the heparin binding motif sequences that are located within the
thyroglobulin type-l repeat motif found in IGFBP-3, IGFBP-5 and IGFBP-6. IGFBP-3, -5
and -6 were demonstrated to inhibit IGFBP-4 degradation of MC3T3-E1 murine osteoblasts
conditioned media. Synthetic C-terminal IGFBP peptides (IGFBP-3, IGFBP-5 and IGFBP-6)
containing the thyroglobulin type-1 motif inhibited IGFBP-4 proteolysis in a dose dependent
manner (Fowlkes et al., 1997). These studies suggest that the roles of IGFBPs are more
complex than regulation of action of IGFs.
IGFBP-4 is N-glycosylated and is more resistant to proteolysis than the non-glycosylated
form. Human IGFBP-4 has a molecular weight of 26kDa and migrates as two isoforms on
non-reducing SDS-PAGE at 28 kDa and24 kDa. IGFBP-4 is present in human serum and has
also been isolated from human bone cells, osteosarcoma cells, prostate cells, neuroblastoma
cells and porcine ovarian follicular fluid (Ooi and Boisclair,1999). IGFBP-4 is abundantly
expressed in adult rat liver and to a much lesser extent in tissues such as the brain cortex,
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hypothalamus, stomach, kidney, lung, heart, spleen, testis and adrenal gland. Embryonic
expression of IGFBP-4 occurs in many tissues at mid and late gestation in rats. Pregnancy
increases IGFBP-4 mRNA levels in liver at least 10 fold in rat. In vitro IGFBP-4 is
synthesised by osteoblasts and acts to inhibit osteoblast proliferation. Parathyroid hormone
treatment (3 hr) of osteoblast-like osteosarcoma cells (SaOS-2) increased the expression of
IGFBP-4 6RNA and decreased IGFBP-4 protease activity (Kudo et a1., 1997). Treatment of
prepubertal pig sertoli cells with thyroid hormone (T3) and retinoic acid increased their
expression of IGFBP-4 mRNA in a dose dependent manner (Bardi et al., 1999). Proteolysis
of IGFBP-4 is inhibited by binding of IGFs. IGF analogs that do not bind IGFBP-4 were
found not to prevent proteolysis (Conover, 1999;Qin et al., 1999)'
IGFBP-s is a252 amino acid protein with a molecular weight of 29 V,Ða.It is O-glycosylated
and appears in nonreducing SDS-PAGE as three molecular forms29,32 and43 kDa' The
protein contains a string of Arg- Arg residues that allow binding to glycosaminoglycaus and
extra cellular matrix resulting in a7 to12 fold decrease in binding affinity for IGF-I (Collett
Solberg and Cohen , 1996). Phosphorylation of IGFBP-5 facilitates the connection to
hydroxyapatite in bone matrix allowing preferentialy delivery of IGF-tr for bone growth.
IGFBP-S is present in human serum. Recently IGFBP-5 has been demonstrated to bind ALS
(Twigg et al., 2000) thus enabling formation of a ternary complex with IGF-I or tr. This may
be an alternative transport and storage system analogous to the 150 kDa complex containing
IGFBP-3 or it may deliver IGFs to specific tissues. IGFBP-5 is expressed as early as day 10.5
of gestation in the rat embryo. In the adult rat IGFBP-S mRNA is abundant in the kidney and
white adipose tissue but is also present in lower amounts in skeletal muscle, brain, stomach,
lung heart, adrenal, intestine, liver and spleen. Hypophysectomy reduces the abundance of
IGFBP-j 6RNA in skeletal muscle and white adipose tissue which can be partially restored
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with IGF-I and completely by treatment with GH (Ooi and Boisclair, L999). Thus GH
regulates IGFBP-S similarly to IGFBP-3
IGFBP-6 was first isolated from SV-40 transformed or nontransformed human lung
fibroblasts andIJ-2 human osteosarcoma cells (Ooi and Boisclair, 1999). Human IGFBP-6 is
O-glycosylated, has a molecular weight of 22.8 kDa and migrates on a nonreducing SDS-
PAGE gel at 28 to 34 kDa. IGFBP-6 is found in human serum, CSF, and porcine follicular
fluid. IGFBP-6 binds IGF-tr with much greater affinity than IGF-I and the glycosylated form
has a 5 fold higher affinity for IGF-I compared with the nonglycosylated form. Retinoic acid
increased the expression of IGFBP-6 mRNA in cultured osteoblasts and the IGFBP-6 protein
in the culture medium (Gabbitas et al., 1996). Abundance of IGFBP-6 mRNA in rat ovary is
increased after hypophysectomy. Treatment with FSH decreased ovarian IGFBP-6 mRNA at
least 2-fold (Rohan et al., 1993).
1.4.1.2 Proteases
IGFBP proteolytic activity was identified initially in serum of pregnant women (Gargosky et
a1.,I992;Hossenlopp et al., 1990) and in states of severe illness and other catabolic states.
Proteases have been identified that modify other IGFBPs (Table 1.1). Human pregnancy
serum proteases have the ability to degrade circulating IGFBPs. A serum protease of 70 to 90
kDa in size is present in pregnant and nonpregnant human serum and a larger 150 kDa
protease was only present in pregnant serum (Bang and Fielder, 1991). Protease inhibitors
aprotinin and a-2-antiplasmin inhibited proteolytic cleavage of radiolabelled IGFBP-3 when
incubated with pregnancy serum suggesting that one of the proteases is plasmin. EDTA and
zinc prevent the proteolytic degradation of radiolabelled IGFBP-3 indicating a cation
dependent protease (Bang and Fielder, 1997). This protease was subsequently identified to be
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a disintegrin metalloproteinase (Kubler et a1.,1993). Human stomelysin-3 has been shown to
degrade IGFBP-I into two fragments 16 kDa and 9 kÐa in vitro (Manes et a1., 1997). All
IGFBPs, except IGFBP-6, are proteolytically degraded by Cathepsin D (Claussen et aI.,1997).
Human placental trophoblasts have been demonstrated to secrete an IGFBP-3 protease similar
to that found in pregnant serum. Protease inhibitors EDTA, (4-(2-aminoethyl) benesulfonyl
fluoride (AEBSF), aprotinin and o-phenanthroline prevented proteolysis of IGFBP-3 in
pregnant serum and trophoblast conditioned medium. These inhibitors suggest the enzyme to
be a disintegrin metalloproteinase (Irwin et al., 2000). IGFBP-5 proteolytic activity was
identified in pregnant serum and amniotic fluid by the presence of fragments o122 kDa and 15
kDa. EDTA, phenanthroline and PMSF inhibited this activity which is suggestive of á cation
dependent serine protease, similar to proteases which degrade IGFBP-3 and IGFBP-2
(Claussen et al., 1994). Pregnancy-associated Plasma Protein-A2 has been identified as an
IGFBP-5 protease (Overgaard et al., 2001). Proteolysis of the binding proteins may result in
altered binding affinity for the IGFs, increased bioavailability of the IGFs and increased IGF-
independent activity of IGFBPs.
Many proteases for which IGFBPs are substrates have been identified and these include
plasmin, prostate-specific antigen, nerve growth factor, matrix metalloproteases, cathepsin D
(Conover, 1999) with many yet to be defined. Regulation of IGFs and IGFBPs by proteases
and the mechanisms involved remain to be elucidated, although specific tissue and cell
proteases have the potential to convey precise and specific regulation of the IGF axis.
An acid protease in rat serum has been identified that cleaves IGF-I forming the des-(l-3)
variant of IGF-I (Yamamoto and Murphy, 1994), which has very poor affinity for IGFBPs.
The growth hormone-dependent serine protease inhibitor Spi 2.1 has been suggested as a
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mechanism of regulating the acid protease responsible for generating des(1-3) IGF-I (Maake
et a1., 1997). In general proteases alter the bioavailablity of IGFs and may also generate
variant forms with altered bioactivity.
Table L.L Insulin-like binding protein specifÏc proteases
































(Bang and Fielder, 1997;Byun et al., 2001;Claussen et al., 1997;Claussen et aI., 1994;Collett Solberg and Cohen,
1996;Conover et a1., 1999;Irwin et al., 2000;Kubler et al., 1998;Lawrence et al., 1999;Manes et al.,
1997;Overgaard et al., 2001;Rajah et al., 1995)
1.5 Regulation of insulin-like growth factor'I abundance
1.5.1 Growth hormone
Growth hormone promotes the expression of IGF-I in adult rat liver. Hypophysectomized rats
have reduced abundance of hepatic IGF-I mRNA and reduced IGF-I in plasma. Growth
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hormone treatment of hypophysectomized rats restores the levels of IGF-I mRNA to near
normal (Roberts et al., 1986). Growth hormone also regulates the expression of IGF-I mRNA
in pig adipocytes as well as rat heart and skeletal muscle (Coleman et a1., L994;Isgaard et a1.,
1989). In rats abundance of hepatic IGF-I mRNA correlates positively with circulating levels
of IGF-I suggesting that the liver is the major source of endocrine IGF-I in this species. Rat
liver has higher abundance of IGF-Ib mRNA than heart, lung, muscle, testes, stomach, kidney
and brain. IGF-Ia mRNA abundance is similar in most tissues in adult rats. GH treatment
increases both IGF-Ia mRNA and IGF-Ib mRNA simultaneously in many tissues. In liver,
however, the increase in IGF-Ib mRNA in response to GH is much greater in rats (Lowe et al.,
1938). The use of antibodies specific to the E peptide region EIa qr-ro¡ of the IGF-Ia
prohormone revealed that human hepatoma cells secrete prohormone IGF-Ia in culture and
human growth hormone increased the secretion in a dose dependent manner (Conover et al.,
1993). Cell density has been reported to regulate the expression of IGF-I (Wang and Adamo,
2000). Adipose tissue has been suggested to be a major source of circulating IGF-I in both
humans (Moller et aL.,1991) and pigs (Coleman et al., 1994). Growth hormone regulation of
IGF-I mRNA in hepatic and non-hepatic tissues suggests it controls endocrine, paracrine and
autocrine actions of IGF-I.
The mechanism by which GH increases IGF-I expression has not been elucidated. However,
potential GH responsive sites in the IGF-I gene promoter may be involved. GH binds to the
GH receptor activating the expression of STAT-5, which is involved in insulin gene
transcription. Growth hormone treatment of human hepatoma-derived Hep3B cells
transfected with salmon IGF-I (sIGF-I) promoter-luciferase constructs simultaneously
overexpressed both STAT5 and HNF-1ø resulting in a 35 fold increase in sIGF-I promoter
activity while STAT5 and HNF-1o alone showed no effect (Meton, 1999). This observation
indicates that more than one transcription factor may be required to initiate IGF-I promoter
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activity. Growth hormone treatment increased liver IGF-I mRNA expression in
hypophysectomized wild type mice but this effect was not observed in STAT5b knockout
mice @avey et al., 2001). This indicates that STAT5b plays a significant role in GH induced
IGF-I gene expression in the liver. A GH dependent DNAse I hypersensitive site, HS7, in the
rat IGF-I gene has been identified. The DNAse sensitivity of the HS7 site disappeared after
hypophysectomy of rats and was restored 30 mins after GH injections (Bichell et al.,
1992;Rotwein et al.,1993). The mechanism by which GH alters chromatin structure in the
IGF locus has yet to be defined.
1.5.2 Nutrition
Dietary energy restriction in adults and children reduces the concentration of IGF-I in blood
while those of IGFBP-I are increased in adults but not in children. Energy restriction did not
alter IGFBP-2 in either group and blood levels of IGFBP-3 fell significantly in children but
not in adults (Smith et al., 1995). Dietary protein restriction reduces circulating levels of IGF-
I in both adults and children but increases those of IGFBP-2.
Fasting for 48 hr has been shown to reduce plasma IGF-I (Adamo et a1., I99Ia) and the
expression of IGF-IEb, but not IGF-IEa transcripts, in rat liver (Zhang et al., 1997). Fasting
resulted in the reduced abundance of 0.9 -l.2kb and 1.5 -1.9 kb, but not theT .5 kb, IGF-I
mRNA species in rat liver. Invitro translation of liver mRNAs followed by
immunoprecipitation with antibodies directed against pro-IGF-IEa, pro-IGF-IEb and the
mature IGF-I peptide, indicated that fasting decreased both peptides and refeeding restored
them to normal. The above results suggest fasting differentially regulates IGF-IEb and IGF-
IEa mRNA from leader exon 1. A decline in translatable IGF-I mRNAs may account for the
observed decrease in peptides, or alternatively efficiency of IGF-I mRNA translation was
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lower. Reduced hepatic expression of IGF-I mRNA observed in fasted rats was not due to
decreased IGF-I gene transcription, but rather a delay in pre-mRNA splicing, leading to an
accumulation of IGF-I pre-mRNA in the cytoplasm (Zhanget al., 1998). The abundance of
O.g - L2kb, 1.5 -1.9 kb and7.5 kb IGF-I mRNA species were all lower in rat hepatocytes
cultured in amino acid deplete (5-fold) medium. The 7.5 kb IGF-I mRNA species degraded
faster than the two smaller 0.9-I.2 kb and 1.5 -1.9 kb forms, suggesting protein restriction
increases the rate of degradation of all the IGF-I mRNA species.
Nutrition and growth hormone have been shown to regulate the hepatic expression of leader
exon class 1 and class 2 transcripts in sheep. Higher dietary protein and ad libitum feeding of
lambs increased hepatic class 1 and class 2 transcripts although class 2 transcripts were 5-fold
more abundant than class 1 in the liver. However growth hormone was shown to increase
class 2 transcripts by more than I007o (Pell et al., 1993). Circulating concentrations of IGF-I
were positively related to the ratio of class 2 to class 1 transcripts. Pell et al (1993) suggested
that the ratio of the class 2 to class 1 transcripts somehow determines plasma IGF-I
concentrations.
Growth hormone treatment of pigs increases hepatic abundance of leader exon class 1
transcripts 4-fold and class 2 transcripts 8-fold (Brameld et al., 1996;Dunaiski et a1.,1999).
Dietary protein composition had no effect on abundance of class 1 or class 2 transcripts in the
porcine liver. However increased dietary protein levels or growth hormone treatment
increased the expression of class I transcripts in semitendinous muscle, subcutaneous fat,
perirenal fat and omental fat but not in longissimus dorsi muscle in this species (Brameld et
a1.,1996). In general in pigs regulation of liver IGF-I mRNA transcripts appears to be growth
hormone dependent while nonhepatic IGF-I mRNA transcripts are regulated by nutrition and
GH in a tissue specific manner.
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Table 1,.2 Growth hormone and nutritional responsiveness of the leader exons
Species Leader Exon Growth Increased nutrition


















(Brameld et al., 1996;Dunshea et al.,1999;Ohlsen et al., L993;Pell and Gilmour, 1993;Weller
et a1.,I993;Zhang et al., 1997)
1.5.3 Insulin
Young rats treated with streptozotocin to induce insulin deficiency grow poorly and have low
levels of hepatic IGF-I mRNA and serum concentrations of IGF-I and GH (Fagin et al.,
1989;Menon et al., 1994;Yanget al., 1990). Insulin deficiency in human subjects increases
circulating levels of IGFBP-1, IGFBP-2 and increases proteolysis of IGFBP-3 (Bereket et al.,
lggg). Insulin administration to streptozotocin treated rats restores hepatic IGF-I mRNA and
serum IGF-I concentrations to those of untreated normal rats (Yang et al., 1990;Zapf ,1998)'
Northern blot and ribonuclease protection assay showed that the expression of growth
hormone receptor/growth hormone binding protein mRNA was reduced in liver and heart and
increased in the kidney of insulin deficient rats. Insulin deficiency induces a GH resistance
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state that is tissue specific (Menon et al., L994). Growth hormone plasma levels are also
elevated in insulin deficiency possibly due to a diminished negative feedback by IGF-I that
normally inhibits GH expression (Bereket et al., 1999). Insulin treatment partially restored
hepatic IGF-I mRNA and IGFBPs mRNA in food restricted hypoinsulinemic rats. However,
insulin and re-feeding returned hepatic IGF-I mRNA and plasma IGFBPs concentrations back
to that of control rats (Goya et al., 1999). The effect of insulin deficiency on IGF-I
abundance may be altered by pregnancy. Insulin deficiency in pregnant pigs increased the
abundance of IGF-I mRNA in fetal skeletal muscle, liver, heart, kidney and placenta and
reduced it in fetal adipose and brain tissue (Ramsay et al., 1994)'
1.5.4 Other Hormones
Estrogen and progesterone increase the abundance of IGF-I mRNA in female reproductive
tissues. Gonadotrophins also increase expression of IGF-I mRNA in the ovary and testes.
Thyroid hormone (T3) in conjunction with GH stimulates the expression of IGF-I in cultured
GH¡ rat pituitary cells and primary cultures of rat hepatocytes. Thyroidectomy of neonatal,
weaning and adult rats decreases body weight. In the neonatal rat plasma insulin, plasma
GH, pituitary GH, plasma IGF-I and hepatic IGF-I mRNA are increased by thyroidectomy.
However, in weaning rats and adult rats removal of the thyroid decreased plasma GH,
pituitary GH, plasma IGF-I and hepatic IGF-I mRNA (Ramos et a1., 1998). This indicates
developmental regulation of IGF-I response to thyroid hormones in the rat.
Parathyroid hormone (PTH) is a trophic factor for bone and has been shown to increase the
abundance of IGF-I mRNA in cultured preosteoblast cells. PTH also decreased the
abundance of IGFBP-3 mRNA, with no significant effect on IGF-I mRNA.
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Infusion of cortisol into adrenalectomized fetal sheep late in gestation increased hepatic
abundance of IGF-I mRNA and GH receptor mRNA. Positive relationships were found
between plasma concentrations of cortisol, total hepatic IGF-I mRNA and the abundance of
leader exon class 1 and class 2IGF-I transcripts (Li et a1.,1996). Dexamethasone, a synthetic
glucocorticoid, decreases GH receptor mRNA in cultured rat chondrocytes thereby inhibiting
GH stimulation of IGF-I in a dose and time dependent manner (Jux et al', 1998).
Preincubation of osteoblasts with dexamethasone increased the ability of low concentrations
of prostaglandins (PGE2) to actively stimulate the IGF-I promoter, however high or sustained
levels of PGEz inhibit IGF-I expression (McCarthy et a1., 2000).
1.5.5 DevelopmentalRegulation
Synthesis of IGF-I and IGF-tr are developmentally regulated. IGF-I mRNA transcripts have
been identified in the preimplantation mouse embryo and uterus (Doherty et al.,
L994;Henemyre and Markoff, 1993). In the rat embryo expression of IGF-I mRNA increases
9-fold between days 11 to 13 of gestation (Adamo et al., 1989;Bondy et al., 1990). In humans
circulating IGF-I levels are low in fetal life, increase progressively with age from birth, peak
during puberty and slowly decline with increasing age. In rats liver IGF-I mRNA abundance
increases 10 to 100-fold from birth to adulthood and correlates with plasma IGF-I suggesting
that the liver is the major endocrine source of IGF-I peptide (Hoyt et al., 1988).
The Cre/loxP system has been used to abolish IGF-I gene expression in the murine liver. This
resulted in a757o reduction in plasma IGF-I and IGFBP-3 confirming the liver as a major
source of endocrine IGF-I in the nonpregnant mice (I-e Roith et al., 2001;Yakar et a1., 1999).
However these liver-specific IGF-I knockout mice grow normally suggesting liver derived
IGF-I is not essential for postnatal growth in mice.
Chapter 1-35
Developmentally the leader exon class 1 transcripts increase from birth in the rat, whereas
class 2 transcripts do not appear until 20-30 days postnatally, consistent with the appearance
of GH receptors in liver of this species (Adamo et al., 1989;Hoyt et al., 1988). However in
the sheep expression of hepatic class 1 and class 2 IGF-I mRNA transcripts increased from
100 to 145 days gestation in the fetus (Li et a1.,1996). Leader exon class land class 2
transcripts are also present in ovine fetal and adult brain, heart, kidney, liver, lung, skeletal
muscle and spleen (Ohlsen et al., 1993). Adrenalectomy of fetal sheep at - day 117 (term is -
145 d) decreased hepatic expression of IGF-I class 1 and class 2 transcnpts (Li et al., 1996).
Leader exon class 1 IGF-IEa transcripts increase in abundance in rat liver from birth to 30
days of age. In rats the stomach, brain, lung, kidney, ovary and testes of fetal and adult origin
(Hoyt et al., 1988;Murphy et al., 1987) also express IGF-IEa class 1 transcripts. However
adult rat liver expresses class land class 2 transcripts encoding the IGF-IEa E domain and
class 1 and class 2 transcripts encoding the IGF-IEb E domain. Non hepatic synthesis of IGF-
I mRNA would suggest autocrine and paracrine action pre and postnatally.
In human fetal tissues of 10 to 16 weeks gestation IGFBP-1 mRNA was found to be expressed
in the liver,IGFBP-2 mRNA was moderately expressed in every tissue examined with the
highest levels in the liver, IGFBP-3 was abundantly expressed in the skin, muscle and heart
while IGFBP-4 was equally expressed in all tissues. In fetal pigs the abundance of IGFBP-2
mRNA in the liver and concentrations of plasma IGFBP-2 increase with gestation but decline
postnatally. Plasma levels of IGF-I and IGFBP-3 are low in the fetal pig but increase
postnatally (Lee et al.,I99l;Lne et al., 1993). The abundance of IGF-I mRNA and IGFBP-3
mRNA in skeletal muscle, lung and kidney was similar to that in liver of fetal pigs. Their
expression postnatally did not increase in contrast to that seen in rats. Differences in the type
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and abundance of IGF-I transcripts in both fetal and adult tissues indicate complex regulation
of IGF-I synthesis
Plasma levels of IGF-tr in rats are 20-100 fold lower at day 2l of age than those at birth
(Brown et al., 1986) and IGF-tr mRNA is much more abundant in fetalrat tissue compared to
adult tissue. Many fetal tissues including intestine, muscle, skin and heart express IGF-tr up
to 11 days after birth whereas liver IGF-tr mRNA persists to day 22 in rats. Expression of
IGF-tr completely disappears from the lungs, thymus and kidney 2 days after birth (Brown et
al., 1986;Lund et al., 1936). The cerebral cortex and hypothalamus (Hynes et al',1988) are
the only adult tissues to consistently express IGF-tr mRNA in adult rats suggesting a role for
IGF-tr in the central nervous system. Concentrations of IGF-tr in serum and plasma of adult
rats are negligible. In guinea pigs serum IGF-tr concentrations in adults are higher than those
of IGF-I as is the case in human, pig, sheep and cow. Abundance of IGF-tr mRNA is 30 times
greater in fetal guinea pig liver, 18 times greater in skeletal muscle and 5 times gteater in the
kidney compared with adult guinea pig liver. Adult guinea pig tissues persistently express
IGF-tr pRNA, although it is 5 times more abundant in skeletal muscle than liver (Levinovitz
et a1.,1992).
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1.6 Biological activity of Insulin-like growth factors
1.6.1 In-vitro
CeII proliferation
IGFs are mitogenic for a wide number of cell types in culture including fibroblasts,
chondrocytes, osteoblasts, keratinocytes, thyroid follicular cells, mammary epithelial cells,
erythroid progenitor cells, thymic epithelium, oocytes, granulosa cells, spermatogonia, sertoli
cells and a number of cancer cell lines. These actions arc generally mediated by type I IGF
receptors (Jones and Clemmons, 1995).
CeIl dffirentiation
IGFs also promote differentiation of many cell types. Treatment of cultured myoblasts with
IGF-I increases myogenin mRNA abundance and has been associated with differentiation to
myotubes (Florini et al., 1996). Myoblast differentiation was inhibited by a
phosphatidylinositol (PI) 3-kinase inhibitor LY294002 (Tureckova et al., 2001). IGF-I
activation of the type I IGF receptor can stimulate proliferation and differentiation by
activating distinct signalling pathways in myoblasts. LY294002 inhibited Pl¡-kinase/p70s6k
abolishing myotube formation. Inhibition of MEK in the MAP-kinase pathway by PD098059
inhibitor stimulated differentiation of cultured L6A1 myoblasts (Coolican et a1., 1997)' IGF
stimulation of myogenic differentiation requires the activation of the phosphatidylinositol 3-
kinase/p70s6k pathway (Coolican et al., I99l). IGF-I promotes differentiation of secondary
spermatogonia into primary spermatocytes (Yamamoto et al., 2001). Primary cultures of
preadipocytes and cultured 3T3-L1 preadipocytes when treated with IGF-I undergo
differentiation when cells reach confluency (Boney et al., 1998).
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Apoptosis
IGFs stimulate both proliferation and differentiation and also protect cells from apoptosis
(Butt et al., 1999). Overexpression of IGF-I in the cental nervous system of transgenic mice
reduces the number of apoptotic cells in7,14 and21r day old mice. This was associated with
an increase in anti-apoptotic Bcl genes, Bcl-x(L) and Bcl-2 and a concomitant decrease in pro-
apoptotic Bcl genes, Bax and Bad by 2I days postnatally (Chrysis et al', 2001). IGF-I
increases the number of human embryos forming blastocysts and decreases the number of
apoptotic nuclèi measured by DNA fragmentation (TUNEL) and nuclear fragmentation
(Spanos et al., 2000). However high levels of IGF-I and insulin stimulate apoptosis in the
mouse blastocyst inner cell mass. It has been suggested that high levels of IGF-I decrease the
abundance of the type I IGF receptor preventing activation of the anti-apoptotic signalling
cascade.
IGFBP-3 also plays a role in regulating apoptosis by sequestering IGFs away from the type 1
receptor and /or by independent action with cell surface receptors for IGFBP-3. Cultured
Hs578T breast carcinoma cells proteolytically fragment IGFBP-3 and increase ceramide
induced apoptosis. However this effect was inhibited by IGF-I which prevented proteolytic
degradation and cell surface association. Hs578T breast carcinoma cells are unusual in that
they lack the type I IGF receptor and do not secrete detectable amounts of IGF-I or IGF-tr.
IGFBP-3 appears to be proteolysed on the surface of these cells and this mechanism then
predisposes the Hs578T cells to enhanced ceramide apoptosis (Maile et al., 1999). A critical
balance between interaction of IGF-I and IGFBP-3 and subsequent activation of anti-apoptotic
and pro-apoptotic transduction pathway genes appears to be the mechanism controlling
apoptosis. Actions of IGF-I promoting cellular proliferation and IGFBP-3's ability to inhibit
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or sequester IGF-I can contribute to the survival of mutated cells and progression to tumours
(Holly et al., 1999).
Cell metabolism
Some of the biological actions of IGF-I and IGF-tr are similar to those of insulin. In rat
adipocytes the IGFs and insulin increase glucose uptake, glucose oxidation and lipid synthesis
and inhibit lypolysis and glycogen synthesis. Neutralization of the insulin receptor by anti-
insulin receptor antibodies demonstrated that the IGFs actions were mediated by the insulin
receptor in the rat adipocyte (Zapf,1999). IGF-I and IGF-tr are 50 to 100 times less potent
than insulin in this action. However, in isolated soleus muscle cells competitive binding
studies showed that IGF actions are mediated via the IGF-I receptor. These actions include
stimulation of glucose uptake, glycogen synthesis as well as increased amino acid uptake and
protein synthesis. (Zapf , 1999).
1.6.2 In-vivo
Administered IGF-I
In normal human subjects infusion of IGF-I has been shown to increase glucose uptake
producing hypoglycemia. Plasma insulin levels are also reduced. IGF-I infusion at0.4 Vg lkg
per min over 3 hours with a constant infusion of glucose increased ¡3H1 glucose uptake, and
reduced plasma concentrations of amino acids and free fatty acids (Boulware et al.,
1992;Sherwinetal., 1994). Ratsreceivinga4hourinfusionof IGF-I (Iþglkgpermin)
supplemented with amino acids had higher rates of protein synthesis in the gastrocnemius,
oblique and soleus muscle (Jacob et al., 1996). IGF-I acutely inhibits muscle protein
degradation (Oddy and Owens , 1996). Infusion of IGF-I into normal rats has been shown to
increase growth through an increase in nitrogen retention. IGF-I at 1.2 or 2.9 mdkg per day
for seven days was able to improve nitrogen retention in protein restricted rats (Tomas et al.,
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1991). Organ weights in these animals were not altered except for the kidneys, which
increased at the higher dose of IGF-I. Hypophysectomized female rats have been infused with
IGF-I for 6 days (L.25 mglkg per day). After 6 days body weight, spleen weight and plasma
IGF-I increased. IGF-I treatment decreased insulin stimulated tac-glucose incorporation into
isolated rat adipocytes which was probably due to the reduced abundance of insulin receptors
secondary to decreased plasma insulin levels caused by IGF-I treatment (Frick et al., 2000).
IGF-I increased glucose incorporation into glycogen in soleus muscle of hypophysectomized
female rats. Exercise induced protein synthesis was reduced by a neutralizing anti-IGF-I
antibody in diabetic rats (Fedele et al., 2001). IGF-I treatment of insulin deficient rats
restored glucose transporters Glut 2 and Glut 4 back to that of the normal rat (Asada et al.,
1ee8).
Fetal sheep treated with IGF-I (26 ¡tglh.kg) between day 120 to 130 of gestation had higher
weights of several organs including liver, lung, heart, kidneys spleen adrenals and pituitary
(Lok et al., L996). IGF-I treatment did not significantly affect total placental weight and
average placentomes weight but increased placentome in the weight range of 12 to 13.9 g.
Infused IGF-I increased the cross sectional area of long bones while length was unaffected.
IGF-I therefore has specific effects on fetal organ development, endocrine glands and skeletal
growth in fetal sheep. Hepatic abundance of IGF-I mRNA was decreased in fetal liver, but
not skeletal muscle, suggesting administered IGF-I negatively regulates hepatic expression of
IGF-I. Conversely fetal plasma levels of IGFBP-I and IGFBP-3 were increased by IGF-I
treatment (Kind et al., 1996) suggesting IGF-I may play a role in regulating hepatic synthesis
of IGFBP- 1 and -3 . IGF-I at 9 .9 , 20.1 , 40 .2 nmol/h infused from I22 to L27 days in ovine
fetuses increased glucose uptake, while plasma insulin was decreased at the two higher doses,
IGF-I treatment of the ovine fetus increased amino acid metabolism, as indicated by the
increased transfer of phenylalanine from the mother to the fetus and decrease in amino acid
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loss from the fetus to the placenta (Liechty et a1.,1999). IGF-I acutely increases glucose
uptake by muscle and reduces degradation of muscle protein regardless of nutrition (Oddy and
Owens, 1996).
Gene lcnockout
Null mutations of the genes for IGF-I, IGF-tr, type 1 IGF receptor, type 2IGF receptor and
multiple gene deletions have further elucidated their roles in developmental biology of the
mouse (Table 1.3). Expression of IGF-I and the type I IGF receptor are both required for
normal fetal growth (Powell-Braxton et al., 1993) as IGF-I gene deletion results in birth
weight that is -60Vo that of normal mice. Placental growth was unaffected but perinatal
survival and postnatal growth is very poor in IGF-I gene knockout mice. Gene deletion of the
type I IGF receptor affects fetal growth as early as -10.5 days gestation, reducing birth weight
to -457o of normal wild type mice. Mice lacking the type I IGF receptor do not survive. IGF-
II gene deletion affects intrauterine growth and reduces birth weight by -407o. Placental
growth is decreased in IGF-tr knock out mice similar to that seen in type tr IGF receptor
knockout mice (Baker et al., 1993), suggesting placental development is regulated by IGF-tr
and the type tr IGF receptor. A type tr IGF receptor deletion results in an increase in birth
weight of -35 to 407o and reduced placental development from day 13 of gestation. IGF-tr
levels are increased in this experimental animal promoting overgrowth of the fetus, possibly
acting through the type I IGF receptor (Morison et al., 1996). Insulin receptor gene deletion
reduced fetal growth from -18.5 days of gestation resulting in birth weight -907o that of wild















































































Table 1.3 Growth, survival and birth'weight characteristics of knockout mice with single oI multiple gene deletions of
the IGF system
In multiple gene knockout mice, where both type I IGF receptor and type tr IGF receptor are
deleted, birth weight, fetal growth was near normal and placental growth was increased. This
suggests that fetal growth and placental growth can be mediated by another receptor that is
normally redundant. This is probably the insulin receptor. In mice lacking either type I IGF
receptor and/or type tr IGF receptor, plasma IGF-I and IGF-II are increased. This may be
necessary before signalling occurs through an alternate receptor, possibly the insulin receptor.
In double knockout mice, lacking both the insulin receptor and type I IGF I receptor, fetal
growth is more severely reduced than the single gene deletion of type I IGF receptor.
Placental growth was unaffected in the insulin receptor and type I IGF receptor double
knockout mice. This indicates that IGF-tr acts through the type tr IGF receptor to promote
placental growth. Gene deletion of both IGF-tr and type tr IGF receptor reduced birth weight
by -75Vo but postnatal growth rate (fractional) and survival was almost normal. Triple gene
ablation of IGF-tr, type I IGF receptor and type tr IGF receptor caused a 65 7o reduction in
birth weight with none surviving.
Null mutation of IGFBPs did not result in major phenotypic alterations and this is probably
due to other IGFBps compensating. IGFBP-2 gene deletion decreased spleen weight in adult
males (Wood et al., lgg3). IGFBP-4 null mutation resulted in slightly smaller mice.
Overexpression of IGFs and IGFBPs in transgenic mice
Several transgenic mice lines over expressing IGF-I driven by different promoters have been
developed. The tissue that expresses the IGF-I transgene determines the effects of IGF-I
trangenesis. IGF-I transgenic mice driven by the mouse metallothionein promoter overexpress
IGF-I in many tissues, except the liver. Weights of brain, pancreas, kidney, spleen and carcass
are increased, however, bone growth was unaffected in these IGF-I mice. IGF-I transgenic
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mice crossed with GH deficient mice provided further evidence for a GH mediated IGF-I
action on bone growth and somatic growth (Behringer et a1.,1990). This transgenic model
highlights IGF-I independent actions as brain size was increased and liver weight decreased.
Skeletal muscle overexpression of IGF-I results in myofibril hypertrophy. In transgenic mice
expressing IGF-tr under the control of the rat PEPCK promoter IGF-tr was expressed in liver,
kidney and several parts of the gastrointestinal tract, increasing plasma IGF-tr concentrations
by 2 to 3 fold in 4 and 12 week old mice. There were no noticeable changes in body weight in
4 week old transgenic animals, but kidney and testis weights were increased at 4 weeks of age
while adrenal weight was increased at 12 weeks of age (V/olf et al., 1994).
Many transgenic mice expressing IGFBP transgenes have been developed (Schneider et al.,
2000). Two IGFBP-I transgenic mice lines have been developed, one controlled by
metallothionein promoter MT-hIGFBP-1 and another by the phosphoglycerate kinase
promoter PGK-TIGFBP-1. Transgenic mice overexpressing IGFBP-I were characterised by
reduced somatic growth, reduced birth weight (83 to 92 Vo of the wild type), altered glucose
homeostasis and altered pancreatic structure (Rajkumar et a1.,1999). In IGFBP-2 transgenic
mice controlled by the cytomegalovirus promoter, the transgene was expressed in pancreas,
stomach, skeletal muscle, heart, colon, spleen, adipose tissue, brain and kidney'
Overexpression of IGFBP-2 resulted in a 3-fold increase in plasma IGFBP-2, decreased
carcass weight, body weight and spleen weight (Hoeflich et al., 1999). IGFBP-3 transgenic
mice driven by the mouse MT promoter express the IGFBP-3 transgene in the kidney, small
intestine, and colon (Murphy et al., 1995). The spleen, liver and heart were enlarged in
IGFBP-3 transgenic mice.
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1.7 Insulin-like growth factors in pregnancy
1.7.1 Effect of pregnancy on the endocrine IGF system
In rats plasma IGF-I is increased from early to mid pregnancy then progressively declines
from day 14 to term at day 21 (Davenport et al., l99O;Gargosky et a1., 199Ob;Travers et al',
1993). IGF-I protein concentrations in liver are lower on day 2l of pregnancy compared with
day 4 postpartum and non-pregnant rats. A decline in IGF-I synthesis by liver therefore
appears responsible for decreased serum concentrations (Davenport et al., 1990). IGF-tr is
found circulating in adults of most mammalian species, except for rats and mice where IGF-tr
is not present in adult plasma (Daughaday and Rotwein, 1989). Pregnancy increases plasma
levels of IGF-tr in humans, rabbits and baboons (Gargosky et al., 1995;Giudice et al.,
1990;Nason et al., 1996).
Early studies show that pregnancy does not affect plasma IGF-I and IGF-tr in guinea pigs
(Daughaday et al., 1936). However, after removal of IGF-binding proteins from guinea pig
plasma before assay it was found that IGF-I levels in blood were elevated by pregnancy in this
species (Sohlstrom et al., 1993). Pregnancy did not alter circulating IGF-tr in guinea pigs
(Sohlstrom et a1.,1993). Pregnancy increased plasma IGFBP-4, but not IGFBP-3, in guinea
pigs.
Plasma levels of IGFBP-3 are increased 10 fold by pregnancy in baboons (Giudice et al.,
Ig93). IGFBP-3 normally circulates as two molecular fbrms in nonpregnant baboon plasma,
one of 40 to 45 kDa and another of 26 to 28 kDa. In pregnancy a third molecular form of 18
kDa appears. On further investigation it was found that pregnant baboon decidua produced
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identical molecular forms of IGFBP-3 to that found in pregnant serum. In many species
proteolysis of plasma IGFBP-3 has not been demonstrated. Tissue specific proteases may be
effective in posttranslational modification of IGFBPs as seen in human decidua (section
t.4.2).
Plasma levels of IGFBP-3, as detected by western ligand blotting, were found to be very low
between days 12 to 2l of pregnancy in rats (Davenport et al., l990;Gargosky et al', 1990b).
Incubation of pregnant rat serum with 25mM antipain, which is known to inhibit serine and
cysteine proteases, inhibited proteolytic fragmentation of IGFBP-3 by serum from pregnant
rats. These pregnancy-induced proteases are thought to alter the bioavailability and
bioactivity of endocrine IGFs. Protease activity decreases IGFBP-3 affinity for IGFs thereby
increasing the clearance of IGFs from the circulation of pregnant rats (Bastian et al.,
1993;Davenport et al., 1990). Radiolabelled Ir25IGF-I was cleared 3 to 5 times faster in
pregnant rats than nonpregnant rats. Increased clearance was accompanied by an increased
uptake of Ir25IGF-I by tissues (Bastian et al., Igg3). Radiolabelled Ir25IGF-I was detected in
the placenta, fetus and fetal plasma (Bastian et al., 1993). It is also been reported that IGFBP-
3 fragments bind to IGFBP-3 receptors on the cell surface (Baxter, 2000). This may alter
IGF-I presentation to cell receptors increasing its delivery to certain cells. Proteolysed
IGFBP-3 fragments retain the ability to bind IGFs and the ALS, but with reduced affinity
(Suikkari and Baxter, 1992).
IGFBP-3 at concentrations of 100 to 300 pmol did not inhibit binding of insulin to a crude
preparation of human placental microsomal membranes, however, IGFBP-7lmac25 inhibited
60 to gTEo of the binding at the respective concentrations. The ability of IGFBPs to bind
insulin and to prevent insulin binding to insulin receptors suggests a potential role in
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maintaining insulin resistance states as seen in pregnancy and diabetes (Yamanaka et al.,
reeT).
Pregnancy also increases serum IGF-I in humans. Plasma IGF-I reaches maximum
concentrations between 33 and 38 weeks (Gargosky et al., 1990a). Pregnancy decreases
IGFBP-3, IGFBP-2, and IGFBP-4 andincreases IGFBP-1 in the human as seen by western
ligand blotting. The 45 kDa form of IGFBP-3 in human serum seen in western ligand blots
disappeared during pregnancy similar to that observed in the rat. However, immunoreactive
IGFBP-3 was unaltered by pregnancy in humans. Proteolysis changes the affinity of IGFBP-3
for radiolabelled IGF-I, but not for native IGF-I (Gargosky et al., l992;Suikkari and Baxter,
1992).
IGFBP-1 is increased in mid and late pregnancy in the human (Giudice et al., 1990), baboon
(Gargosky et al., 1995), rhesus monkey (Tarantal and Gargosky, 1995), rat (Donovan et al.,
1991) and guinea pig (Sohlstrom et al., 1998). The ratio of highly phosphorylated isoforms to
low phosphorylated isoforms of IGFBP-I was negatively related to birth weight in normal and
type I diabetic patients (Gibson et a1.,1999). Low levels of phosphorylated isoforms were
positively related to maternal weight through gestation and initial body mass index in diabetic
subjects (Gibson et a1., 1999). Maternal IGFBP-I levels are higher in mothers carrying a fetus
that is small for gestational age and lower for a large fetus (Hills et a1.,1996). The degree of
phosphorylation of IGFBP-1 carried in pregnancy may be potential regulators of the actions of
IGF-I and -II on maternal metabolism. IGFBP-3 and IGFBP-I both regulate the
hypoglycemic activity of the IGFs and this characteristic may be important in protecting
pregnant women from the adverse effect of increased IGF-I on glucose metabolism (Baxter,
1995). Glucose sparing in the mother occurs to ensure a supply of substrate for fetal growth.
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The IGFs and IGFBPs can be thought of as a fine-tuning mechanism regulating circulating
glucose levels (Bang et al., 1994).
Table 1.4 Effect of pregnancy on maternal endocrine IGF system
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References: (Daughaday et al., 1986;Gargosky et al., 1995;Gargosky et al., l99Oa;Gargosky et al.,
|99Qb;Giudice et al., 1993;Hossner et al., 1997;Nason et al., 1996;Sohlstrom et al., 1998;Tarantal and Gargosky,
1995;Travers et al., 1990;Van Vliet et al., 1983).
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1.7.2 Effect of pregnancy on expression of IGF-I, IGF'II and IGFBPs in liver
The abundance of all size classes of IGF-I mRNA transcripts (0.9 -I.2 kb, 1.5-1.9 kb, 4'7 kb,
7.5 kb) are reported to be lower in livers from2I d pregnant rats than those from normal rats
(Davenport et al., 1990) although in another study the 0.9 -l.2kb transcript was unaffected
(Travers et al., 1993). 'When IGF-I mRNA data was corrected for liver weight and total RNA
content, total body content of hepatic IGF-I mRNA content did not decrease in pregnancy.
The abundance of liver IGF-I mRNA was also unaffected by a40Vo reduction in food intake in
pregnant rats (Monaco and Donovan, 1996).
Pregnancy did not affect the hepatic abundance of IGFBP-3 mRNA in rats (Donovan et al.,
1991). Food restriction increased expression of hepatic IGFBP-I mRNA in pregnant and
nonpregnant rats (Monaco and Donovan, 1996). There was no effect of pregnancy or feed
restriction on hepatic abundance of IGFBP-4 in rats.
The major source of elevated endocrine IGF-I in pregnancy has yet to be determined'
Proteolytic modification of IGFBP-3 appears to account for the decline in plasma IGF-I late in
rat pregnancy. However in humans and guinea pigs plasma concentrations of IGF-I remain
elevated throughout pregnancy despite the presence of proteases for IGFBP-3 in human.
Factors responsible for the increase of endocrine IGF-I in pregnancy have not been
determined.
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1.7.3 Effect of nutrition during pregnancy on endocrine IGFs
The timing, duration and degree of food restriction during pregnancy determine the response
of serum IGF-I concentrations and liver IGF-I mRNA abundance in the mother and on the
growth of the fetus. Fasting in mid pregnancy reduces circulating IGF-I, but not IGF-tr, in
guinea pigs (Jones et al., 1990). Pregnant rats fed 307o less than ad libitum for the first 10
days of pregnancy, followed by 407o less thereafter, had 777o lowet plasma IGF-I from day 5
to day 20 of pregnancy (Monaco and Donovan, 1996). This food restriction significantly
decreased fetal and placental weight, lowered body weight gain of mothers, but did not alter
litter size at term. Hepatic IGF-I mRNA was unaffected by food restriction in pregnant rats
(Monaco and Donov an,1996). Thus the reduced circulating IGF-I levels may be due to
increased clearance from blood because of proteolytic modifications of binding proteins,
especially IGFBP-3, in rats.
Restriction of dietary protein intake either throughout or during the last week of pregnancy in
rats decreases maternal plasma IGF-I and birth weight (Muaku et al', 1995a;Muaku et al.,
1995b). However, dietary protein restriction through the first two weeks of pregnancy in rats
had no effect on birth weight. In the mother weight gain, liver weight, plasma IGF-I, total
hepatic IGF-I pRNA and all classes of IGF-I mRNA transcripts were reduced with the 7.5 kb
transcript being most affected (Muaku et al., 1995b). Protein deprivation early in pregnancy
in rats restricts maternal anabolism, therefore reducing maternal protein stores and fetal
growth. Continuation of protein restriction late in pregnancy in rats results in severe
retardation of fetal growth. Restoration of a normal protein diet in the last two weeks of
pregnancy was sufficient to prevent fetal growth restriction in rats. Pregnant rats fed a low
protein diet with the same calorie intake as those on a normal protein diet had lower plasma
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IGF-I concentrations and hepatic IGF-I mRNA. Pups of mothers fed a low protein diet with
the same caloric intake as control animals had lower birth weight and smaller livers (Muaku et
al., 1995a). Protein content of the mothers diet therefore plays an important role in fetal
growth in rats by regulating abundance of IGF-I mRNA in maternal liver and blood levels of
IGF-I in the mother.
In guinea pigs, plasma IGF-I is increased by pregnancy in both feed restricted and ad libitum
fed guinea pigs (Dwyer and Stickland, L992;Sohlstrom et aI.,1998). The duration of reduced
food intake is important in regulating IGF-tr during pregnancy in guinea pigs. Chronic feed
restriction (-307o lor -I2 weeks) reduces plasma IGF-tr concentrations but pregnancy has no
effect in guinea pigs (Sohlstrom et al., 1998).
1.7.4 Treatment with growth hormone during pregnancy
Infusion of growth hormone 2 þglgbody weight/day for 10 days during the last half of
pregnancy into ad libitum fed rats increased maternal plasma IGF-I, maternal weight gain,
spleen and carcass fractional weight (carcass weight as a Vo of body weight) (Woodall et al.,
1999). Fetal and placental weights were unaffected. However growth hormone treatment
(100 pglrat per day for three days) late in pregnancy did not affect maternal plasma
concentrations of IGF-I in ad libitum fed animals (Nakago et al., 1999). Maternal nitrogen
retention is increased early in pregnancy in rats which was positively related to maternal
plasma IGF-I, suggesting IGF-I has anabolic effects on mothers in early pregnancy. Gilts
treated with growth hormone (5 mg/day) in the second quarter of pregnancy had higher
plasma IGF-I, higher hepatic IGF-I mRNA and greater fetal and placental weights (Sterle et
al., 1998;Sterle et aL.,1995). Growth hormone treatment of pregnant pigs fed 30 7o less than
ad libitum have reduced back fat and increased maternal plasma IGF-I, fetal body weight,
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liver weight and skull width. Pregnant ewes treated with 0.1 mg/kg of bovine GH twice a day
for 10 days from I25 days (term is -145d) had twice the normal level of plasma IGF-I. GH
increased placental uptake of glucose 3-O-[methyl-3H] and ¡14C1 urea but did not change fetal
and placental weight (Harding et al., 1997). These studies suggest that growth hormone
administered in pregnancy affects maternal metabolism either directly or indirectly through
increases in maternal IGF-I.
1.7.5 Treatment with IGF-I during pregnancy
Rars infused during the 2"d half of pregnancy with IGF-I at I.4 mg /kg body weight per day
over 10 days had higher maternal weight gain and plasma IGF-I concentrations were almost
twice those of vehicle treated rats. Fetal and placental weights were unaffected (Gargosky et
al., 1991). However administration of IGF-I at2 mglkgbody weight per day to feed restricted
pregnant rats between days 10 to 20 failed to increase maternal plasma IGF-I, maternal body
weight gain nor weights of maternal liver, heart, spleen, kidney and carcass nor fetal weight
and placental weight (Woodall et al., ßgg). Since IGF-I infused in the 2"d half of pregnancy
in rats had anabolic effects on the mother. This may suggest the infused IGF-I was
preferentially delivered to maternal tissues and not the fetus or placenta.
Ewes at 129 to 133 days of pregnancy infused with IGF-I (30 pg/kg.h) over 4 hrs had higher
plasma IGF-I and higher maternal and fetal blood glucose concentrations. IGF-I also acutely
elevates blood glucose in nonpregnant sheep by reducing insulin levels and hence increasing
hepatic glucose production (Oddy and Owens ,1996). Placental lactate production and fetal
lactate uptake were increased by IGF-I while amino nitrogen levels fell slightly in both mother
and fetus (Liu et a1.,1994). This study suggested that the ratio of maternal IGF-I to fetal IGF-I
late in pregnancy might regulate substrate partitioning of glucose, lactate and amino acids
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between mother and conceptus. Intrauterine growth retarded fetuses have lower plasma IGF-I
levels than normal fetuses. Increased glucose delivery to the fetus could increase fetal
production of IGF-I.
IGF-I infusion at 50 ¡rglh per kg into the ovine fetus decreased umbilical blood levels of serine
and glycine while fetal uptake of serine and glycine was unaltered. However fetal hindlimb
uptake of amino acids was decreased (Jensen et a1.,2000). IGF-I appears to regulate amino
acid distribution to selected tissues in the fetus. Infusion of IGF-I at26 ¡t'glh per kg into fetal
sheep between 120 days to 130 days of gestation increased plasma IGF-I concentrations and
weights of selective organs, including liver, lungs, heart, kidneys, spleen, pituitary and adrenal
glands (Lok et aI., t996). IGF-I treatment of fetal sheep was shown to increase the cross
sectional area of epiphysial areas in fetal bones. Administration of IGF-I (40 nmol/h) for 8
hours into a 130 day old ovine fetus increased circulating levels of IGF-I, IGFBP-I, IGFBP-3
and hepatic abundance of IGFBP-1 mRNA (Shen et al., 2001). Co-infusion of IGF-I and
insulin reduced the effect on IGFBP-I and IGBP-3 seen by IGF-I alone.
Increases in IGFBp-1 and -3 in fetal plasma following infusion of IGF-I suggests that binding
proteins are either preventing IGF-I induced hypoglycaemia by inhibiting IGF-I actions or that
IGFBP-I and -3 bind IGF-I and deliver it to selective tissues. Alternatively the pool of free
IGF-I acts to promote anabolic growth of selective organs and skeletal maturation (Lok et al.,
r9e6).
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1.8 Aims of the study
In general the aim of this study was to determine if the liver was the major source of
endocrine IGF-I in pregnancy and the effect of pregnancy on associations between hepatic
abundance of IGF-I mRNA, plasma IGFs and pregnancy phenotype'
Experiments were designed to test the following hypotheses
L. Pregnancy increases the abundance of IGF-I mRNA in the liver and the concentration of
IGF-I protein in blood in guinea pigs.
2. Guinea pig liver is the major source of endocrine IGF-I in pregnancy.
3. The circulating levels of IGF-I and hepatic abundance of IGF-I mRNA in the mother are
related to the weights of the conceptus in late pregnancy
4. Insulin-like binding proteins in maternal blood in pregnancy direct endocrine IGF actions to
particular tissues.
Specific Aims
1. To determine the effect of pregnancy and nutrition on the expression of IGF-I mRNA in
livers of guinea pigs.
2. To determine the relationship between the relative abundance of hepatic IGF-I mRNA and
circulating concentrations of IGF-I.
3. To identify the source of circulating IGF-I in pregnant guinea pigs.
4. To examine quantitative relationships between hepatic abundance of IGF-I mRNA and







EXPRESSION OF IGF.I MRNA IN THE GI'III\EA PIG.
DEVELOPMENT AND VALIDATION OF A REVBRSE TRANSCRIPTION





Quantitative measurement of messenger RNA is controversial. In this study, two different
nonisotopic methods were evaluated for their suitability for the quantitation of mRNA.
Polymerase chain reaction (PCR) aims to amplify a defined section of DNA using repeat
reactions with DNA polymerase simultaneously copying complementary DNA templates.
Amplified oDNA products were evaluated by densitometric analysis of ethidium bromide
stained cDNA on agarose gels or by digoxigenin ELISA where labelled digoxigenin-cDNA
products were measured. RT-PCR was chosen as transcripts of low abundance can be
amplified from relatively small amounts of RNA.
Quality of RNA extracted from tissues affects performance of reverse transcription of mRNA
to first strand cDNA and subsequent PCR amplification as the product of both depends on the
condition of the RNA template and the presence of contaminants, including DNase and
RNase. Extraction of RNA must be performed under extremely clean RNase free conditions
(Coleman, 1997). Integrity of RNA on an ethidium bromide stained agarose gel provides
information with respect to RNase contamination by evaluation of ribosomal RNA
degradation. Greater than 8O7o of RNA in an RNA extract from tissue will be ribosomal RNA
(2SS) and (18S) and will be electrophorectically separated into two distinct bands on an
agarose gel (Jones, 1994). RNase activity degrades the 28S ribosomal band into many smaller
bands that appear as a smear on the gel.
Complementary DNA was synthesised from a RNA template using the enzyme reverse
transcriptase and random hexamer primers which produces cDNAs of variable lengths. Oligo
(dT) primers are also commonly used for reverse transcription. They hybridise with the poly
(A) tail found in most mRNA and lead to transcription from the 3'end producing full-length
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cDNAs. Transcription of the gene of interest may be missed if its mRNA is lacking a poly
(A) tail or may occur with variable efficiency if variable polyadenylation occurs.
For PCR of the initial cDNA reverse transcribed from mRNA, two oligonucleotide primers
that span the target sequence are designed to be complementary to nucleotide sequences in
opposing complementary DNA. The general method of PCR involves the amplification of
cDNA by multiple cycles of heat denaturing allowing double stranded cDNA to be separated
into single complementary strands, followed by cooling to anneal the oligonucleotide primers
to complementary cDNA, followed by an extension step at an intermediary temperature where
DNA polymerase elongates the primers and synthesises copies of the DNA. Each DNA copy
then acts as template for the subsequent cycle. This amplification typically requires 20 to 30
repetitive cycles to produce sufficient DNA of interest to be detected, depending on the
sensitivity of the detection system and the efficiency of amplification.
When using RT-PCR to quantify mRNA the quality of RNA extracted, efficiency of the
reverse transcriptase and the efficiency of amplification of cDNA in the PCR reaction must be
controlled. The amount of product produced is doubled after every cycle of PCR
amplification only under ideal theoretical conditions which are rurely achieved in practice.
Amplification efficiency experimentally is often much less than 1007o. If efficiency of
amplification varies by even a small amount between different specimens the effect on
amplicon product yield is very large over 20 to 30 repetitive cycles. Amplification efficiency
is influenced by reaction buffer components, concentration of nucleotide reactants, primer
concentration, reaction times and temperatures, polymerase concentration and stability and
cDNA contaminants.
Quantification of amplified PCR products is commonly based on the measurement of density
of each cDNA product, expressed relative to a known standard or an internal control, after
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agarose gel electrophoresis and ethidium bromide staining. The development of computer
software and digital cameras has greatly improved the accuracy of measurement of these
electrophoretic bands. However, sensitivity and linearity of response in these methods are not
generally evaluated. Therefore different approaches have been taken for the quantitative
evaluation of PCR amplified cDNA. Quantitative multiplex RT-PCR was developed so that
the gene in question and an internal standard were co-amplified in simultaneous reactions and
the amounts of each product can be compared. However this method has several
disadvantages (Bustin, 2000).
For the purpose of this present study IGF-I mRNA was amplified by RT-PCR in a separate
reaction to an internal reference gene B-actin. IGF-I mRNA gene expression was expressed
relative to the abundance of p-actin mRNA in the same preparation of first strand cDNA.
This approach enables amplification of both IGF-I and B-actin cDNA to be achieved without
competition for reactants by different reactions and reduces nonspecific hybridisation that is
often significant in multiplex assays. B-actin is ubiquitously expressed and is highly abundant
in liver and adipose tissue. Expression patterns of many alternative genes used as a reference
can vary due to developmental state and./or experimental treatment including use of
anaesthetics (Thellin et al., 1999). Thus selection of reference genes must be based around
specific tissues and cells and the study design. Ideally more than one reference gene with
constitutive expression should be used to normalise the expression of the target mRNA.
However the use of one gene has been widely accepted and B-actin is a common choice
(Sturzenbaum and Kille, 2001;Thellin et al., 1999).
Two size classes of IGF-I mRNA transcripts have been reported in liver, bone and cartilage of
guinea pigs by Northern blotting (Gosiewska et al., 1994). The abundance of IGF-I mRNA in
liver was higher than in bone and cartilage. In rats and mice the liver is the major source of
endocrine IGF-I, while in pigs and humans adipose tissue may be an alternative source of
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endocrine IGF-I (Coleman et al., 1994;Moller et a1.,1991). Therefore expression of IGF-I
6RNA in guinea pig liver and adipose tissue was compared. Specific assays for guinea pig
IGF-I mRNA and guinea pig B-actin mRNA were developed'
In order to quantitatively measure abundance of IGF-I mRNA in the guinea pig a suitable RT-
pCR method was developed. In developing this method several steps were evaluated to be
certain the gene of interest was amplified and that physiologically significant differences in
expression of IGF-I 6RNA were detectable. Amplified PCR products must be of expected
size and identity of PCR products can be confirmed by nucleotide sequencing. Quantitative
evaluation of amplified PCR products was performed by ethidium bromide staining of PCR
products after agarose gel electrophoresis and by digoxigenin-EllSA. The efficiency of
amplification, sensitivity, specificity, reproducibility and throughput were determined for both
methods
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aluminium foil covered block was chilled in an esky containing ice and was used as a
chopping board. A small piece of autoclaved aluminium foil pre chilled at -20oC for t hour
was placed on the top of the chilled block. A piece of tissue of -160 mg was excised and
minced with ice-chilled scissors. Tissues were homogenised in 1 ml of TRIZOL per 100 mg
of tissue (see below) using a chilled glass tissue grinder (Kontes Glass Company, Vineland,
New Jersey). The minced tissue was placed into pre-weighed sterile tubes (Falcon, Becton
Dickinson Labware, New Jersey) containing 1.6 ml of TRIZOL reagent. The tubes were then
reweighed and the weight of tissue excised determined. The mixture was homogenized with
15-20 strokes of the chilled glass tissue grinder until a homogeneous pink suspension was
obtained. The homogenate was decanted into a sterile 2 ml safe lock tube (cat no.0030
I20.O14I Eppendorf- Netheler-Hinz-GmbH Germany tube) and held on ice until all samples
were processed (between2.5 to 4 h).
After use the tissue grinder was washed twice with lM sodium hydroxide performing 10
strokes each wash, then two washes wtth l%o SDS in sterile water, two washes with I7o Titon
X-100 in sterile water and finally washed with sterile water until all bubbles were removed.
The cleaned grinder was returned to ice for re-use when required. This wash procedure was
repeated after every tissue homogenisation to minimise contamination.
Safe lock tubes containing homogenates were centrifuged at 12 000 x g for 10 mins at 4"C
(Eppendorf ,5415 C centrifuge) to pellet cellular debris. Five hundred ¡rl of supernatants were
pipetted to fresh safe lock tubes and incubated at room temperature (23'C) for 5 mins to
permit dissociation of nucleoprotein complexes. Chloroform (0.32 ml) was added to each
supernatant, which was then shaken vigorously by hand for 15 secs followed by incubation at
room temperature for 3 mins. RNA remains in the upper aqueous phase while DNA is in the
interphase and protein is in the lower organic phase. The three phases were separated by
centrifugation for 15 mins at 12 000 x g at 4oC. Most of the colourless upper aqueous phase
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containing the RNA (0.S ml) was carefully removed and pipetted into fresh safe lock tubes
carefully avoiding disturbance or removal of the interphase and lower organic phase. RNA
was precipitated from this supernatant by mixing with 0.8 ml of isopropyl alcohol, incubation
at room temperature for 10 mins, then centrifugation at 12 000 x g for 10 mins at 4oC' The
resultant gel-like pellet was washed by re-suspension in 0.5 ml of 75Vo ethanol in sterile
water. The RNA was pelleted by centrifugation at 7 500 g for 5 min at 40C. The supernatant
was aspirated and the pellet was air-dried for 15 mins at room temperature then dissolved in
50 ¡rl of sterile water. The aqueous solution of RNA was divided into two aliquots. 
One was
stored at -80oC and the second aliquot was stored at -80oC under 2.5 volumes of 1007o ethanol
and Il25th volume of 5M sodium chloride (Sambrook, 1989)'
Concentration and integrity of RNA
The concentration and purity of RNA was determined from its UV absorbance spectrum
(Beckman DU-50 Spectrophotometer Fullarton CA USA). Two ¡rl of RNA was diluted with
198 pl of molecular grade water (Fluka, Chemika-Biochemika, Messerschmittstr, GmbH) and
the absorbance spectrum from 260 nm to 300 nm was measured. Phenol contamination of
samples was assessed by a shift in the peak absorbance from 260 nmto 270 nm. A ratio of
absorbance at260nm to 280 nm of 1.6 or greater indicates RNA of acceptable purity (Davis,
1986). Protein contamination will be evident if the ratio is less than 1'6' An absorbance of 1
at260 nm is equivalent to 40 pglml of RNA (Davis, 1986)'
Total RNA concentration extracted was calculated by:
Concentration of RNA Wgltul = Azoo x 100 x 40/1000
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Agarose gel electrophoresis of RNA extracts followed by staining with ethidium bromide
allowed the integrity of the RNA to be assessed by examination of the ribosomal RNA
subunits 28S and 185. RNA extracted from liver and fat were electrophoresed at 70 V for 1.5
hrs through a I7o (wlv) agarose gel in 0.5 x TBE buffer (0.089 M Tris-borate, 0.089 M boric
acid and 0.002 M EDTA pH 8.0). The gel was then stained by soaking in 0.5 pglml of
ethidium bromide for 30 mins, de-stained with water, transilluminated with UV light
(Chromato-VUl Transilluminator TM-15, San Gabriel USA) and photographed with Kodak
digital camera. Densitometric analysis was performed by Kodak dS Digital Scienceru, lD
Image Analysis Software Electrophoresis Documentation and Analysis System 120 (EDAS
120) (Kodak, Rochester, NY).
2.2.3 Reverse Transcription (RT)
Total RNA was reverse transcribed to cDNA using RNA-directed DNA polymerase
(Expandru reverse transcriptase, Cat No. 1785826 Boehringer Mannheim, Mannheim
Germany). This is a Moloney murine leukaemia virus reverse transcriptase genetically
engineered to remove RNase H activity. The enzyme was suitable for use with the PCR
enzyme Taq polymerase, and incorporation of digoxigenin-labelled nucleotides (Bustin,
2000;Coleman,1997).
There are three different forms of primers commonly used for cDNA synthesis prior to
quantitation by PCR. These are oligo(dT), random sequence hexanucleotides and sequence
specific primers. Random hexamers were used in the present study to produce alarge
population of cDNA fragments. Two pg of RNA extract in 20 ¡rl of sterile water was mixed
wlth2 pl of random hexamer primers (100 pglml in sterile water, GeneWorks Pty. Ltd.
Adelaide Aust. Cat rp-6), heated to 650C for 10 mins and then cooled on ice for 3 mins. A
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"master mix" comprising of 8 ¡r,l of 5 x cDNA synthesis buffer (250 mM Tris-HCl, 200 mM
KCl,25 mM MgCl2,2.5%o Tween-20, pH 8.3),4 ¡"tl of 100 mM dithiothreitol (DTT) in water,
4 pl of Ultrapure dNTPs (10 mM each dATP, dCTP, dGTP, dTTP in water p}J7 .5
(Amersham Pharmacia Biotech)) and2 pl of Expandru reverse transcriptase enzyme (100
units) was prepared. Eighteen pl of the "master mix" was added to the cooled 22 ¡tl of RNA
and random hexamer solution. The reaction mixture was incubated for 10 mins at 300C, to
allow the random hexamers to anneal to the RNA. The mixture was heated for 45 mins at
420C allowing the reverse transcriptase enzyme to synthesise cDNA. RNA secondary
structures that may hinder progression are minimised above 42oC (Coleman,I99l;Lewin,
1987). Finally the enzyme was inactivated by denaturation at 950C for 2 mins. The solution
was stored at -2OoC.
2.2.4Primer design for Polymerase Chain Reaction (PCR) amplifTcation of guinea pig
IGF-I cDNA and B-actin cDNA
The design of primers affects specificity of hybridisation, size or length of cDNA amplified
(amplicon) and efficiency of PCR amplification. Two primers are designed to be
complimentary to the opposite complementary strands of the target DNA template and flank a
sequence of interest. If they flank a genomic sequence that spans an intron it is possible to
detect genomic DNA contamination of RNA preparations because genomic DNA
amplification will give rise to a PCR product of greater length than that derived from cDNA.
Several guidelines are well established in the literature (Coyne, 1996;Mullis, 1994;Ruiz,
1997) and those guidelines used for designing IGF-I and B-actin primers are listed in Table
2.1. The primer length and G + C content are important in determining the melting
temperatures (T.) of the primer-cDNA hybrid. The annealing temperature chosen is usually
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5oC below the melting temperature. However the annealing temperature affects specificity
and amplification yield. In general the longer the primer and higher G +C content the higher
the melting temperature. Primers are designed to have between 50 to 607o G+C bases and to
be 18 to 28 nucleotides in length. Primers smaller than 18 nt are less representative of a
unique DNA sequence and have a greater chance of hybridising to non-target DNA and hence
lead to amplification of nonspecific cDNA products(Coleman, 1997;Coyne, 1996). Yields for
amplicons greater than 2000 bp in length are generally very poor and amplicons less than 200
bp are difficult to resolve (from primer oligomers) on an agarose gel. Primers should be
designed with less than 3 complementary bases at the 3'end to minimise formation of primer
polymers. Primers should contain less than 3 G or C at the 3'end to avoid nonspecific
hybridisation to cDNA, although including two has been suggested to anchor the primer to the
recognition site. The concentrations of primers used in the present study were between 0.1-
0.5 pM, which is reported to minimise mis-priming and accumulation of non-specific
products and primer polymerisation (Coyne, 1996;Innis, 1990).
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Table 2.1
Criteria for design and use of primers
Primer length
G + C content










range 55o - 80oC
T-= 2oc x (A+T) +4oc x (c + G) *
for primers 2Obp or less






T-: melting temperature,*4, T, G, C, are the number of bases in the designed oligonucleotide.
References: (Coyne, 1996;Mullis, 1994;Ruiz, 1997)
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Polymerase Chain Reaction Primer Pairs
Guinea pig IGF-I
primers (Table 2.2) were designed to hybridise to the sense and antisense partial cDNA
sequence for guinea pig IGF-I DNA (GenBank X 5295I) (Bell et a1', 1990)' PRIMER
DESIGNER software package (Scientific and Educational Software, Stateline PA USA,
Version 2) was used for designing primers following the criteria in Table 2.1. Figure 2'I is a
schematic representation of the guinea pig IGF-I partial gene structure. Reverse-phase FIPLC
quality (90 -977o purity) IGF-I primers were synthesised by SIGMA GENOSYS (Sigma-
Aldrich, Castle Hill NSW























F Forward prirner, R Reverse primer, * denotes expected amplicon size using the rat B -actin Sene sequence












Figure 2.1 Schematic representation of the partial guinea pig IGF-I gene and rat B-actin
gene.
From the 5' flanking region the coding regions of exons (blue) for guine pig IGF-I and (green)
for rat p-actin. Introns are red lines and flanking regions are thin black line. Introns for
gpIGF-I gene were based on the human IGF-I gene. The black arrows indicate primer binding
sites. tGF-t (Genebank accession number X52951), B-actin (Genebank accession number






Measurement of the abundance of p-actin mRNA was used as a reference for IGF-I mRNA
abundance in the same first strand cDNA. Primers for the amplification of guinea pig p-actin
cDNA were designed using the rat DNA sequence (GenBank V0I2L7 J00691). The B-actin
sequence available for the guinea pig was only 138 bp, which is too short to design useful
primers for PCR amplification. Rat B-actin cDNA sequence was found to have 887o
homology with guinea pig B-actin cDNA (partial cDNA sequence Genbank accession No
4F193571) after analysis by BLASTIN 2.1.2 software available at
http ://www.ncbi.nlm.nih. gov : 8O/blasUb I 2seql.
2.2.5 P oly merase Chain Reaction
PCR amplification of 5 ul of çDNA preparations (section 2.2.3) was performed using the Taq
DNA Polymerase Kit (Fisher Biotech International, WA) in PCR buffer (67 mM Tris-HCl, pH
g.g lat ZSDC),16.6 mM [N]I412SO4,0.457o Triton X-100, 0.2mglml gelatin), also containing
2 mM MgCl2,200 uM of ultrapure dNTPs IdATP, dCTP, dGTP, dTTP], (Pharmacia Biotech),
0.5 pM of primers IGF-I¡ro and IGF-Is¿5 or p-actinr¿so ând þ-actin22el plus 0.02 U/ul of Taq
DNA polymerase, in a final volume of 50 ¡rl.
IGF-I and p-actin cDNA fragments were amplified by PCR in different reactions performed
under the same conditions. PCR was performed in a thermal cycler (PCR Express, Hybaid
Ltd., UK). An initial denaturation at94oC was performed for 3 mins followed by repeated
cycles of denaturation at 94oC for 15 sec, annealing at 58oC for 15 sec and extension at72oC
for 45 sec. A terminal extension at'72oC was performed for 3 mins
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The amount of DNA in PCR products was determined from spectrophotometric analysis at
260nm where 5Opg/ml of DNA = 1 absorbance unit'
2.2.6 Calculation of the molecular size of PCR products
The IGF-I DNA PCR product was diluted 1:5, 1:10 and l:20 and 4 replicates of 7 ul of each
solution and duplicates (0.25 Fg) of a DNA molecular size standard pUC19 DNA digested
wrth HpaII (GeneWorks, Adelaide, Australia) were electrophoresed at 90V for 45 mins
through a27o (wlv) agarose gel in 0.5 x TBE buffer. The gel was stained and analysed as
described in section 2.2.2. PCR product abundance as quantitatively determined by measuring
the density in pixels (net intensity) of selected bands, expressed as a 7o of the net intensity of
the 404 bp fragment of known mass of the pUC19 DNNHpa 11 standard. The results
presented are the mean net intensity of the replicates of the PCR products electrophoresed'
The Kodak EDAS 120 (section 2.2.2) was used to measure the mobilities of the
pUClgDN NHpaII fragments of known size and the IGF-I and B-actin cDNA products whose
size was to be measured. The size of the DNA fragment was calculated by plotting log DNA
size in nucleotides for the duplicate pUCIglHpaII standards (y) versus distance migrated, (x).
A linear regression was performed (Sigma Stat) to generate a linear equation. The equation is
of the format ! = mx + b, therefore the equation of this plot is Log DNA size = slope x
mobility + y-intercept. The distance migrated of each of the replicates IGF-I and B-actin DNA
was measured and the size calculated by use of the equation.
2.2.7 Sequencing of Polymerase Chain Reaction products
Products amplified with IGF-Izrcls+s or B-actinlas6t22srprimers were purified with the
elAquick PCR Purification Kit (QIAGEN, Melbourne Vic) and sequenced using the ABI
PRISM TM Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer,
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Branchburg NJ USA). The following reagents were added to PCR tubes; 8 ¡rl of ready
reaction mix (BigDyeru primers, dNTPs, AmpliTaqR FS enzyme, MgCl2 and reaction buffer),
24 ngof purified PCR product DNA, 4 pl of primer (3.2 pmol), to a final reaction volume of
20 pl with sterile water. Each primer IGF-I31s, IGF-I5a5, 0-actinr¿so and p-actin22s1wîs added
to different aliquots of purified PCR products, thus, producing 4 products for nucleotide
sequencing. Amplification of cDNA was performed by heating the reaction mixture to 96oC
followed by 25 cycles at96"C for 30 secs, 50oC for 15 secs and 60oC for 4 mins' Amplified
products labelled with terminator dye were placed directly on ice on completion. The cDNA
in 20 pr,l of the reaction mix was precipitated by mixing with 2 pl of 3M sodium acetate pH 5.4
and 50 ¡tl of 957o ethanol and incubated on ice for 10 mins followed by centrifugation at 12
000 x g for 30 mins. The resultant pellet \vas resuspended in 250 ¡t"l of 70Vo ethanol. The
gDNA was re-pelleted by centrifugation at 12 000 x g for 20 mins at 4"C. The pellets were
partially air-dried. Sequencing of the pellets was performed by the sequencing centre at the
Institute of Medical and Veterinary Science (IMVS, Frome Rd Adelaide SA).
2.2.8 Determination of IGF-I and B-actin efficiency of amplifrcation
To determine the efficiency of amplification of IGF-I and B-actin alarge stock of liver cDNA
was prepared by reverse transcription of guinea pig liver RNA (section 2.2.3) for this purpose.
Reverse transcription of 15 replicates of 2 ¡tgof liver RNA extract was performed, at the end
of which all çDNA products were pooled making alarge stock of guinea pig liver cDNA' The
stock was divided into duplicate aliquots designated as oDNAI and cDNAz. A PCR master
mix with IGF-I310/IGF-I5a5 primers, as described in 2.2.6, was prepared and addedto 22
replicates of either gp liver cDNAr or gp liver cDNAz to a final volume of 50 ¡11 A second
master mix with p-actin primer pairs was added to another 22 teplicates of gp liver cDNAr to
a final volume of 50 pl. They were then subjected to PCR using the same cycling parameters
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as described in section 2.2.6, excluding the final extension cycle of 3 min at72oC. Duplicates
were removed from the thermal cycler every 2"d cycle from20-36 cycles at the end of the 45
sec,72oC extension step and placed directly on ice. The thermal cycler was not stopped at any
time and only opened and quickly closed at the end of the 45 sec extension step. PCR
products were then prepared for agarose electrophoresis by mixing 14 ¡r,l of each with 4 pl of
6x loading buffer (0.257o (wiv) bromophenol blue, 0 .257o (w/v) xylene cyanol, 3OVo (v lv)
glycerol in water (Sambrook, 1989). Five ¡rl of solution was placed in each well in the
electrophoresis gel, which was equivalent to 3.8 pl of PCR product. A standard pUC19
DNNHpa ll was also loaded into a well on every gel (0.25 þgl5 ltl,2.5 ¡tl of a 500 ngl¡rl
stock was diluted with 5 ul of loading buffer and I7 .5 ¡rl of water). Electrophoresis was
performed as described in section 2.2.2.
Calculation of fficiency of amplification
The theoretical maximum efficiency of PCR is 1007o in which the amount of PCR product
doubles every cycle. Product formation in PCR follows the general equation y = aV, where y
= amount of product, a = amount of initial template, x = number of cycles, b = amplification
factor(1<b <2), whereb = 1+E, andEis thePCRefficiency. Theefficiencyof





Linear regression of a plot of log(amount of PCR product) versus number of cycles has an
intercept of log (amount of initial template) on the y axis and a slope of log (1 + E). The
antilog of this slope is equal to 1 + E.
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P re ci sion and rep ro duc ib ilitY
precision and reproducibility of the amplification of PCR products measured by densitometric
analysis within and between electrophoretic gels was evaluated. The within assay variability
was determined by amplifying cDNAr with IGF-I primers for 24 cycles, diluting 1:5, 1:10 or
1:20 with water and analysing each in quadruplicate on a single gel. Quadruplicates of each
solution (7 pl) were applied to a 27o agarcse gel and electrophoresed as described in section
2.2.2. The between-assay variability was determined by using duplicates of cDNAr and
cDNAz. These çDNA duplicates were amplified with IGF-I310/IGF-I5a5 primers under the
same amplification conditions described in section 2.2.5. Duplicate cDNAs were amplified
for 22 to 26 cycles inclusive in the same thermal cycling batch. PCR product was analysed in
duplicate on separate gels (Figure 2) resulting in quadruplicates for each cDNA at each of the
cycle numbers listed above. PCR products (14 pl) were diluted with 4þl of electrophoresis
loading buffer and 5pl was loaded per well and subjected to electrophoresis as in section
2.2.2. The intensity of the ethidium bromide stained band was determined using the Kodak
EDAS 120 system calibrated using the density of the 4}4bp pUCIglHpa IIDNA standard
(0.25 t¡g) loaded per well. The pUClg lHpa II DNA (0.25¡t{5¡tl) standard was loaded in at
least two wells per gel and the average used for mass calibration.
2.2.g. Enzyme Linked Immunosorbent Assay of Digoxigenin-labelled cDNA
Roche Diagnostics GmbH, Mannheim (Mannheim, Germany) have developed a method for
the quantitative analysis of PCR products which involves the incorporation of a digoxigenin-
labelled nucleotide, digoxigenin-11-dUTP, by including it with the nucleotide reactants in the
PCR reaction. The Dig-labelled cDNA product is then hybridised to a biotinylated
complementary oligonucleotide. The resultant biotinylated hybrid is bound to a streptavidin
coated microtitre plate. The amount of digoxigenin captured to the microtitre plate is detected
by monitoring the formation of a coloured product at absorbance 405 nm following the
addition of a peroxidase-conjugated anti-digoxigenin antibody and ABTS (2,2'-Azino-di-[3-
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ethylbenzthiazoline sulfonatel diammonium salt) substrate. This provides a highly sensitive
and specific DNA ELISA system
B iotinylat e d c apture oli gonucle otide s
Biotinylated oligonucleotides, gp IGF-I and gp p-actin, were designed to be complementary to
the sequences obtained from section 2.2.7 andwere synthesised and desalted by Gene'Works
and Genosys respectively. The 5'-biotinylated oligonucleotides are described in Table 2.3'
Table 2.3 Biotinylated oligonucleotides that bind streptavidin coated ELISA plates for
the immobilisation of Dig-labelled PCR products
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Digoxigenin labelling of IGF-I and B-actin PCR products
Dig-labelling (Figure 2.2) ofcDNA was performed using PCR conditions as described in
section 2.2.5. The effect of the concentration of Dig-dNTPs (Boehringer Mannheim GmbH),
amount of template cDNA and amount of PCR product added to the ELISA was determined.
Five¡rlof guineapiglivercDNA,equivalentto0.25 pgof RNA, and2.5 plequivalentto
0.125 pg of RNA, were each aliquoted into 6 replicate PCR tubes containing variable
concentrations of Dig-dNTP mixture (40, 80, 100 and 200 ¡"lM). These aliquots were
subjected to PCR, as describedin2.2.5 for 30 cycles, placed on ice then frozen. Quantitation




D i g o xi g enin -l ab ell e d c D N A Enzym e Linke d Immun o s o rb ent As s ay
Dig-labelled PCR products were thawed on ice and 10 ¡rl diluted to a final volume of 250 pl
with ELISA buffer (0.05M Phosphate buffer, pH 7.5) containing the appropriate biotinylated
oligonucleotide ("capture probe") at 50 ng/ml. The mixtures were heat denatured at94"C for
10 mins then incubated at 60oC for 10 mins to allow hybridisation to occur between the
biotinylated capture oligonucleotide and the Dig-labelled PCR product followed by incubation
at room temperature for 10 mins. The solution of hybridised biotinylated oligonucleotide and
Dig-labelled PCR product were mixed and centrifu ged at 10 000 rpm for 30 secs and 200 pl
was added to a streptavidin-coated microtiter plate well (cat no 1734776, Boehringer
Mannheim, GmbH, Germany). The plate was covered with transparent adhesive film and
incubated for 3 hrs at37oC shaking at 160 rpm in an orbital incubator (Orbital Mixer
Incubator, Ratek Instruments). The plate was washed 3 times with wash buffer (Boehringer
Mannheim, Germany). The anti-digoxigenin-polyperoxidase conjugate antibody (Fab
fragments), 200 pl of 40 U/l (Boehringer Mannheim), diluted in Conjugate Buffer (100 mM
Na-pO¿, 50 mM NaCl, 0.5 mM EDTA, 0.IVoTween*2O, lVo casein, pH 7.5) was added and
incubated for 30 mins at 37oC shaking at 160 rpm. The plate was washed a further 3 times
with wash buffer. The substrate ABTS (0.5 mg/ml) was made by dissolving one tablet of
ABTSR (2,2'-Azino-di-[3-ethylbenzthiazoline sulfonate] diammonium salt) in 10 ml of a 1/10
aqueous dilution of ABTSR buffer (sodium perborate, citric acid and disodium hydrogen
phosphate) in the dark. Two hundred ¡rl of the ABTS solution was added per well and the
plate was wrapped in foil, as the substrate is light sensitive. The reaction was allowed to
proceed for 15-30 mins at 37oC shaking at 160 rpm. The spectrophotometric absorbance was









Figure 2.2 Schematic diagram of digoxigenin labelling of
amplifTed PCR products
DIG -dUTP




















Figure 2.3 Schematic of PCR ELISA
procedure for the quantitation of Dig labelled PCR products
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Efficiency of PCR amplification of DigJabelled IGF-I and B-actin
The efficiency of amplification of Dig-IGF-I cDNA was determined as described in section
2.2.8. except that a Dig-labelled dNTP solution replaced the unlabelled dNTP solution in the
master mix. Dig-dNTP solution was used at a final concentration of 100 ¡tM. A solution
sufficient for 22Dig-IGF-I PCR reactions was prepared. Sterile water (2.5 pl) was substituted
for cDNA in replicate reactions as a negative control or PCR blank. Sixteen replicates of
guinea pig liver cDNA (2.5 t"rl) were aliquoted into flat top PCR tubes with 47.5 pl of the Dig-
IGF-I PCR master mix. PCR was performed by heating at94oC for 3 mins, followed by 36
cycles of 94oC for 15 secs, 58oC for 15 secs and 72oC for 45 secs. Replicates were removed
every second cycle at the end of the extension phase (72'C) from cycle 18 to 36. The Dig-
IGF-I cDNA products v/ere measured by Dig-IGF-I DNA ELISA as described above.
Amplification efficiency of Dig-B-actin cDNA was determined as described above except a
Dig-B-actin PCR solution was prepared sufficient for 16 reactions and replicates were
removed every second cycle from 16 to 26 and the Dig-p-actin cDNA products were
measured by Dig-p-actin DNA ELISA'
P recision and reproducibilitY
The between PCR batch coefficient of variation was measured in one ELISA. This was
determined by amplification in triplicate of guinea pig liver cDNAr and cDNAzQ.5 V"l).
Replicates cDNAr and cDNA2waraDigJabelled in three independent PCRs. Ten ¡rl of each
Dig-IGF-I cDNAr or Dig-IGF-I cDNAz product was assayed in duplicate in ELISA, therefore
for each Dig-IGF-I cDNAr and cDNA26 rcplicate wells were measured (section2.2-9) for
each PCR.
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Precision of the Dig-labelled PCR ELISA was evaluated. The within PCR variability was
determined using triplicates of a guinea pig liver cDNA amplified for 24 cycles in one IGF-I
PCR. The Dig-IGF-I cDNA products (n = 3) are diluted I:25 and assayed in duplicate (200 pl)
in the ELISA (n =6). The mean and standard deviation was used to calculate the coefficient of
variation ToCY - (standard deviation/mean) x 100. The between assay variability was
determined by using Dig-labelled IGF-I cDNA as a calibration standard (see below for its
preparation). The coefficient of variation was evaluated from three independent assays using
the absorbance measurement of 2 ¡i of the DigJabelled IGF-I cDNA standard.
Preparation and quantitation of a Dig-labelled guinea pig liver IGF-I and B-actin
PCR standard
Standards were prepared to calibrate measurement of Dig-DNA. Guinea pig liver RNA was
reverse transcribed, as per 2.2.3, to produce a stock of gp liver cDNA, which was employed
for the preparation of a stock of Dig-IGF-I DNA and a stock of Dig-p-actin DNA as follows'
Each stock cDNA (10 pl) was aliquoted into 36 tubes. A master mix containing gp IGF-I
primers and DigJabelled dNTP was added to 18 of the tubes up to a final volume of 50 ¡r,l and
the remaining 18 aliquots were made up to 50 pl with a master mix containing gp B-actin
primers and Dig-labelled dNTP. Negative controls were included for both primer pairs in
which molecular grade water (10 pl) replaced cDNA for a PCR control as well as aliquots (10
pl) in which molecular grade water has been substituted for RNA in the RT reaction (negative
control for RT). PCR was performed by heating to 94"C for 3 mins, followed by 36 cycles of
94oC for 15 secs, 58oC for 15 secs andT2oC for 45 secs and a final extension at72oC fot 2
mins. The resultant Dig-cDNA products for each primer pair were pooled and re-aliquoted
into 50 pl lots for storage. Each Dig-cDNA standard was quantified by agarose gel
electrophoresis (section 2.2.8). Each amplified product was serially diluted 1:5, 1: I0, l:20
and.] pl was loaded in quadruplicate onto a 2Vo agarose gel that was subjected to
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electrophoresis. The gel was stained by ethidium bromide and densitometric analysis
performed as described in section 2.2.2, and the amount of product was determined by





Total RNA was extracted from guinea liver with a yield ranging from 1.4 to 1.95 ¡tg of RNA
per mg of wet tissue weight. Total RNA was extracted from guinea pig parametrial fat,
interscapular fat and retroperitoneal fat with yields ranging from 0'9 to 3.6 Wg/mg,,0.6 to 1'1
Wglmg,and 1.9 to Z l*glm1respectively. RNA extracts examined in ethidium 
bromide stained
agarose gels showed two distinct bands, consistent with the 28S and 18S ribosomal RNA
subunits at 4.5 and 1.9 kb (Figure 2.4). Yery little smearing was observed migrating ahead of
the 28S rRNA, indicating very little RNase activity. The ratio of 28S to 18S, assessed by
densitometric scanning,was 1.5 f 0.08. The ratio of absorbance at Azøo and A2ss for RNA
extracted from liver was greater than 1.8 indicating that there was minimal contamination by
proteins, DNA or phenol.
2.3.2 Amplification of IGF'I and B'actin cDNA fragments
The reverse transcription products from guinea pig liver RNA subjected to PCR with primer
pair gp IGF-I¡ro¡s+s amplified a single product (Figure 2.5 A). Dilution of the amplified
products from the IGF-I PCR showed that the intensity of ethidium bromide staining was
reduced with increasing dilution. Negative controls containing water (RT and PCR) amplified
with primer pair gp IGF-I:ro/s4s resulted in no product formation. The size of the IGF-I DNA
fragment was calculated by graphing Log pUClg lHpa IIDNA fragment size versus distance
migrated in an agarose gel (Figure 2.5 B). Linear regression analysis was applied to the
duplicate pUC19 DNA lHpa II standard data which had a linear relationship of Log size DNA
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fragment = -7.I9l x 10-3 * (mobility) + 2.96. The mobility of each product was used to
calculate the size of the fragment and the mean I sem. Guinea pig IGF-I cDNA was found to
be 243.2 t2$ bp compared to its predicted size of 236 bp. Amplification of guinea pig F-
actin cDNA, produced fragments of 383 t I2.2 bp when calculated from the linear
relationship of Log size DNA fragment = -I.692 x 10-3 * (mobility) + 2.295, compared to its




Figure 2.4 Agarose gel electrophoresis of total RNA
Agarose gel electrophoresis of 1.7 pg of liver RNA from 60 day pregnant guinea
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Figure 2.5 Agarose gel electrophoresis of RT-PCR products
(A) RNA from guinea pig liver was reverse transcribed and PCR performed using
primers gp IGF-I'0,'45. IGF-I cDNA was diluted 1:5 (Lanes 2 to 5), 1: 10 (lanes 6
to 9) and 1:20 (lanes 11 to 14) and subjected to agarose electrophoresis. Negative
PCR contains IGF-I primer pair, sterile water and PCR reaction solution. Negative
RT contains IGF-I primer pair, water (substituted for RNA in RT reaction
mixture) and PCR reaction solution. M = 0.25 pg of pUCl9 DNNHpa /1 standard
(range 111 - 501 bp fragments). (B) The size of the band was estimated to be
243.2 +2.5bp (mean + sem) by comparing the distance migrated by the amplicon
against the migration of the DNA markers.
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A single cDNA product was amplified from parametrial fat, interscapular fat and
retroperitoneal fat with gpIGF-I primer pair and rB-actin primer pair (Figure 2.6). The size of
the IGF-I product was estimated as described above and was 241+ 2.2bp with a predicted
size of 236bp. The reference gene B-actin was estimated as 393 + 3 bp with a predicted size
of 372 bp. IGF-I was expressed in parametrial fat, interscapular fat and retroperitoneal fat as
shown on agarose gel electrophoresis of RT-PCR products. Amplified IGF-I PCR products
from fat tissues were undiluted, but liver IGF-I PCR products were diluted 1:10 before being
subjected to agarose gel electrophoresis. Qualitative estimation of the ethidium bromide
stained PCR products, subjected to agarose gel electrophoresis, suggests IGF-I mRNA was
more abundantly expressed in the liver than any of the fat depots analysed.
2.3.3 Sequence of amplified PCR products
The fragments amplified from guinea pig liver cDNA by gpIGF-I1¡¡ts4s and rat p-actin primers
were purified for sequencing. Sequence data was obtained for 17I bases out of the possible
243 for gpIGF-I (gpIGF-I375-5a5) and 295 bases were sequenced for gp B-actin. The sequences
were analysed by the BLASTIN 2.1.2 software (see section 2.2.4). The cDNA product
amplified by gplGF-I3rc64s aligned with 171 bases between nucleotides 375-545 and had a
I007o identityto gpIGF-ImRNA (Bell et al., 1990) (Figure 2.7). A295base product
sequence from gp liver cDNA, amplified using rat B-actin primers, aligned with the partial
guinea pig heart B-actin sequence
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Figure 2.6 Agmose gel electrophoresis of adipose fat RT-PCR products
RNA from guinea pig pararnetrial, interscapular, retroperitoneal fat was reverse
transcribedandPCRperformedusingprimers gp lGF-Irrcys¿s or rþ-actin"5*on 
.
M = 0.25 pg of pUCl9DNNHpalI standard Gange 111 - 501 bp fragments).
IGF-I cDNA products for parametrial fat shown in lanes 3 and 7, interscapular
fat are shown in lanes 1,4, and 11 andretroperitoneal fat is shown in lane 9.
Ê-actin cDNA products for pararrrctrial fat are in lane 5 and 8, interscapular fat
are in lanes 2, 6, and 12 andretroperitoneal fat is in lane 10.
The size of the IGF-I cDNAproduct was estimated tobe%I +2.2bp (rnean +
sem) and the p-actin cDNA product was 393 t 3 bp by corrparing the distance













CTCTGC GC,CGCTGAGCTGGTTGACGC GCTCCAGTTCGTGTGC GGAGATAGGGGCTTCTAT 94
TTCAACAAGC CCAC GC,GGTACGGCTCCAGCAGTCGGAGGGCACCACAGACC GGCATCGTG 1 54
GACGAGTGCTGTTTCCGGAC,CTC,CGACCTGCGGAGGCTGGAGATGTACTGC 205
Figure 2.7 Proposed organisation of the guinea pig IGF-I cDNA and the partial nucleotide sequence of the
amplifred fragment using gplGF-Irrorro. primers
The hatched lines are aligned with 375bp to 545bp of the guinea pig IGF-I oDNA sequenoe (Bell, 1990). The amplifred product

















(GenBank AF 193571) at nucleotides 130 to 265 with 867o homology in this region. The
amplified product of 295 bases was also aligned with the rat gene encoding cytoplasmic beta-
actin (GenBank Vo1217). The sequence aligned at nucleotides 1473-1691 and2l55-2224 and
was 857o andgIVo homologous respectively to rat cytoplasmic p-actin (Figure 2.8).
2.3.4 Effïciency of amplifïcation of guinea pig IGF-I cDNA and B-actin cDNA
estimated by densitometric analysis.
RT-PCR of guinea pig liver RNA was performed and the efficiency of amplification
calculated from the densitometric analysis of the PCR products after agarose gel
electrophoresis and ethidium bromide staining. Guinea pig liver RNA was reverse transcribed
in duplicate and then subjected to PCR either in duplicate or quadruplicate to assess the error
contributed by RT, PCR and densitometric analysis in the quantitation of mRNA.
Amplification of IGF-I and B-actin by PCR produced single products whose migration was
intermediate of the 242 and 331 bp and the 404 and 501 bp markers respectively, which was
consistent with the expected sizes. The efficiency of amplification (E) as calculated by the
equation y = ab* (section 2.2.8), was 267o for IGF-I between cycles 20 to 24 inclusive, (Figure
2.9) andwas 34.57o for B-actin between cycles 22 to 26 inclusive (Figure 2.IO).
Precision
The coefficient of variation associated with estimation of the density of IGF-I PCR products
the amplicons on agarose gels ranged from 1.9 7o at cycle 28 to 20.5 Vo at cycle 20 (Figure
2.II). This indicates that densitometric measurement at lower numbers of amplification
cycles is more variable. The within-assay variability was determined using the same cDNA
which was amplified for 24 cycles, diluted 1:5, 1: l0,l:20 and analysed in quadruplicate on a
single gel. Within-assay variability was found to range from3To to 127o. The between gel
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Figure 2.8. Sequence alignment of rat cytoplasmic, guinea pig liver and heart B'actin.
The invariant nucleotides in the guinea pig liver oDNA (coloured red) compared to the rat
p-actin sequence. Comparison of guinea pig liver and guinea pig heart B-actin oDNA
show that L47o of the nucleotides differ and these are shown in gteen.
RAT
p-actin cDNA product 346 GTCA GATTCCTACGTGGGCGACGAGGCCCAGAGCAAGCGCGGTATCNTGACCCTAA2ST
RAT
p-actin cDNA product
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pUC19 404 bp fragment
26 28 30
PCR Cycle number
Figure 2.9 RT-PCR amplification profile of guinea pig liver IGF-I quantitated by
agarose gel etectrophoresis, ethidium bromide staining and transillumination with
UV light.
Samples were resolved on a 2Vo agarose gel electrophoresed at90V for'45 mins. The
gel was stained with ethidium bromide and amplicons were visualised by UV light. M
= 0.25 pg of pUC 1 9 DN AlHpø 11 standard. The numbers above the lanes indicate the
number of PCR cycles. In the negative RT RNA was substituted with sterile water in
the reaction mixture. In the negative PCR cDNA was replaced by sterile water in the
reaction mixture. The density of amplified IGF-I cDNA fragment is expressed as a Eo





















pUCl9 404 bp fragment 59
0
20 30
Figure 2.10 RT-PCR amplification profile of guinea pig liver p-actin quantitated
by agarose gel electrophoresis, ethidiumbromide staining and transillumination with
UV light.
Samples were resolved on a 2Eo agarose gel elecffophoresed at 90V for 45 mins. The gel
was stained with ethidiumbromide and amplicons were visualised by W light. M =0.25
¡rg of pUC19 DNNHpa.I/ standard. The numbers above the lanes indicate the number of
PCR cycles. In the negative RT RNA was substituted by sterile water in the RT reaction
mixture. In the negative PCR cDNA was replacedby sterile water in the reaction mixture.
Thedensityof amplifiedB-actincDNAfragmentisexpressed asa%o of thepUCl9 404bp
fragment.
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+ mean + SEMq- Vo CY
Figure 2.1.1 Variability of RT-PCR amplification of guinea pig liver IGF-I
and the coefficient of variation associated with replicates run on the same gel
and measured by densitometry.
Amplification of IGF-I was assessed in duplicate for 20 and 28 cycles and in
quadruplicate for 22,24 aîd26 cycles. The amount of amplified IGF-I fragment






variability was determined by using the density of the 4}4bp pUCl9/Hpa tr DNA standard on
three different gels and was found tobe 167o
2.3.5 Effect of concentration of cDNA template and digoxigenin-labelling reactants on
Dig-ELISA estimation of IGF-I mRNA.
Digoxigenin labelling of IGF-I cDNA products was performed as in 2.2.5. The volume of
reverse transcribed cDNA, concentration of Dig-dNTPs and volume of Dig-IGF-I cDNA PCR
products added to the ELISA microtitre wells were evaluated to determine their effect on the
Dig-ELISA estimation of IGF-I mRNA (Figure 2.12). The concentration of Dig-dNTPs that
yielded maximal Dig-IGF-I labelled cDNA product from2.5 pl of guinea pig liver cDNA
preparation (equivalent to 0.125 pg of total RNA) was 100 pM when 10 ¡rl of the Dig-IGF-I
cDNA PCR product was measured in the dig ELISA. However, doubling the volume of guinea
pig liver cDNA preparation to 5 pl (0.25 ¡tg of total RNA) increased the incorporation of Dig-
dNTPs at200 ¡rM which was the maximum concentration tested (Figure 2.I2). The greater the
incorporation of digoxigenin-dNTPs into IGF-I cDNA the greater the absorbance, irrespective
of the amount of reverse transcribed cDNA initially amplified in the PCR reaction. A greater
amount of bound hybrid (Dig-IGF-I cDNA hybridised to biotinylated gpIGF-I) was detected in
10 ¡r,l of amplified PCR products from 2.5 ¡tl of liver cDNA than from 5 pl of liver cDNA at a
concentration of 100 ¡rM Dig-dNTPs (Figure 2.12). This may result from the presence of PCR
inhibitors contaminating the cDNA preparation that may be affecting the polymerase enzyme
reaction therefore reducing efficiency and dig incorporation rates.
Measurement in the Dig-ELISA was routinely performed by Dig-labelling 2.5 ¡tl of guinea pig
liver cDNA preparation (0.125 pg of RNA) using 100 ¡"tM Dig-dNTPs, followed by













-a- 10 ul of dig-IGF-I cDNA from 5 ul of liver cDNA
+- 5 ul of dig-IGF-I from 5 ul of liver cDNA
4 negativeRTr,'
--ç- negative PCR.,l
-G 10 ul of dig-IGF-I from 2.5 ul of liver cDNA
{- 5 ul of dig-IGF-I from 2.5 ul of liver cDNA
4 've RTr.ru,
* -ve PCR2.sul
Figure 2.1^2F;ffect of concentration of digoxigenin'dNTP and liver cDNA
template on Dig-IGF-I cDNA measured in the Dig-ELISA
Immobilisation of biotinylated guinea pig IGF-I oligonucleotide hybridised to
dig-IGF-I cDNA on a streptavidin-coated microtitre plate. Detection of bound
hybrid was performed with peroxidase conjugated anti-digoxigenin antibody.
negative RT (sterile water substituted for RNA in reaction mixture)
negative PCR (sterile water substituted for cDNA in reaction mixture)




which 200 pl of the hybridised solution was added to the streptavidin-coated microtitre
plate well.
2.3.6 Effrciency of amplification estimated by Dig ELISA
The average amplification efficiency estimated by Dig-ELISA was 647o for IGF-I after 22,24
and 26 cycles inclusive and 537o for B-actin between cycles 18-20 inclusive (Figure 2.13).
This was much greater than the amplification efficiencies for PCR assessed by densitometric
analysis of ethidium bromide stained agarose gels (section 2.3.4). Detection of ethidium
bromide stained PCR products for both amplicons was detectable from cycle 20.
The variability of DigJabelling of cDNA in the PCR reaction using the same guinea pig liver
cDNA was calculated to be between 5.47o and2oVo. The within-assay variability was
determined using a single Dig-labelled cDNA hybridised in triplicate in solution to the capture
oligonucleotide and then each hybridised cDNA was measured in duplicate in the ELISA and
the variability was found tobe 3.2Vo (n = 5). The variability between three ELISA assays of
the Dig-labelled IGF-I cDNA standard was found tobe 14.67o. Comparison of the twö
methods for quantitation of mRNA has shown that there is greater variability at lower
amplification cycles associated with gel analysis than that observed with the ELISA.
These results indicate that PCR Dig-ELISA can be used to quantify IGF-I mRNA and p-actin
mRNA. The throughput of analyses per gel is limited to 16 and will be insufficient for the
analysis of 31 test samples and standards. The coefficient of variation between gels was 437o
indicating reproducibility was poorer. A major advantage of the ELISA system over gel
analysis was that it allowed an increased throughput of 90 analyses, allowing comparisons
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Figure 2.13 The efficiency of amplification of IGF'I and B'actin,
measured by PCR Dig-ELISA
Amplification of dig-labelled PCR products are measured by the
increase in absorbance at 405 nm in the ELISA.
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2.3.7 Specificity
The specificity of the PCR ELISA was tested using a non-complementary capture
oligonucleotide. A dig labelled PCR product produced using gp IGF-I:ro¡s+s primers was
hybridised to the biotinylated capture oligonucleotide for B-actin or that for IGF-I. A Dig-
labelled PCR product produced using B-actin primers was treated similarly. All were then
measured by Dig-ELISA (Table 2.4).
Table 2.4 Specifïcity of capture oligonucleotide for respective Dig labelled PCR
amplicon.
Dig labelled PCR product










2.3.8 Dig labetled IGF-I and p-actin calibration standards for Dig-ELISAs
The sizes of the Dig-labelled IGF-I and B-actin PCR products used as ELISA calibration
standards were found to be 243.2 t 2.5 bp and 383 t I2.2 bp respectively by gel analysis.
Their DNA concentrations were determined by electrophoresis and comparison with a known
mass of pUC19/Hpa tr DNA standard. IGF-I and p-actin PCR ELISA standards were serially
diluted and the density of each measured after electrophoresis and ethidium bromide staining.
The mass of IGF-I cDNA and B-actin cDNA as calculated from the plot of net intensity of
pUC19/Hpa tr DNA fragments versus the Log Mass (ng) of each standard Dig-amplicon. The
DNA concentrations of 1:5, 1:10 and 1:20 quadruplicate dilutions of IGF-IDig-ELISA
standards were 16.3, IO.7 , 12.7 mg/l respectively and the mean t sem was L3.2 t2.0 mgll.
The mean DNA concentration of quadruplicate Dig-B-actin cDNA ELISA standard diluted




RT-PCR is a sensitive, specific and quick nonisotopic method for the detection of mRNA.
This method works very effectively with small amounts of RNA and total RNA preparations.
Useful RNA can be successfully extracted from tissues if ribonuclease activity is inhibited or
kept to a minimum. This can be achieved by the choice of reagents inhibiting RNases activity
(guanidinium isothiocyanate) as well as using solutions and glassware that are RNase free and
careful extraction to remove DNA, protein and lipid. Extraction of total RNA and the yield
from various tissues varies widely and must be considered when embarking on a study
involving the quantitation of mRNA by any method. The yield of RNA obtained from guinea
pig liver in this study was reasonably reproducible. Extracted liver RNA had an A26s¡2ss ratio
greater than 1.8 indicating the preparation had minimal protein and phenol contamination.
Others have shown that total RNA extracted by TRIZOL reagent gives consistent yields and
high purity (Chadderton et al., 1991).
A single dsDNA product from liver, parametrial fat, interscapular fat and retroperitoneal fat of
guinea pigs was obtained for both IGF-I and B-actin. The relative abundance of IGF-I mRNA
estimated from ethidium stained agarose gels after RT-PCR of total RNA was qualitatively
much greater in liver than in the three major fat sites measured. A previous study also showed
that guinea pig liver abundantly expresses IGF-I mRNA compared with bone and cartilage
(Gosiewska et al., 1994).
Use of guinea pig IGF-I specific primers permitted amplification of a product when sequenced
was 1007o identical to guinea pig IGF-I cDNA (Bell et a1., 1990). Use of rat p-actin
primersled to amplification of a product, which had 867o sequence homology with guinea pig
p-actin (GenBank 4F193571) andS6Vo homology with rat p-actin nucleotides 1473 to 1697
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andglVo with nucleotides 2155 to 2224 (GenBank Y0I2I7). The discrepancy between the
published sequence and the sequence of the amplified product could be explained by strain to
strain variation in the sequence of guinea pig p-actin.
PCR reagent and cycling conditions for both IGF-I and B-actin were established and the
efficiency of amplification estimated for two methods.
The successful performance of RT-PCR is dependent on many factors including
reproducibility of reverse transcription. Often this step can introduce large variation. In this
study the CV for reverse transcription ranged from 5.47o to 207o. For this reason an internal
reference is required in the analysis.
Throughput and v ariance
Sample throughput limited the suitability of the method based on densitometric analysis of
PCR products on ethidium bromide stained gels. A maximum of nine analyses in duplicate
per gel can be performed. Approximately five gels would be required to analyse the same
number than can be analysed by one Dig-ELISA. Two fold changes in levels of transcripts
can be missed due to between gel variation. The Dig-ELISA allows 40 analyses per batch in
duplicate minimising between-batch errors.
Efficiency
The efficiency of amplification determined by densitometric analysis of ethidium bromide
stained bands after agarose gel electrophoresis for IGF-I between cycle 20 to 24 is 267o and
between cycle 22 to 26 for p-actin was 34.5Vo. Using this method of analysis the efficiency of
amplification was considerably low for each PCR reaction, thus contributing to quantitation
error. Slight changes in amplification efficiency expand into greater changes in the amount of
reaction product, leading to errors in accurate quantitation. If PCR is a I00Vo efficient then a
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doubling of cDNA products occur per cycle however as efficiency for this study for the gel
method is much less than 507o. In comparison the efficiency of amplification determined by
ELISA for IGF-I between cycle 22 to 26 was 647o and for B-actin between cycle 18 to 20 was
53Vo . The efficiency of amplification was increased at least 2 fold for IGF-I and 1 .5 times for
p-actin when quantitation was performed by Dig-ELISA. Dig-ELISA estimation of Dig-
cDNA products for either IGF-I or p-actin was far superior over the densitometric gel
analysis. The small linear range and accuracy of measuring the intensity of the bands limit
densitometric analysis of ethidium bromide stained gels which may account for the higher
efficiencies observed for Dig-ELISA detection. As amplification increases the intensity of the
bands increase but becomes indistinguishable in the exponential phase and the plateau phase.
The ELISA can detect accurate changes in amplification as this detection method uses a
specific capture oligonucleotide sequence and an enzyme detection system to quantify the
PCR products.
Sensitivity
Sensitivity of both techniques is acceptable for this study. PCR products can be detected at
cycle 20 for IGF-I by both detection systems, while B-actin was detected in the Dig-ELISA
two cycles earlier. Gel analysis was performed on undiluted PCR product whereas Dig-Þ-
actin PCR products were diluted for measurement in the ELISA. This suggests that the Dig-
ELISA is a more sensitive method than the gel method. At cycle 20IGF-I mRNA products
were just visible on ethidium bromide stained agarose gel.
Specificity
Specificity of detection of amplified PCR products by the ELISA is potentially increased by
having a third oligonucleotide "capture" probe, which is specific for the amplified product.
Densitometric analysis of amplified PCR products measures the band at a predicted size and
the identity of this product was verified by sequencing. Therefore the use of a third
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oligonucleotide designed specifically for the gene of interest increases the specificity of the
Dig-ELISA approach over that of the densitometric analysis of amplified PCR products.
Reproducibility
For densitometric analysis of ethidium bromide stained PCR products precision between
replicate samples on the same gel was3Vo, however, the between assay variability ranged
fuom 167o to 43Vo. This variation was unsuitable for analyses aimed at detecting smaller
differences between experimental treatment groups. Analysis of the variation of IGF-I cDNA
product between cycle numbers 20 to 28 indicated that at lower cycle numbers the coefficient
of variation was 2O7o, indicating the high variability in densitometric measurement. As cycle
number increases and the cDNA product increases exponentially the coefficient of variation
decreased to L.97o. This suggests that the exponential phase of the reaction can be assessed
accurately. In summary, densitometric analysis of ethidium stained agarose gel has good
reproducibility if all samples are run on one gel but has large inter assay variation and
therefore would not be ideal as an analytical tool for this study. In comparison the Dig-ELISA
within-assay variation was3.27o which was compafable with the gel method.
These results suggest that the Dig-ELISA can be used to quantify IGF-I mRNA and p-actin
mRNA. Reverse transcription of up to 40 experimental samples should be performed in
duplicate in a single batch, followed by a single PCR amplification batch and Dig-PCR
products measured in a single Dig-ELISA assay. This will eliminate the variation associated
with multiple RT and PCR batches. Quantitation of IGF-I cDNA and p-actin was therefore
performed by Dig-ELISA. The main advantage of the Dig-ELISA over the gel densitometric
analysis is the large throughput resulting in a lower level of within-assay variation.
In summary, guinea pig liver expresses more IGF-I mRNA than parametrial fat, interscapular
fat and retroperitoneal fat, suggesting liver as a major source of IGF-L A RT-PCR ELISA has
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THE EFFECT OF PREGNANCY AND NUTRITION ON
HEPATIC BXPRESSION OF IGF.I:
ROLE OF THE IGF EI\DOCRINB SYSTEM IN PREGNANCY
Chapter 3-1
3.l INTRODUCTION
In humans and in other mammals IGF-I concentrations in maternal blood are related to fetal
body weight and size (Caufriez et aI.,l994;Mclntyre et al., 2000). In mothers cartying ruGR
fetuses maternal plasma IGF-I was lower than normal and correlated with fetal weight
(Lassarre et al., L99I). High plasma IGF-I in pregnant mice abolished the negative
relationship seen between fetal weight and litter size (Gluckman et al., 1992), suggesting IGF-
I may have a role in enhancing nutrient availability or placental capacity to deliver nutrients.
IGF-I has been suggested to act as a regulator of maternal metabolism during pregnancy'
IGF-I promotes glucose and amino acid uptake and inhibits protein degradation in muscle
(Oddy and Owens , t996). Infusion of IGF-I into pregnant ewes stimulates placental lactate
production, which is taken up by the fetus (Liu et a1,,1994). IGF-I also has anabolic effects
on maternal tissues in pregnant rats (Gargosky et al., 1991). Therefore, circulating IGF-I may
play an important role in regulating maternal metabolism and partitioning substrates to supply
fetal and/or placental growth.
Circulating IGF-I levels increase progressively with advancing pregnancy in humans and
guinea pigs (Gargosky et al., 1990a;Sohlstrom et al., 1998). In rodents IGF-I increases during
the first half and then declines in the second half of pregnancy (Gargosky et al., 1990b).
Pregnancy also increases IGFBP-3 protease activity in blood in rats and humans, which
potentially alters the bioavailability of IGF-I and its clearance from the circulation. In humans
and rats proteolytic modification of IGFBP-3 by pregnancy specific proteases lowers the
binding affinity for IGFs affecting bioavailability for target tissues (Baxter, 1994;Blat et al.,
1994;Lassarre and Binoux, 1994). In guinea pig plasma, pregnancy specific proteases for
IGFBP-3 have not yet been identified (Sohlstrom et al., 1993). However tissue specific
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proteases may be present similar to those identified in human placental trophoblast cells and
decidua, affecting the availability of IGFs to selected tissues (kwin et al., 2000;Rajah et al',
rees).
Liver is known to be the major source of endocrine IGF-I in nonpregnant rats. However it is
uncertain whether the increase in plasma IGF-I seen early in pregnancy in rats is due to
increased hepatic production or due to increased clearance of IGF-I (Davenport et al.,
1990;Monaco and Donovan, 1997). Hepatic abundance of IGF-I mRNA increased in sows
treated with GH in the second quarter of pregnancy and this increase was associated with
increased maternal plasma IGF-I (Sterle et al., 1998).
The effect of pregnancy on endocrine IGF-I is similar in humans and guinea pigs where
pregnancy progressively increases concentrations of IGF-I and IGF-tr is also present in
relatively large amounts. Preliminary studies (section 2.3.2) indicated that liver is the major
site of IGF-I synthesis in guinea pigs. This study therefore measured IGF-I mRNA in liver
using the RT-PCR dig-ELISA developed in chapter 2. The aim was to determine the effects
of pregnancy and nutrition on IGF-I expression. The effects of pregnancy and nutrition on
relationships between hepatic abundance of IGF-I mRNA, plasma IGFs and IGF binding
proteins and pregnancy phenotype \ryere also investigated.
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3.2 MATERIALS AND METHODS
3.2.1 ExperimentalDesign
Nulliparous female guinea pigs (IMVS coloured strain) aged 3 to 4 months weighing 472! 56
g (n = 31) were from the Gilles Plains Animal Resource Centre SA. Animals were given
unrestricted access to a guinea piglrabbit ration supplemented with vitamin E (165 mdkg)
which was prepared by Milling Industries Stockfeeds, Murray Bridge. Water containing
vitamin C (400 mgl) was freely available. Animals were housed under a 12 hours light and
dark cycle with temperature maintained at25oC.
The animals used in this study were a subset of those described in Sohlstrom et al 1998,
where plasma IGFs and body composition for the whole cohort were reported. Guinea pigs
were allocated to four treatments (Figure 3.1). They were either fed ad libitum (n=8) or 307o
less than ad libitum (per g body weight) for 28 days prior to mating and for the first 34 days of
pregnancy, then lÙVo less than ad libitum (per g body weight) for the next 26 days (n=8).
Term is 69 days. The attenuation of feed restriction over the last 26 d of pregnancy minimises
fetal loss. Food intake and body weight were measured three times per week. The maternal
weight gain and net maternal weight gain (maternal weight minus the weight of the uterus
containing fetal and placental tissue) was taken from day 1 of pregnancy to day 60 of
pregnancy. Nonpregnant animals were weighed for the same time period as for the pregnant
animals. Nonpregnant guinea pigs were similarly fed (ad libitum, n=5; feed restricted, n=10)
for 88 days. Pregnant animals were humanely killed on day 60 of pregnancy and nonpregnant











Figure 3.1. Schematic representation of nutritional treatments of pregnant and
nonpregnant guinea pigs.
Animals were fed either ad l¡b¡tum or 30o/o less than ad libitum per kg body weight for 28
days prior to mating. Nutritionally restricted animals were maintained on the 30% less than
ad libitum for 62 days after which the diet was altered to l0o/o less than ad librtum. Animals
were euthanased at day 60 of pregnancy (term is 69 days).








3,2.2 Collection of blood and tissues
The Adelaide University Animal Ethics Committee approved this study design. Animals were
killed by an intraperitoneal overdose of pentobarbital sodium. Blood (10 ml) was collected
immediately by cardiac puncture into a heparinised syringe and stored on ice until
centrifugation at 4oC for 10 mins at2500 rpm (J-68 Beckman Instruments USA). Plasma was
stored at -20oC. The following tissues were immediately removed weighed and snap ftozen'.
adrenals, kidneys, spleen, pancreas, liver, gastrointestinal tract, retroperitoneal fat,
interscapular fat,parametrial fat, heart, lungs, thymus, thyroids as well as the biceps brachii,
soleus, and gastronemius muscles. All tissues were stored at -80oC. All fetal and placental
weights were also determined.
3.2.3 IGF-I Radioimmunoassay
Acid column chromatography of plasma samples
Plasma IGF-I and IGF-tr were measured by radioimmunoassay after removal of IGFBPs by
size exclusion high performance liquid chromatography (FIPLC) at pH 2.5 (Owens et al.,
1990). Plasma samples (90 pl) were diluted in 360 pl water, acidified with 150 pl of 4 times
concentrated FIPLC mobile phase, mixed and incubated at room temperature for 30 mins. The
acidified solution was defatted by mixing with an equal volume of freon (I,1,2-trichloto-I,2,
2-trifluoroethane). The organic and aqueous phases were separated by centrifugation at 10
000 rpm for 10 mins at 4oC. A portion of the upper aqueous phase (a00 pl) was filtered
through a0.45 ¡rm cellulose acetate micro-spin filter membrane (cat no. 2485, Alltech
Associates Inc.) by centrifugation at 10 000 rpm for 3 mins at 4oC. Two hundred pl of filtrate,
equivalent to 30 pl of plasma, was injected (Shimadzu SIL-94, Japan) onto a Protein-Pak 125
HPLC size exclusion column (Waters Millipore, Lane Cove, NSW, Australia) equilibrated at
1 ml/min with 200 mM acetic acid, 50 mM trimethylamine, 0.057o Tween-20 atpH2.5
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(mobile phase). The recovery from the Protein-PakL25 column was estimated by injecting
-20 000 cpm of radiolabelled IGF-I and counting the eluted radioactivity. Recovery was 95 f
0.6 7o (n= 8). Four fractions of eluate were routinely collected for each acidified plasma
specimen. Fraction 1 was collected between 6.25 to 8.25 mins (2.0 ml), fraction 2 from 8.25
to 8.75 mins (0.5 ml), fraction 3 from 8.75 to 10.75 mins (2.0 ml), and fraction 4 from I0.15
to 11.25 mins (0.5 ml) after injection. Quality control was maintained by the inclusion of
pooled guinea pig plasma, which had been stored in 500 ¡ll aliquots at -20"C, and was
extracted and chromatographed as above at least once per FIPLC run. An average of 15 test
specimens were injected at intervals of 30 mins in each IIPLC batch run. A large pool of
chromatographed pig plasma, previously eluted in fraction 3 from many HPLC runs, was also
used as a quality control specimen in every RIA. Routinely, all four fractions from the pooled
guinea pig plasma (chromatographed quality control) and randomly selected test specimens,
fraction 3 for the remaining test specimens (15< n <20) and the pig plasma pooled eluate
were included in every RIA of IGF-I and IGF-tr.
Measurement of IGF-I by radioimmunoassay
Recombinant human IGF-I (Gropep Pty. Ltd, Adelaide) was used to prepare the standard and
radiolabelled ligand for RIA. IGF-I was iodinated using chloramine-T and Nal2sl (Gargosky
et al., 1990a;Owens et a1., 1990). Specific radioactivity of ¡r2sI1-iodo-IGF-I was 80 Cil g.
Rabbit anti-human IGF-I antibody (MAC Ab 89/1) was used at a final dilution of 1:60 000.
IGF-tr has less than l7o of the potency of IGb-l in this assay (Francis et al., l989a;Francis et
al., 1989b). Guinea pig IGF-I and IGF-tr are identical to the human polypeptides. All
measurements were performed in triplicate.
One hundred pl of the chromatography fraction was added to a polystyrene tube, followed by
two hundred ¡rl of RIA buffer (30 mM NazHPO¿; 0.027o (w/v) protamine sulphate; 10 mM
disodiumEDTA; O.05Vo (v/v)Tween-2};0.02%o (w/v)NaN3,pH7.5)and60plof 0.4MTris
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base to bring the pH to 1.4. A stock solution of 10 nglml IGF-I standard in RIA buffer stored
at -20oC was serially diluted in IGF RIA buffer to prepare a standard of < 5 to 500 pglttbe
which was added in 200 pl. Mobile phase (100 ¡r1) and 60 pl of 0.4 M Tris base was added to
each standard tube as neutralized eluate blank. Anti-human IGF-I (50 pl) and 50 pl of
radioiodinated h-IGF-I (20 000 cpm) were added per tube. Tubes containing 50 ¡rl
radiolabelled IGF-I only, provided a measure of total radioactivity added and tubes with RIA
buffer and radiolabelled IGF-I only provided a blank (no IGF-I antiserum). The tubes were
mixed and incubated for 22hrs at 4oC. Ten pl of a I:20 dilution in RIA buffer of rabbit IgG
(cat no. P0448, DAKO, Australia Pty Ltd) and 50 ¡rl of a 1:20 dilution in RIA buffer of sheep
anti-rabbit IgG (cat no. RC, Silenus, Victoria, Australia) were added. The tubes were mixed
and incubated for 30 mins at 4oC. One ml of ice cold polyethylene glycol 6000 (67o w/v) in
150 mM of aqueous NaCl was added and the tubes were centrifuged at 4000 rpm for 25 mins
at 4"C (J-6B Beckman, Instruments USA). The supernatant was aspirated and radioactivity in
the pellet was measured in a gamma scintillation spectrometer (1261MULTIGAMMA, LKB
Pharmacia, and Wallac Oy). The RiaCalc tr data management program (Pharmacia, Wallac
Oy) calculated IGF-I concentrations and the minimal detectable concentration, which was 6.5
pgltube on average. This is equivalent to 4.9 ng of IGF-I per ml of plasma. The coefficient of
variation for the guinea pig plasma pool was 2 Vo. The intra and inter assay coefficients of
variation, assessed by repeated measures of the pig pool in the RIA, were 5.57o and7.87o
respectively.
Measurement of IGF-II by radioimmunoassay
Recombinant human IGF-tr receptor grade (Gropep Pty. Ltd.) was used for preparation of the
standard and radiolabelled ligand. IGF-tr was iodinated using chloramine-T and Na12sI
(Owens et al., 1990). Specific activity of the radioJigand was 10 Cil g. A mouse anti-rat
Chapter 3-8
IGF-tr monoclonal antibody (Dr K Nishikawa,Kanazawa, Medical University, Ishikawa,
Japan) was used at a final dilution of 1: 500 in RIA buffer. IGF-I has 2.57o of the activity of
IGF-tr in this RIA (Carr et al 199516). All measurements were performed in triplicate. Fifty
pl of the appropriate IIPLC fraction was added to a polystyrene tube followed by RIA buffer
(200 pl), and 30 p,l of 0.4 M Tris base to bring the pH to 7 .4. A stock solution of 10 nglml
IGF-tr standard in RIA buffer stored at-20"C was serially diluted in IGF RIA buffer for use in
generating the standard of < 5 to 500 pgltube which was added to RIA tubes in 200 ¡rl.
Mobile phase (50 pl) and 30 ¡rl of 0.4 M Tris base were added per standard tube as neutralized
eluate blank. Anti-rat IGF-tr (50 pl) and 50 pl of radioiodinated h-IGF-tr (20 000 cpm) were
added to each tube. Tubes with radiolabelled IGF-tr provided a measure of total counts and
tubes with RIA buffer and radiolabelled IGF-tr (no IGF-tr antiserum) provided a measure of
the blank. The tubes were mixed and incubated for 22hrs at 4"C. Ten ¡rl of a I:20 dilution in
RIA buffer of mouse serum (IMVS, Gilles Plains, South Australia) and 50 pl of a 1:20
dilution in RIA buffer of sheep anti-mouse IgG (cat DS, Silenus, Victoria, Australia) were
added. The tubes were mixed and incubated for 30 mins at 4"C. One ml of ice cold
polyethylene glycol 6000 (6Vo w/v) in 150 mM of aqueous NaCl was added and the tubes
were centrifuged at 4000 rpm for 25 mins at4"C (J-6B Beckman,Instruments USA). The
supernatant was aspirated and the radioactivity in the pellet was measured in a ganìma
counter. The minimal detectable concentration (see IGF-I RIA above) was 19 pgltube. The
intra and inter assay coefficient of variation were J .87o and l0.l%o respectively.
Measurement of IGFBPs by western ligand blot analysis.
IGF-binding proteins in plasma were measured by western ligand blotting (Hossenlopp et al.,
1986). Ten ¡rl of guinea pig plasma was diluted with 90 pl of water and 100 pl of 4 x sodium
dodecyl sulfate (SDS) gel loading buffer (0.25 M Tris base, 87o SDS wlv,2O7o glycerol v/v
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and0.047o bromophenol blue w/v). Samples were heated at 650C for 15 mins before loading
20 ¡rl (equivalent to 1 ¡ll guinea pig plasma) onto a non-reducing discontinuous sodium
dodecyl sulfate-polyacrylamide gel with a 47o stackjng gel and a IOTo separating gel prepared
as follows.
The separating gel was prepared by mixing 15 ml of lower gel buffer (1.5 M Trisbase,4 Vo
SDS, pH 8.8), 15 ml of a4O7o solution of acrylamide (w/v) (17-1303-01, Pharmacia,
Biotech), 8 ml of 27o methylene-bis acrylamide (w/v) solution (17-1306-01, Parmacia,
Biotech), 22 mI of water, 105 ¡"rl of tetramethylethylenediamine (TEMED) and 105 ¡.tl of I07o
solution of ammonium persulphate (APS). The separating gel solution was poured between
the sandwiched glass plates and overlaid with water. After polymerization the water was
aspirated. The stacking gel, which was prepared by mixing 5 ml of upper gel buffer (0.5 M
Tris base, 4% SDS, pH 6.8), 2.2m1of 407o (w/v) acrylamide, L2 ml of 27o (w/v) methylene-
bis acrylamide, 1 1.6 ml of water, 100 ¡"ú of IOTo APS (w/v) and 20 pl of TEMED, was poured
over the separating gel and a 10 well comb was inserted. After polymerisation of the stacking
gel the comb was removed and the wells were filled with running buffer (0.025 M Tris base,
0J92 M glycine and I7o SDS).
Included on each gel were Rainbowru [laC] methylated protein molecular weight markers
I4.3 to 220k<Da (cat CFA 756, Amersham Life Science, Buckinghamshire, England)
RainbowrM ¡14C1 was diluted I in 2 with 4 x SDS loading buffer and aliquots of 10 pl are
frozen at -20oC for routine use. A pooled guinea pig plasma sample, made up of equal
volumes of plasma from all treatment groups and divided into 50 pl aliquots, was also stored
at -20"C and included on each gel. The molecular weight of IGFBPs was estimated by
comparison with the electrophoretic mobility of the Rainbowru standards. Electrophoresis
was performed for 2 hours at 20 mA followed by 18 hrs at 8 mA in running buffer.
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The proteins were transferred onto nitrocellulose membranes (0.45 pm) by electroelution
(Schleicher and Schuell, Dassel, Germany) at250 mA for 3.5 hours in tris/glycine buffer (0.2
M Tris base, 0.15 M glycine and20Vo ethanol v/v). Nitrocellulose membranes were prepared
by shaking for 30 mins in 250 ml of washing buffer (2 M NaCl, 0.5 M Tris base) containing
lVo (vlv) Triton X-100 before use.
Following electroelution membranes were incubated rn250 ml of washing buffer containing
1gll bovine serum albumin (BSA) for 90 mins at 2IoC, shaking at 160 rpm. The membranes
were then soaked for 10 mins in washing buffer containing O.IVo(vlv) Tween. Radiolabelled
t2sI-IGF-tr (10,000,000 cpm) was added to 250 ml of washing buffer containing 1 g/l of BSA
and the membranes were incubated for 2.5 hours, shaking at 160 rpm at 23oC. Membranes
were then washed for 30 mins x 3 with fresh wash buffer containing 0.I7o (vlv) Tween.
Membranes were airdried overnight at23oC and were exposed at -80oC with intensifying
scfeens to duplicate Fujifilm X-ray film (RX, Fuji Photo Film Co, Ltd, Tokyo). One was
exposed for one week to measure IGFBP-3 and the other was exposed for two weeks to
measure the other IGFBPs. The X-ray films were scanned (Image Quant, version3.22,
Computing Densitometer, model 3004, Molecular Dynamics, Sunnyvale, CA) and the density
of each electrophoretic band was measured and expressed as a 7o of the corresponding band in
the pooled guinea pig plasma reference that was included in all gels and blots.
3.2.4 Isolation of RNA
Total RNA was extracted from livers of 35 guinea pigs as described in section 2.2.2. These
extractions were performed over 4 days. RNA was extracted from a designated reference liver
on each day and livers from each of the treatment groups were extracted each day. Extraction
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of RNA from 9 experimental livers and the reference liver was performed on days 1 and 4 and
from 8 experimental livers and reference liver on days 2 and 3. Tissue pieces used for RNA
extraction ranged from 81 to 322 mg wet weight. The integrity of RNA for each liver extract
was assessed as described in section2.2.2. Two ¡rl of loading buffer was added to 20 ¡rl of
RNA (2 þg) in molecular grade water and 11 pl was loaded per well of an agarose gel which
was equivalent to 1 ¡"lg of RNA per liver. Ten pl of a RNA marker, 0.363 kb to 9.5 kb (cat no.
]lr_76200, Scientific Imaging Systems, Eastman Kodak Co., New Haven, CT), was loaded into
one well per gel. The density of the 28S and 18S ribosomal RNA was quantified by
comparison with the density of the 3.9II kb fragment of the RNA size markers after staining
with ethidium bromide and LIV transillumination.
Each RNA extract was divided into two aliquots, one stored at -80oC in ethanol and the other
in aqueous 5 M NaCl as described in section 2.2.2. The second aliquot was further diluted
with molecular grade water to a final concentration of 0.I ¡tglþI and stored at -80oC. The
diluted RNA solutions were used for reverse transcription to produce cDNA.
3.2.5 Reverse Transcription of RNA from experimental guinea pig livers
Reverse transcription was performed as describedin2.2.3 in duplicate batches containing
each test and control RNA. 4110.1 W11þIRNA solutions were thawed on ice simultaneously
and20 pl of the RNA solution (equivalent to 2 ¡t"g of RNA) was transferred to 0.5 ml flat cap
PCR tubes (cat no. 13320-00 Astral Scientific, Gymea, NSW). After the addition of 2 ¡rl of
random hexamers (100 pglml) (section 2.2.3) in sterile water the tubes were incubated at 65oC
for 10 mins then placed on ice for 5 mins. A master mix sufficient for 42 reactions (168 pl of
100 mM dithiothreitol,336 pl of 5 x cDNA synthesis buffer (250 mM Tris-HCl, 200 mM
KCl, 25 mM MgCl z,2.5ZoTween*20, pH 8.3), 168 pl of 10 mM dNTPs and 84 prl of
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ExpandrMRT enzyme) was prepared. After cooling, 18 ¡rl of the master mix was added per
tube. A negative control was also included which contained water instead of RNA. The
reaction solutions were then heated to 30oC for 10 mins, 42oC for 45 mins followed by 95"C
for 2 mins. The reaction solutions were placed on ice and diluted to 160 ¡rl by addingI20 ¡t"l
of molecul ar grade water. The cDNA preparations were then stored at -ZOoC. These reverse
transcribed products are designated cDNAr. The above reverse transcription was repeated for
all RNA solutions on a separate day, resulting in duplicate cDNA preparations (designated
cDNAz) for each liver RNA extract. The solutions of RNA were frozen and thawed once for
the duplicate RT (cDNAz).
3.2.6 Dig-labelling of IGF-I and B-actin cDNA from guinea pig liver by PCR
All cDNAr solutions were subjected to digoxigenin labelling PCR. Ten pl of cDNA
preparation from each liver (equivalent to 0.125 pg of RNA) was added to flat cap PCR tubes.
Molecular grade water (10 pl) replaced oDNA as negative controls. Forty ¡ll of a solution
sufficient for 44 reactions containing 110 pl of 2mMDigoxigenin-dNTPs, 176 ¡A of 25 mM
MgCl2, 220 ¡tl of 10x Taq reaction buffer, 220 ¡il of gpIGF-I31e oligonucleotide primer (5
¡rmol), 220 ¡*lof gpIGF-I5a5 oligonucleotide primer(5 pmol), 220 ¡tl Taq Polymerase 0'2
U/¡rl and 594 ¡tl of molecular grade water was added to each PCR tube. PCR reactants were
heated to 94oC for 3 mins followed by 24 repeated cycles of denaturation at 94"C for 15 secs,
annealing at 58oC for 15 secs, extension at T2oCfor 45 secs. A final extension atT2oCfor 5
mins was performed after 24 cycles and the products were frozen at -2O"C. IGF-I cDNA
products from cDNAr are referred to as dig-IGF-I1 Digoxigenin labelling of IGF-I cDNA was
performed on duplicate oDNA2 reverse transcription product, referred to as dig-IGF-I2.
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Amplification and dig-labelling of B-actin cDNA was also performed. Molecular grade water
(10 pl) was substituted for cDNA as a negative control and 10 pl of the reverse transcribed
water solution (RT negative control) was also included in the PCR batch. Forty pl of a
solution sufficient for 44 reactions containing 110 ¡rl of 2mMOigoxigenin-dNTPs, 176 ¡tl of
25 mM MgClr, 220 ¡tI of 10x Taq reaction buffer, 220 ¡tI of rp-actin¡a56 oligonucleotide
primer (5 pmol), 220 ¡tl of rB-actin22el oligonucleotide primer (5 pmol), 220 ¡tlTaq
Polymerase 0 .2 U lþl and 594 pl of molecular grade water was added to each PCR tube. PCR
reactants were heated to 94oC for 3 mins followed by 2l repetitive cycles of denaturation at
g4oCfor 15 secs, annealing at 58oC for 15 secs, extension at l2oCfor 45 secs. A final
extension atJZ,C for 5 mins was performed after 21 PCR cycles and the products were stored
at -20oC. Digoxigenin labelled B-actin cDNA products are denoted dig-B-actinl or dig-B-
acttn2 depending on whether they originated from reverse transcription products cDNAI and
cDNA2 respectively. The relative abundance of IGF-I mRNA in guinea pig livers was
expressed as the ratio of dig-IGF-I to dig-B-actin cDNA products derived from RNA extracted
from the same liver. Figure 3.2 summarises steps 3.2.4 to 3.2.1 .
3.2.7 Measurement of guinea pig hepatic IGF-I and B-actin DigJabelled cDNA by
enzyme linked immunosorbent assay
Frozen dig-labelled IGF-I cDNAr and negative controls were thawed on ice and diluted 1:25
with ELISA solution containing biotinylated IGF-I oligonucleotide (section2.2.9). The
nixtures were firstly heated at94oC for 10 mins, then hybridisation of the biotinylated IGF-I
capture oligonucleotide (section2.2.9) to the dig-labelled IGF-I cDNA was permitted at 60oC
for 10 mins followed by cooling to 23uC for 10 mins. Once cooled,2OO pl aliquots of each
solution were added in duplicate to wells of a streptavidin-coated microtitre plate. Serial
dilutions of quantitated standards for dig-labelled IGF-I (section 2.2.9.) were included. The
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standarddigJabelledIGF-I (0.25,0.5, 1,2,4¡;Jof 13.2 ng/pl) was dilutedinELISA solution
and allowed to hybridise to the biotinylated IGF-I oligonucleotide as above. Section 2.3.8
describes the quantitation of the dig-IGF-I ELISA standards. The diluted digJabelled
standards (200 pl) were added to the plate in duplicate. On each microtitre plate duplicate
wells containing 200 pl of ELISA solution only (blank) were also added. After standards,
unknowns and controls are added to the microtitre plate wells, the plate was covered and
incubated at37oC for 3 hrs shaking at 160 rpm. The plate was washed 3 times with wash
buffer (section 2.2.9). The anti-digoxigenin-antibody polyperoxidase conjugate was diluted
I:3750 in conjugate buffer (section 2.2.9),200 pl added per well and incubated at 37oC for 30
mins shaking at 160 rpm. The micotitre plate was washed 3 times with wash buffer. Two
hundred pl of ABTS solution (section 2.2.9) was added per well and incubated in the dark at
37oC for 30 mins shaking at 160 rpm. Dig-IGF-Iz cDNA products were measured as
described above. Dig-B-actinl and dig-B -actin2 cDNA products were measured as above
except a biotinylated gp B-actin oligonucleotide (section 2.2.9) was used at 50 nglml. The
spectrophotometric absorbance was measured at 405 nm. The relative abundance of IGF-I
mRNA was expressed as a ratio of dig-IGF-I / dig-p-actin cDNA products derived from the




Figure 3,2. FIow chart representing the processing of all liver samples from RNA
extraction to RTPCR and DIG ELISA for the quantitation of IGF-I nRNA and p-actin
mRNA.
Total RNA was extracted from 31 liver samples. RNA (2uÐ extracted from each liver was
reverse transcribed (RT) twice in independent reverse transcription batches. Each RT product
oDNAI or oDNA2 was subjected to PCR amplification with digoxigenin-nucleotide
triphosphates to produce dig-B-actin1, dig-p-actin2, dig-IGF-I1 and dig-IGF-I2 Dig-B-actin
cDNA products were measured in two DIG F-actin ELISAs. Dig-IGF-I oDNA products were
quantified in two DIG IGF-I ELISAs. The average of dig-IGF-I1 and dig-IGF-I2 and dig-B-
actinl and dig-B-actin2 were used to determine the amounts of digJabelled PCR products
derived from each liver RNA extract.
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3.2.8 Statistics
Data are presented as mean t sem. The effects of pregnancy, nutrition and their interaction
were assessed by two way ANOVA. Comparison between experimental groups was
performed using Student-Newman-Keuls Method. Associations were evaluated by
polynomial regression (SigmaStat, Jandel, San Raael, CA, USA). The effect of pregnancy
and nutrition on plasma IGF-I was assessed by one way ANOVA. The effect of nutrition on
fetal and placental weights \ryas assessed by one ìway ANOVA. Pearson product moment
correlation was employed to measure the parametric strength of associations between two
variables. Co-variate analysis was performed using forward stepwise linear regression to
identify the independent variables. Multiple linear regression was then performed to best
describe the data when two or more variables were identified. Simple linear regression was
used when one independent variable was identified. The software package used for all
analyses was SigmaStat (Jandel Scientific, San Raael, CA, USA).
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3.3 RESULTS
3.3.1 Maternal and fetal phenotype
AduIt
Pregnancy did not increase food intake (as a fraction of body weight) in ad libitumfed guinea
pigs compared to nonpregnant animals as previously reported (Sohlstrom et al., 1998) (dta not
shown). Pregnancy increased body weight (p<0.001) in ad libitum fed and feed restricted
guinea pigs (Table 3.1). Feed restriction reduced body weight (p<0.001) in pregnant and
nonpregnant guinea pigs (Table 3.1). Maternal net body weight (total body weight minus that
of the uterus, fetuses and placenta), net weight gain (total weight gain minus the weight of the
uterus, fetuses and placenta for pregnant animals) and carcass weight (eviscerated carcass) and
carcass fractional weight (expressed as a 7o of body weight) were lower in feed restricted
pregnant and nonpregnant animals (p<0.001). Pregnancy increased weight gain (weight
gained from day 1 to day 60 of pregnancy) in ad libitum and feed restricted guinea pigs
(p<0.001). Undernutrition decreased weight gain (p<0.001) in nonpregnant and pregnant
animals.
Pregnancy increased absolute uterine weight (consisting of uterus, fetuses and placentae) and
fractional uterine weight expressed both as a7o of body weight (p<0.001) and of carcass
weight (p<0.001) (Table 3.2). Undernutrition significantly decreased absolute uterine weight
in pregnant animals and fractional uterine weight expressed either as a 7o of body weight
(p<0.005) or as a 7o of carcass weight (p<0.001) (Table 3.2). Liver weight (p<0.001) was
lower in feed restricted pregnant and nonpregnant animals. Undernutrition decreased the
























505.6 + 19.6 951 .4 + 2r.9 656.8 !2t.9
504.8 ! r1.t 712.6 + 19.1 541.3 r 19.1
t9.1 + lr.1 383.5 + 13 t36.4+ 13
18.9 + r2.3 138.1 + l3.l 26.9 + 13.7
244.2+ 9.5 361.6 + 10.7 251.2+ 10.1




F x P p<0.01
F p <0.001
F p <0.001
F p = o.oo5
Table 3.1 Effect of pregnancy and nutrition on maternal phenotype. Expressed as mean * sem. Effects of treatment were assessed by two-way ANOVA with pregnancy
status and nutritional regimen as between factors. All pairwise multiple comparison procedures were performed by Student-Newman-Keuls Method. Net body weight
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F p<0.001, P p<0.001
F x P p<0.001
F p<0.005, P p<0.001
F x P p<0.005
F p<0.001, P p<0.001
F x P p<0.001
F p<0.001







Table 3.2Effect of pregnancy and feed availability on maternal tissue weights. Expressed as mean * sem. Effects of treatment were assessed
by two-way ANOVA with pregnancy status and nutritional regimen as between factors. All pairwise multiple comparison procedures were


































Retroperitoneal fat 1.41+ 0.4
Dorsal fat* 11.8 + 0.75
F p<0.0001
F x p<0.0001
F x P p<0.05
FxPp<0.02
F p<0.0001
P p<0.0001, F p<0.0001
P x F p<0.05Thymus 0.48 + 0.03 0.29 
+ 0.02
Soleus muscle 0.36 + 0.01 0.29 + 0.01 0.39 + 0.01 0.32+0.01 Fp<0.005,Pp<0.0001
Table 3.3 Effect of pregnancy and feed availability on maternal tissue weights. Effects of treatment were assessed by two-way ANOVA with
pregnancy status and nutritional regimen as between factors. All pairwise multiple comparison procedures were performed by the Student-







this effect was smaller in dorsal fat of pregnant animals (Table 3.3). Pregnancy decreased
total gastrointestinal tract weight in ad libitum fed animals only. Feed restriction increased
total gastrointestinal tract weight in pregnant guinea pigs but not in nonpregnant animals.
Pregnancy decreased thymus weight in ad libitum andfeed restricted animals. Undernutrition
(p<0.0001) decreased thymus weight in both pregnant and nonpregnant animals but this effect
was smaller in pregnant guinea pigs. Pregnancy (p<0.0001) increased soleus muscle weight in
feed restricted guinea pigs. Undernutrition (p<0.005) reduced soleus muscle weight in
nonpregnant animals.
Fetus and placenta
Total fetal weight (total weight of fetuses per dam), total placental weight (total weight of
placentae per dam), average fetal weight (mean weight of fetuses per dam), average placental
weight (mean weight of placentae per dam) and average fetal to placental weight ratio (mean
weight of fetuses per dam divided by the mean weight of placentea per dam) were positively
correlated with pregnant uterine weight in ad tibitum andfeed restricted guinea pigs combined
(Figure 3.3). Undernutrition decreased average fetal weight (p<0.001), average placental
weight (p<0.001) and average fetal to placental weight ratio (p<0.005) (Table 3.3). Total fetal
weight was twice as high in ad libitumfedmothers, although litter size was unaffected in my
study. Total placental weight was reduced in feed restricted animals (Table 3.4). Ad libitum
feeding increased average fetal weightby 677o, average placental weight by 367o,total'
placental weight by 92Vo and average fetal to placental weight ratio by 217o. Total fetal
weight expressed as a fraction of total maternal body weight or carcass weight and total
placental weight as a fraction of total body weight were higher in the ad libitum fed mothers
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Figure 3.3 Relationship between pregnant uterine weight'
fetal and placental weights.































Table 3.4 Effect of nutrition on fetal and placental weights at day 60 of pregnancy'
Values are mean -f sem. Data were analysed by one-way ANOVA with nutrition as the
between factor.
Ad libitum fed, Restricted p value
Total fetal weight as Vo 54.5 ! 4.I
carcass
Total placental weight, g t2.9 t0.9
Total uterine weight
Fetuses per dam
Total fetal weight, g
Total fetal weight as 7o
body weight
Total placental weight as
Vobody weight































Average fetal weight, g 69.7 + 1.9
Average placental weight, g 4.5 + 0.18
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3.3.2 Effect of pregnancy and nutrition on circulating IGF-I and IGF-II
Concentrations of IGF-I in adult plasma ranged from32 to 923 nglml. Plasma IGF-I was
increased by pregnancy (p<0.00I) in ad libitum fed animals. Undernutrition decreased plasma
IGF-I in pregnant guinea pigs only (p<0.001) (Figure 3.4). Plasma IGF-tr concentrations were
unaffected by pregnancy, but undernutrition reduced IGF-tr by = 50Eo in both pregnant and
non-pregnant animals (Figure 3.5).
3.3.3 Effect of pregnancy and nutrition on circulating IGFBPs
Pregnancy increased plasma IGFBP-1 in feed restricted but not ad libitum fed animals.
Undernutrition decreased plasma IGFBP-I in nonpregnant guinea pigs but increased IGFBP-I
in pregnant animals. Pregnancy increased plasma IGFBP-2 in nutritionally restricted animals
only. Feed restriction increased IGFBP-2 in pregnant animals only. Plasma IGFBP-3 was
unaffected by pregnancy, but was reduced by more than 5O7o by undernutrition in pregnant
and nonpregnant animals (Figure 3.6). Pregnancy increased IGFBP-  in ad libitum fed and
feed restricted animals (Table 3.5). Nutrition had no effect on IGFBP-4. IGFBP-3 proteolytic
activity was not observed after mixing plasma from nonpregnant guinea pigs with plasma
from pregnant guinea pigs.
3.3.4 Effect of pregnancy and nutrition on the ratio of IGF to IGFBPs
Pregnancy increased the ratio of IGF-I to IGFBP-I in ad libitumfed animals but decreased
this in feed restricted guinea pigs. Undernutrition decreased the ratio of IGF-I to IGFBP-I in
pregnant animals only. Pregnancy increased the ratio of IGF-I to IGFBP-2 in ad libitum fed
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animals and was decreased in feed restricted guinea pigs (Table 3.6). Feed restriction reduced
the ratio of IGF-I to IGFBP-2 in pregnant, but not in nonpregnant animals.
Pregnancy increased the ratio of IGF-I to IGFBP-3 in ad libitum fed animals. Nutritional
restriction decreased the ratio of IGF-I to IGFBP-3 in pregnant animals only. Pregnancy had
no effect on the ratio of plasma IGF-I to plasma IGFBP-4. Undernutrition reduced the
circulating ratio of IGF-I to IGFBP-4 in pregnant and nonpregnant animals.
Pregnancy decreased the ratio of plasma IGF-tr to IGFBP-1 in feed restricted animals only.
Undernutrition reduced the circulating ratio of IGF-tr to IGFBP-I in pregnant but not in
nonpregnant guinea pigs. The ratio of IGF-tr to IGFBP-2 was unaffected by pregnancy. Food
restriction decreased the ratio of IGF-tr to IGFBP-2 in pregnant and nonpregnant animals.
The ratio of plasma IGF-tr to IGFBP-3 was unaffected by pregnancy or nutrition. Pregnancy
decreased the ratio of IGF-tr to IGFBP-4 in ad libitum and feed restricted animals.































IGFBP-I, 7o of reference





F x P p<0.005
Fp<0.001,Pp<0.001
F x P p<:O.O2
IGFBP-3, 7o of reference 2t1 + t4 90!12 223 + 16.7 101 + 11 F p <0.001
IGFBP-4, 7o of reference 145 + 43 tzr + 14 2r5 + 23.6 306+ 63 P p<0.005
Table 3.5 Effects of pregnancy and feed availability on IGF endocrine variables. Results expressed as mean * sem. Effect of treatment was
assessed by two-way ANOVA with pregnancy status and nutritional regimen as between factors. # indicates effects of treatments were

































F x P p<0.001
F p <0.001
F x P p<0.005
P p<0.02
F x P p<0.05
p
lrGF-Il/tIGFBP-31 2.3 + 0.4
trGF-II/[IGFBP-4] 2.6 + 0.6 r.1 + 0.4 3.6 r 0.5 1.4 + 0.5 F p <0.005
lrGF-rIl4rGFBP-11 7.5 + r.5 8.6 + 1.0 1.1 + r.2 2.7 + t.2
P p <0.05
F x P p<0.05
F p<0.001
UGF-III/[IGFBP-2] 18.9 + 2.4 8.1 + 1.7 16.5 r 1.9 3.t + r.9
[rGF-III/IIGFBP-3] 7.4+1.1 9.8 + r.2 7.5 + r.3 8.2+ L.3
lrGF-III/[IGFBP-4] r4.9 + 2.0 6.1 + r.5 8.0 + 1.6 3.8 + 1.6 P p<0.01, F p<0.002
Table 3.6 Effects of pregnancy and feed availability on the ratio of the concentration of IGFs to IGFBPs. Treatment was assessed by two-way
ANOVA with pregnancy status and nutritional regimen as between factors.



















Figure 3.4 Effect of pregnancy and nutrition on plasma IGF-I in guinea pigs.
Animals were provided ad libitum(HlcH) or restricted (LOW) Írccess to feed,
Different letters depict the one-way ANOVA results p<0.001.
















Figure 3.5 Effect of pregnancy and nutrition on plasma IGF-II in guinea pigs.
Animals were provided ad libitum (HIGH) or restricted (LOW) access to feed.
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Figure 3.6 Effect of pregnancy and nutrition on plasma IGFBPs in guinea pigs.
Animals were provided ad libitum (HIGH) or restricted (LOW) access to feed,
Different letters depict two-way ANOVA results, p values are on each graph.
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3.3.5 Effect of pregnancy and nutrition on total RNA content of liver
Guinea pig liver RNA extracted from all experimental tissues had intact 18S and 28S
ribosomal RNA subunits with minimal degradation (Figure 3.7). None of the RNA extracted
from guinea pig livers was excluded from the study.
The total amount of RNA per liver was calculated by:
Total liver RNA (mg) = RNA yield (mg/g) x liver weight (g)
There were no differences in the yield of RNA mg/g of tissue from any of the treatment
groups (Figure 3.8). The amount of total liver RNA in ad libitum fed pregnant (49.2 ! 4 ^g)
and nonpregnant guinea pigs (45.6 + 5.06 mg) was significantly greater (p<0.0001) than in
food restricted pregnant (30.8 t 4 mg) and nonpregnant (26.4 + 3.58 mg) guinea pigs
Ad libitum nutrition increased total liver size and total RNA content but not RNA content per
g of tissue when compared to feed restriction. The mean yield of RNA extracted from the
control liver (Figure 3.8) in the four RNA batch extractions was (1.08 + 0.18 mglg), a










Figure 3.7 Agarue gsl geú{roptrorcsis of total R¡{A
from a rrcpresentative nunber of guinea pig livers
fuarose gel elecftophoresis of 1 pg of total RI.{A from gllnea ptg fivers.
RI.{A from feed resfticted pregnant anirnals are in lanes 2, 6 ü1d7, fd
resfricted nonpegnant animals are in lanes 3,4 arñ,s, adlibinmfd
pregnant aninnls are in lanes 8 and 9 arñadliWtwnfed nongegnant
















































3.3.6 Effect of pregnancy and nutrition on the relative abundance of IGF-I mRNA
Duplicate analyses of IGF-I mRNA and B-actin mRNA, which included reverse transcription,
PCR and Dig-ELISA, were highly correlated (IGF-I, r = 0.77 , p<0.001, B-actin, r = 0.86,
p<0.001) (Figure 3.9). Therefore the average of the duplicate analyses were used in the
quantitative estimation of IGF-I and B-actin PCR products.
The relative abundance of IGF-I mRNA, expressed as the ratio of IGF-I to B-actin RT-PCR
products in cDNAr and cDNA2 was highestin ad libitum fed pregnant guinea pigs (Figure
3.10). Pregnancy and food availability significantly affected hepatic expression of IGF-I
(Table 3.7) whether this was expressed as relative abundance or total abundance (ie relative
abundance multiplied by liver weight or fractional liver weight). Pregnancy had a greater
effect than nutrition on abundance of hepatic IGF-I mRNA. Relative abundance of hepatic
IGF-I mRNA was almost 6-fold higher in pregnant ad libitum fed guinea pigs than in
nonpregnant ad libitum fed guinea pigs.
3.3.7 Relationship between maternal plasma IGF-I and relative abundance of hepatic
IGF-I mRNA
Plasma IGF-I was positively correlated with the relative and total abundance of IGF-I mRNA
in liver in pregnant and ad libitum fed, but not feed restricted guinea pigs (Table 3.8).
Polynomial regression analysis showed the overall relationship between the concentration of
IGF-I in plasma and the relative abundance of IGF-I mRNA in liver (r2 = 0.68, p<0.002) to be














































X'igure 3.9 Repeatability of Dig-ELISA RT-PCR measurements



























Figure 3.10 Relative abundance of hepatic IGF-I nRNA.
Animals were provided unrestricted (HIGH) or restricted (LOW)





























IGF-I mRNA/B-actin x liver
weight
IGF-I mRNA/B-actin x liver




Table 3.7 Effects of pregnancy and feed availability on the relative abundance of IGF-I mRNA. Results expressed as mean * sem. Effect of


















Figure 3.11 Correlation between plasma IGF-I concentration and
relative abundance of hepatic IGF-I mRNA.
Plasma IGF-I was positivelly correlated (r2: 0.68, p<0.002) with the relative
abundance of hepatic IGF-I mRNA.









3.3.8 Relationship between the relative abundance of hepatic IGF-I mRNA and tissue
weights
Table 3.9 and Table 3.10 shows the Pearson correlation coefficients between weights of
tissues and the relative abundance of hepatic IGF-I mRNA. Combining data from all
treatment groups (n = 28) the relative abundance of IGF-I mRNA in liver was positively
correlated with body weight, body weight gain and uterine weight, both as a7o of body weight
and carcass weight. Relative abundance of IGF-I mRNA was also positively correlated with
net body weight, net weight gain and weight of carcass and liver.
In pregnant animals (n = 15) the relative abundance of IGF-I mRNA was positively correlated
with body weight, weight gain, net weight gain, net body weight and uterine weight both as a
7o of body weight and carcass weight (Table 3.9,3.10, Figure 3.I2). Relative abundance of
hepatic IGF-I mRNA did not correlate with carcass weight or liver weight inpregnant, ad
libitumfed or feed restricted guinea pigs. In nonpregnant guinea pigs, liver IGF-I mRNA
correlated with liver weight and liver as a7o of carcass weight, but was not related to carcass
weight.
In all ad tibitum fed animals, hepatic expression of IGF-I was positively correlated with
weight gain (Table 3.9), uterine weight, and uterine weight as a 7o of body weight or as a 7o of
carcass weight (Table 3.10). IGF-I mRNA in feed restricted guinea pigs was positively
correlated with weight gain, uterine weight and uterine weight as aVo of body weight or as a
7o of carcass weight. The relative abundance of IGF-I mRNA in liver of ad libitum fed and
feed restricted guinea pigs was not significantly correlated with absolute weight of liver
(Table 3.10).
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Weights of retroperitoneal fat, dorsal fat, spleen and soleus muscle were positively correlated
overall (n = 28) to the relative abundance of hepatic IGF-I mRNA (Table 3.11).
In pregnant animals (n = 15) the weights of retroperitoneal fat, dorsal fat, spleen and thymus
were positively associated with relative abundance of hepatic IGF-I mRNA (Table 3.11).
Total gastrointestinal tract weight and soleus muscle weight, were not related to hepatic IGF-I
mRNA in pregnant dams. Hepatic IGF-I mRNA was not related to weight of any tissues in
the nonpregnant animals (n = 13). Relative abundance of IGF-I mRNA was negatively
correlated with retroperitoneal fat weight in ad libitum led guinea pigs (n = 11). In
nutritionally restricted animals (n = 17) hepatic IGF-I was negatively correlated with thymus
weight only.
3.3.9 Relationship between plasma IGF-I and IGF-II and tissue weights.
Table 3.I2,Table 3.13 and Table 3.14 show the Pearson correlation coefficients between
weights of maternal tissues and the concentrations of plasma IGF-I. For all data combined (n
- 31), plasma IGF-I was positively correlated with body weight, net body weight, weight gain,
net weight gain and carcass weight. Plasma IGF-I was positively correlated with uterine
weight and uterine weight as a 7o of body weight and as a 7o of carcass weight, liver weight,
retroperitoneal fat weight, dorsal fat weight, spleen weight and soleus muscle weight. In
pregnant and ad libitum fed animals plasma IGF-I was positively correlated with body weight,
weight gain, uterine weight (Figure 3.t2), uterine weight as aVo of body weight and as aVo of
carcass weight, soleus muscle weight and thymus weight.
In pregnant animals, maternal IGF-I was positively correlated with net body weight, net





















































Table 3.8 Associations between plasma IGF-I and abundance of hepatic IGF-I mRNA.






































Figure 3.12 Effect of nutrition on the relationships between uterine


















Relative abundance of IGF-I mRNA
Overall Pregnant Non pregnant Ad libitum fed Restricted
n=28 n=15 n=13 n=11 n=I7
Body weight 0.68,p <0.0001 0.61,P = 0.01 0.52, NS 0.46, NS 0.54, p = 0.02
Net body weight 0.48,p <0.01 0.54,p = 0.03 0.51, NS -0.38, N,S 0.28, NS
Weight gain 0.74, p <0.0001 0.69, p <0.01 0.52, NS 0.61,P =0.04 0.64, P <0.01
Net weight gain 0.47, p =0.01 0.58, p =0.02 0.52, NS -0.34, NS 0.22, NS
Carcass weight 0.47, P= Q.Q1 0.49, NS 0.36, NS -0.37, NS 0.06, NS
Carcass as % ofbody
weight
-0.43, NS -0.12, NS -0.37,N50.29, NS0.23, NS
Table 3.9 Associations between the relative abundance of hepatic IGF-I mRNA with body phenotype. Pearson correlation coefficients r are
tabulated and p is significant at p<0.05. Pregnant and nonpregnant groups include both ad libitum fed and feed restricted animals. The ad










Liver as 7a of body
weight















Uterus, g 0.J, p < 0.0001 0.62, p = 0.01 0.18, NS
Uterus as 7o of bodY
weight
0.67, p < 0.0001 0.56, p = 0.02 -0-23, NS
uterus as vo of carcass 0'65, p <0'0001 0'52' p = 0'04 -0'12' NS
0.6,p=0.04 0.57,p=0.01
0.63, p =0.03 0.56, p =0.01
0.65, p =0.02 0.56, p = 0.01
0.4, p = 0.03 0.49, NS
0.02, NS 0.16, NS
-0.13, NS -0.06, NS
0.56, P = 0.04 -0.57, NS
0.42, NS -0.55, N,S
0.63, P = 0.02 -0.34, NS
Table 3.10 Associations between relative abundance of hepatic IGF-I mRNA with tissue weights and plasma IGF-I. Pearson




Relative abundance of IGF-I mRNA
Tissue weight Overall Pregnant Non pregnant Ad libítum fed. Restricted
(g) n=28 n=15 n=13 n=11 n=17
Retroperitoneal fat 0.45, P<0-02 0.52, p<0.05 0.45, NS -0.64, p<0.05 0.06, NS




-0.25, NS -0.3, N,S -0.29, NS -0.05, NS
0.22, NS
0.22, NS
0.6, p<0.001 0.74, p<0.002 0.47, NS -0.11, NS
Thymus 0.29, NS 0.66, p<0.01 0.39, NS -0.45, NS -0.49, p<0.05
Soleus muscle 0.57, p<0.002 0.5, N^S 0.45, NS 0.14, NS 0.23, NS
Table 3.11 Associations between the relative abundance of hepatic IGF-I mRNA and weights of tissues. Pearson correlation coefficients









Overall Pregnant Non pregnant Ad libitum fed, Restricted
n=31 n=L6 n=L5 n=13 n=18
Body weight 0.82, p < 0.0001 0.87, p < 0.0001 0.44, NS 0.84, p < 0.001 0.4, NS
Net body weight 0.59, p < 0.0001 0.78, p< 0-001 0.44, NS -0.27, NS 0.39, NS
Weight gain 0.82, p<0.0001 0.87, p<0.0001 0.3tNS 0.87, p < 0.0001 0.26, NS
Net weight gain 0.45, p = 0-01 0.67, p < 0.01 0.J5, N,S -0.51, NS 0.06, NS
Carcass weight 0.6, p < 0.001 0.74, p =.001 0.46, NS -0.13, NS 0.31, NS
Carcass as 7o of body 0.32, NS
weight
0.24, NS 0.17, NS -0.14, NS0.4, NS









Tissue weight Overall Pregnant Non pregnant Ad libitum fed Restricted
(g) n=31 n=16 n=15 n=13 n=18
Uterus, g 0.78, p < 0.0001 0.84, p < 0.0001 0.4, NS 0.91, p < 0.0001 0.26, NS
Uterus as 7o of body
weight
0.72, p < 0.0001 0.75, p < 0.001 0.12, NS 0.9, p < 0.0001 0.27, NS
Uterus as 7o of
carcass weight
0.7, p<0.0001 0.74, p<0.01 0.07, NS 0.91, p<0.0001 0.26, NS
Liver, g 0.52, p < 0.01 0.83, p < 0.0001 0.39, NS -0.48, NS 0.49, p = 0.03
Liver as 7o of body
weight
0.18, NS 0.49, P = 0.04 0.18, NS -0.56, P = 0.04 0.25, NS








0.15, NS -0.01, NS -0.49, NS





Retroperitoneal fat 0.56, p<0.002 0.84, p<0.0001 0.21, NS -0.37, NS 0.01, NS
Dorsal fat 0.54, p<0.002 0.81, p<0.0001 0.26, NS -0.3, NS 0.07, NS
Total gastrointestinal -0.29, NS
tract
-0.57, p<0.05 0.42, NS
Spleen 0.56, p<0.001 0.82, p<0.0001 0.32, NS -0.03, NS 0.08, NS
Thymus 0.33, NS 0.87, p<0.0001 0.42, NS -0.73, p<0.005 0.26, NS
Soleus muscle 0.73, p<0.0001 0.78, p<0.0001 0.37, NS 0.55, p<0.05 0.32, NS


















negatively correlated with total gastrointestinal tract weight. In ad libitum fed animals, liver
as a Vo of body weight and thymus were negatively correlated with plasma IGF-I. In feed
restricted animals only liver weight was positively correlated with circulating levels of IGF-I
Tables 3.I5,3.16 and3.L7 shows the Pearson correlation coefficients between weights of
maternal tissues and the concentrations of plasma IGF-tr. For all data combined (n =31),
plasma IGF-tr was highly positively correlated with body weight, net body weight, weight
gain, net weight gain and carcass weight (Table 3.15).
Plasma IGF-tr was positively correlated with uterine weight, liver and with the weights of
retroperitoneal fat, dorsal fat, spleen, soleus muscle and thymus (Table 3.16,3.I7). In
pregnant and nonpregnant animals circulating IGF-tr was positively correlated with body
weight, net body weight, weight gain, net weight gain and carcass weight, uterine weight and
liver weight (Table 3.15, 3.16). Plasma IGF-tr was positively correlated with the weights of
retroperitoneal fat, dorsal fat, spleen, soleus muscle and thymus (Table 3.I7). In pregnant
animals, plasma IGF-tr was positively correlated with uterine weight as a 7o of body weight
and negatively related to total gastrointestinal tract weight. In nonpregnant animals liver as a
7o of body weight was correlated with plasma IGF-tr. Plasma IGF-tr was not related to
maternal body weights or tissue weights in ad libitum fed or feed restricted animals.
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Plasma IGF-II ng/ml
Body weight 0.72, p < 0.0001 0.78, p < 0.0001 0.92, p<0.0001 -0.009, NS 0.29, NS
Net body weight 0.79, p < 0.0001 0.75, p< 0.001 0.92, p<0.0001 0.06, NS
Weight gain 0.67, p<0.0001 0.74, p<0.002 0.89, p<0.0001 0.02, NS
Net weight gain 0.7, p< 0.001 0.75, p< 0.001 0.92, p<0.0001 0.15, NS
Carcass weight 0.77, p < 0.0001 0.68, p<0.005 0.9, p<0.0001 -0.07, NS 0.23, NS
















0.24, NS 0.18, NS -0.28, NS








Tissue weight Overall Pregnant Non pregnant Ad libitum fed Restricted
(g) n=31 n=16 n=1,5 n=13 n=18
Uterus, g 0.4, p < 0.05 0.71, p < 0.005 0.64, p<0.01 -0.03, NS 0.08, NS
Uterus as 7o of body
weight
0.33, NS 0.6, p < 0.02 0.009, NS -0.04, NS 0.08, NS
Uterus as 7o of
carcass
0.3, NS 0.57, NS -0.03, NS -0.02, NS 0.09, NS
Liver, g 0.76, p < 0.0001 0.7j, p < 0.002 0.88, p<0.0001 -0.01, NS 0.4,p = 0.03
Liver as 7o of body
weight
0.34, NS 0.3, NS 0.54, p<0.05 -0.03, NS 0.1, NS
Liver as Vo of carcass 0.09, NS
weight
0.02, NS 0.28, NS -0.01, NS 0.25, NS











Retroperitoneal fat 0.8, p<0.0001 0.77, p<0.0001 0.86, p<0.001 0.08, NS O.O, NS
Dorsal fat 0.8, p<0.0001 0.77, p<0.0001 0.88, p<0.0001 0.28, NS 0.09. NS
Total gastrointestinal -0.29, NS
tract
-0.55, p<0.05 0.33,N5 -0.06, NS 0.05, NS
Spleen 0.82, p<0.0001 0.8, p<0.0001 0.88, p<0.0001 0.37, NS
Thymus 0.75, p<0.0001 0.85, p<0.0001 0.89, p<0.0001 0.23, NS 0.36, NS
Soleus muscle 0.76, p<0.0001 0.82, p<0.0001 0.79, p<0.0001 0.48, NS 0.14, NS




















Tables 3.18, 3.19 and3.20 show the results of analysis of components of the endocrine IGF
system as covariates (independent variable) of tissue weights (dependent variable). Forward
stepwise multiple regression analysis was used to determine whether any combination of IGF
endocrine variables were covariates of the weights of organs or tissues'
The effect of nutrition in nonpregnant animals on weights of most tissues was dependent on
the concentration of IGF-tr in plasma, except for carcass as a fraction of body weight where
IGFBP-2 was the dominant independent covariate and retroperitoneal fat and soleus muscle,
where IGFBP-3 was the dominant independent variable (Table 3.18, 3.19). Pregnancy
abolishes these nutritionally determined relationships except in the case of carcass as a 7o of
body weight and retroperitoneal fat. In the case of uterine weight IGF-tr was the major
nutritionally determined correlate in nonpregnant animals whereas IGF-I was the major
nutritionally determined correlate in pregnancy (Table 3.19). In pregnant animals, IGF-I was
the major nutritionally determined correlate for other tissue weights, including body weight,
liver weight and total gastrointestinal tract weight, with the exception of soleus muscle where
IGF-tr dominates (Table 3.18, 3.19).
The concentration of IGFBP-3 in plasma was the major independent covariate of the effect of
nutrition in pregnant animals on net body weight, weight gain and weights of carcass,
retroperitonealfat, dorsal fat, spleen and thymus while its effect on net weight gain in
pregnancy was related to IGFBP-2 (Table 3.18, 3.19). In pregnant ad libitum fed animals,
body weight, weight gain, uterine weight and thymic weight were related to plasma IGF-I,
whereas, IGF-I and IGFBP-I were the best covariates of soleus muscle weight. There were no
independent covariates for any of the other tissues in pregnant animals.
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In pregnant underfed animals, tissue weights were related to the plasma concentrations of
either IGFBP-2 or IGFBP-I except for liver where IGF-I was the best independent covariate
(Table 3.20). In feed restricted animals, net weight gain and carcass weights were related to
IGFBP-3 (Table 3.18).
In ad libitum fed animals, no independent covariates were identified for retroperitoneal or
dorsal fat. In all undernourished animals circulating concentrations of IGF-binding proteins
are major correlates of tissue weights except for liver where IGF-I is the major independent
covariate (Table 3.20).
The effect of nutrition in pregnancy on the weights of many tissues was dependent on the ratio
of the concentration of IGF-I to that of IGFBP-I in plasma (Table 3.2I,3.22). The exceptions
were body weight, weight gain, carcass weight, carcass weight as a 7o of body weight as well
as uterine, retroperitoneal fat and total gastrointestinal tract weight, where the ratio of the
concentration of IGF-I to the concentration of IGFBP-2 in plasma were the dominant
independent covariates.
In nonpregnant animals tissue weights were related to the ratio of the concentration of IGF-tr
to the concentration of IGFBP-2 in plasma. Uterine weight where the ratio of the
concentration of IGF-tr to that of IGFBP-4 was the major nutritionally determined correlate,
and total gastrointestinal tract weight where the ratio of IGF-tr to IGFBP-1 concentrations was
the major nutritionally dependent correlate were the exceptions (Table 3.21,3.22). In
nonpregnant animals all significant correlations contained plasma IGF-tr concentrations as a
covariate whereas in pregnancy almost all significant relationships contained plasma IGF-I
concentration except for net weight gain for which concentration of plasma IGF-tr was an
independent covariate.
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In ad libitum fed guinea pigs body weight, weight gain, uterine and thymus weight were
dependent on the ratio of the concentration of IGF-I to those of IGFBP-3 in plasma whereas
soleus muscle weight was related to the ratio of IGF-I to IGFBP-I (Table 3.23,3.24). In
nutritionally restricted animals, tissue weights were determined by the ratio of plasma IGF-tr
to IGFBP-I concentrations except for net weight gain, which was related to the ratio of IGF-tr
to IGFBP-3 concentrations (Table 3.23,3.24). Thymus weight was determined by the ratio of
plasma IGF-tr to IGFBP-2 concentrations in the feed restricted animals (Table 3.24). In
undernourished animals all of the IGF to IGFBP ratios which were related to tissue weights
contained plasma IGF-tr and none contained IGF-I concentration.
3.3.10 Relationship between maternal IGF endocrine axis and fetal and placental
weights in pregnant guinea pigs
Relative abundance of hepatic IGF-I to B-actin ratio
The relative abundance of maternal hepatic IGF-I mRNA was positively correlated with total
fetal weight, total placental weight, average fetal weight and the ratio of average fetal to
placental weight (Table 3.25). Total fetal weights, both as a7o of maternal body weight and
as a7o of maternal carcass weight, were significantly associated with maternal hepatic IGF-I
mRNA relative abundance.
Plasma IGFs
Maternal plasma IGF-I concentration was positively correlated with number of fetuses per
dam, total fetal weight, total fetal weight as a 7o of body weight or carcass weight, total
placental weight and total placental weight expressed as 7o of body weight or carcass weight,
average fetal weight and average placental weight (Table 3.25).
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Maternal plasma IGF-tr was positively correlated with average fetal weight, total fetal weight,
the ratio of average fetal to placental weight, total placental weight, total fetal weight as a Vo
of body weight or carcass weight, and average placental weight and total placental weight
expressed as Vo of body weight (Table 3.25).
Insulin-Iike growth factor binding proteins
The concentrations of IGFBP-1 and IGFBP-4 in maternal plasma were not significantly
related to any of the fetal and placental variables measured (data not shown). Maternal
plasma concentrations of IGFBP-3 were positively correlated with total fetal weight and total
fetal weight as a 7o of body weight, total placental weight, average fetal weight, average
placental weight and average fetal to placental weight ratio (Table 3.25). Maternal plasma
concentrations of IGFBP-2 were negatively correlated with total fetal weight, total placental
weight, average fetal weight and average placental weight.
Table 3.27 shows the covariate analyses of determinants of fetal and placental weights
(dependent variables) amongst components of the IGF system (independent variable).
Forward stepwise multiple linear regression analysis was performed with six independent
variables included to determine whether the IGF endocrine variables were predictors of fetal
and/or placental growth
The concentration of IGF-I in maternal plasma was an independent covariate of the number of
fetuses per dam, total fetal weight, total fetal weight as a %o of body weight or carcass weight,
total placental weight, total placental weight as a Vo of body weight or carcass weight and the
ratio of average fetal to placental weight (Table 3.27). Average fetal weight was dependent on
plasma IGFBP-3 and average placental weight was dependent on plasma IGFBP-2 (Table
3.27). In pregnant feed restricted animals number of fetuses per dam was determined by
maternal plasma IGF-I but total placental weight was determined by maternal plasma IGF-tr.
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There were no independent covariates for any other fetal or placental measures in nutritionally
restricted or ad libitum fed pregnant animals
Ratios of insulin-like growth factors to insulin-like growth factor binding proteins
The ratios of the concentrations of IGFs to IGFBPs in plasma were assessed as independent
covariates of maternal and fetal tissues to identify potential IGF/IGFBP complexes as
determinants. The ratio of the concentration of IGF-I to IGFBP-3 in maternal plasma was
positively associated with uterine weight as a Vo of carcass weight, number of fetuses per dam,
total fetal weight as a 7o of body weight or carcass weight and total placental weight as a 7o of
body weight or carcass weight (Table 3.26).
The ratio of the concentrations of IGF-I to IGFBP-I in plasma was a positive independent
covariate of all maternal and fetal tissue weights (Table 3.26) except for number of fetuses per
dam and total placental weight as a Vo of body weight or carcass weight. Ratio of plasma IGF-
I to IGFBP-2 concentrations was a positive independent covariate of uterine weight, uterine
weight as a Vo of body weight or carcass weight, total fetal weight, total fetal weight as a 7o of
body weight or carcass weight, total placental weight as a 7o of body weight, average fetal
weight and average placental weight. The ratio of the concentrations of IGF-I to IGFBP-4 in
plasma was a positive independent covariate of uterine weight, total fetal weight, total
placental weight and average fetal weight.
The ratio of plasma IGF-tr to IGFBP-3 concentrations and the ratio of IGF-tr to IGFBP-4
concentrations were not associated with any maternal or fetal weights (data not shown). The
ratio of plasma IGF-tr to IGFBP-1 and the ratio of IGF-tr to IGFBP-2 concentrations were
positive independent covariates of uterine weight, total fetal weight, total placental weight,
average fetal weight and average placental weight. The ratio of the concentrations of IGF-tr to
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those of IGFBP-2 in plasma was a positive independent covariate of uterine weight as a 7o of
body weight and total fetal weight as a%o of body weight.
Table 3.28 shows the covariate analyses of the dependence of fetal and placental parameters
(dependent variable) on the ratio of the concentrations of IGF-Is in plasma to those of IGFBPs
(independent variable). Forward stepwise regression included eight independent variables.
All fetal and placental weights were independently determined by the ratio of the
concentrations of IGF-I to those of IGFBP-2 in plasma (Table 3.28, Figure 3.13) except for
the ratio of average fetal to placental weight, which was determined by the ratio of plasma
IGF-I to IGFBP-I concentrations, although this was a weak association. In feed restricted
pregnant guinea pigs total fetal and placental weights and fetuses per dam were strongly
dependent on the ratio of plasma IGF-I to IGFBP-lconcentrations (Table 3.29). None of these
above relationships contained IGF-tr as a significant independent covariate. In ad libitumfed
pregnant animals total fetal weight and number of fetuses per dam were dependent on the ratio













+, ô 12 = 0.75, p<0.01
IGFBP-3
+, ô 12 = 0.07, p<0.05
IGFBP-3
* ô, 12 = 0.67, p<0.01
IGF-II
+, ð rz - 0.09, p<o.oo5
IGFBP.3
*, õ r2 = 0.77, p<0.01
IGF-I
*, ô 12 = 0.1, p<0.01
IGFBP-2
-, ô 12 = 0.67, p<0.01
IGFBP-3
*, õ 12 = 0.14, p<0.01
IGFBP-3
*, ô r2 = 0.7, p<0.001
IGFBP-2
+, ô r2= 0.47, p<0.001
IGF-II
IGF-II
*, ô 12= 0]9,p<0.002
IGF-II
+, ô ¡2= 0.79,p<0.002
IGF-II
+, ô 12 - 0.83, p<0.02
IGFBP-3
+, ô r2 - 0.06, p<0.05
IGFBP-2
-, ô 12 = 0.32, p<0.05
IGF-I
*, õ ¡2 = 0.77, p<0.001
Restricted
IGFBP-1
+, ô 12 = 0.49, p<0.001
IGF-II
*, ô r2 = 0.2, p<0.01
IGFBP-2




+, ô 12= 0.2,p<0.02
IGFBP-1
+, ô 12 = 0.75, p<0.001
IGFBP-3
*, õ 12 = 0.35, p<0.01
IGFBP-3
+, õ 12 = 0.23, p<0.05
IGFBP-2
*, ô 12 = 0.26, p<0.01
IGFBP-4
Nonpregnant Ad-Iíbitumfed,
+, ô 12 = 0.85, p<0.01
IGF_I
+, ô 12 = 0.72, p<0.001
IGF-II








+ ô 12 = 0.21
Tabte 3.18 Summary of endocrine IGF variables as independent covariates identified as predictors of body phenotype in pregnant, nonpregnant, ad líbitum fed and feed
restricted guinea pigs. A combination of 6 independent IGF endocrine variables were entered into forward stepwise linear regression.
Table 3.19 Summary of endocrine IGF variables as independent covariates identified as predictors of tissue
weights in pregnant and nonpregnant guinea pigs. A combination of 6 independent IGF endocrine variables were
entered into forward stepwise linear regression.
Dependent variable Independent Covariates of IGF endocrine factors
Tissue weight (g) Pregnant Nonpregnant
Uterus, g IGF-I IGF-tr











-,ô 12 = 0.11, p<0.01
IGFBP-1
-,812 = 0.07, p<0.02
IGFBP-3
+, ô 12 = 0.78, p<0.0001
IGF-tr
+, ô 12 = 0.15, p<0.001
IGF-tr
+,8 12 = 0.6J , p<0.0001
IGF-I
IGF-tr
+, ô 12 = 0.8, p<0.0001
IGFBP-3
+, ô 12 =O.JI,p<0.0001
IGF-tr
+, ô r2 - 0.78, p<0.005
IGFBP-1
+, ô r2 = 0.05, p=0.06
IGFBP-3
+, ô 12 = 0.8, p<0.0001
IGFBP-3 IGF-tr




-,õ12 = 0.08, p<0.01
IGF-I
-, õ t' = 0.32, p<0.005
IGFBP-4
-, ð r'= 0.18, P=0.05
IGFBP-3 IGF-tr
+, õ 12 = 0.J3, p<0.001 +,ô12 =0.77,p<0.0001
IGF-tr
+, ô 12 = 0.13, p<0.005
Liver, g
+, ô 12 = 0.69, p<0.0001
Chapter 3-61
Table 3.20 Summary of endocrine IGF variables as independent covariates identified as predictors of tissue
weights in ad tibitum fed and feed restricted guinea pigs. A combination of 6 independent IGF endocrine
variables were entered into forward stepwise linear regression.
Dependent variable Independent Covariates of IGF endocrine factors
Tissue weights (g) ad libítum fed, pregnant and Underfed, pregnant and
nonpregnant nonpregnant
Uterus, g IGF-I IGFBP-2
+, ô 12 = 0.83, p<0.0001 +, õ 12 = 0.57 , p<0.0002
IGF-tr IGFBP-1
+, õ 12 = 0.16, p<0.02
IGF-I
+, ô 12 = 0.06, p<0.05
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Table 3.2L Summary of independent covariates identified as predictors of body phenotype in
pregnant and nonpregnant guinea pigs. A combination of eight independent variables the ratio
of IGF-I, -tr to IGFBP-I, -2, -3, -4 were included in the analysis.
Dependent variable Independent Covariates ratio of IGFs/IGFBPs
Pregnant Nonpregnant
Body weight Ratio of IGF-I/IGFBP-2 Ratio of IGF-IVIGFBP-2
+, ô 12 = 0.61, p<0.001 +, ô 12 = 0.62,p<0.001
Net body weight Ratio of IGF-I/IGFBP-1 Ratio of IGF-IVIGFBP-2
+, ô 12 = 0.62, p<0.001+, ô 12 = 0.58, p<0.001
Weight gain Ratio of IGF-I/IGFBP-2 Ratio of IGF-IVIGFBP-2
+, õ 12 = 0.66,p<0.005 +, ô 12 = 0.64, p<0.001
Ratio of IGF-I/IGFBP-1
-, ôr'=O.IJ,p<0.01
Net weight gain Ratio of IGF-II/IGFBP-3 Ratio of IGF-II/IGFBP-2
-, õ r' = 0.53, p<0.001 +, ô 12 = 0.64, p<0.001
Ratio of IGF-MGFBP-I Ratio of IGF-I/IGFBP-1
+, ð 12 = 0.25,p<0.001 -, ô ,' = 0.17, p<0.01
Carcass weight Ratio of IGF-VIGFBP-2 Ratio of IGF-II/IGFBP-2
+, ô 12 = 0.56, p<0.001 +, ô 12 = O.64, p<0.001
Ratio of IGF-VIGFBP-I
-, ô t'= 0.1, p<0.05
Carcass as Vo of body
weight
Ratio of IGF-I/IGFBP-2
+, ô r2 = 0.28, p<0.0001
Ratio of IGF-I/IGFBP-3
-, ô r'= 0.19 .05
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Table 3.22 Summary of independent covariates identified as predictors of tissue weights in
the pregnant and nonpregnant guinea pig. A combination of eight independent variables the
ratio of IGF-I, -tr to IGFBP-I, -2, -3, -4 were included in the analysis'
Dependent variable Independent Covariates ratio of IGFstoIGFBPs
Tissue weight (g) Pregnant Nonpregnant
Uterus, g Ratio of IGF-I/IGFBP-2
+,ô12=0.52,p<0.01
Ratio of IGF-II/IGFBP-2
-, ô r'= 0.13, p<0.05













Ratio of IGF-I/IGFBP-2 Ratio of IGF-IIIGFBP-1
-, ô r'= 0.35, p<0.02 -, ô.'= 0.53, p<0.002
Ratio of IGF-VIGFBP-I Ratio of IGF-II/IGFBP-2
+, ô 12 = 0.59, p<0.001 +, ô 12 = 0.65, p<0.0001
Ratio of IGF-I/IGFBP-3
-, ô r'= 0.13, p<0.02
Ratio of IGF-VIGFBP-I Ratio of IGF-II/IGFBP-2
+, ô 12 = 0.73, p<0.0001 +, ô 12 = 0.63, p<0.001
Ratio of IGF-II/IGFBP-3 Ratio of IGF-VIGFBP-3
-, ô r'= 0.08, p<0.05 -, ô r' =o'I2,p<0.05
Ratio of IGF-I/IGFBP-1 Ratio of IGF-II/IGFBP-2
+, õ 12 - 0.7g,p<0.0001 +, ô 12= 0.8, p<0.0001
Ratio of IGF-I/IGFBP-3 Ratio of IGF-I/IGFBP-3
-, ô r'= 0.06, p<0.05 -, õ.'= 0.09, p<0.01
Ratio of IGF-VIGFBP-I Ratio of IGF-II/IGFBP-2
+, ô 12 = 0.67,p<0.0001 +, ô r2 = 0.65, p<0.001
Ratio of IGF-II/IGFBP-3 Ratio of IGF-I/IGFBP-1
Ratio of IGF-II/IGFBP-4
+, õ 12 = 0.3, p<0.05
Ratio of IGF-MGFBP-2
+, ô 12 = 0.54, p<0.005
Ratio of IGF-I/IGFBP-3
-, ô r' =0.24,p<0.005
Ratio of IGF-II/IGFBP-2
+, ô 12 = 0.58, p<0.001
Ratio of IGF-I/IGFBP-1
-, ôrt =O.I7,p<0.02
-, ô ,' = 0.08, p=0.05 -, ô ,' = O'I4, p<0.02
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Table 3.23 Summary of independent covariates identified as predictors of body phenotype in
ad libitum fed and underfed guinea pigs. A combination of eight independent variables the
ratio of IGF-I, -tr to IGFBP-I, -2, -3, -4 were included in the analysis.
Dependent variable Independent Covariates ratio of IGFs/IGFBPs







Carcass as Vo of body
weight
Ratio of IGF-VIGFBP-3
+, ô 12 = 0.48, p<0.001
Ratio of IGF-II/IGFBP-3
-,ðt'=0.24,p<0.02
Ratio of IGF-II/IGFBP- 1
-, õ.'= 0.35, p<0.005
Ratio of IGF-VIGFBP-3
+, õ 12 = 0.16, p<0.05
Ratio of IGF-I/IGFBP-3 Ratio of IGF-MGFBP-1
+, ô 12 = 0.61, p<0.001 -, ô tt = 0.57 , p<0.001
Ratio of IGF-II/IGFBP-3
-, ô r' = 0.19, p<0.02
Ratio of IGF-II/IGFBP-3
-, ô r'= 0.31, p<0.02
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Table 3.24 Summary of independent covariates identified as predictors of tissue weights in
ad libitum fed and underfed guinea pigs. A combination of eight independent variables the
ratio of IGF-I, -tr to IGFBP-I, -2, -3, -4 were included in the analysis.
Dependent variable Independent Covariates ratio of IGFs/IGFBPs




















+, ô 12 = 0.08, p<0.02
Ratio of IGF-II/IGFBP-2
-, ô .' = 0.28, p<0.002
Ratio of IGF-II/IGFBP- 1
-, õ r' - 0.26, p<0.02
Ratio of IGF-I/IGFBP-3
+, ô 12 = 0.19, p<0.001
Ratio of IGF-II/IGFBP- 1
+, ô 12 = O.22, p<0.05
Ratio of IGF-II/IGFBP- 1
-, õ.'=0.4,p<0.01
Ratio of IGF-IilGFBP-2
+, õ 12 = 0.34, p<0.02
Ratio of IGF-VIGFBP-1 Ratio of IGF-II/IGFBP-1
+, ô 12 = 0.7 ,p<0.0001 +, ô 12 = 0.33, p<0.02
Ratio of IGF-I/IGFBP-2
+, õ 12 = 0.1, p<0.01
Ratio of IGF-I/IGFBP-3
-, ô r'= 0.09, p<0.02
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IGF-I mRNA IGFBP.3 IGFBP.2
Fetuses per dam 0.39, N,S 0.6I, p = 0.01 0.41, NS 0.31, NS -0.16, NS






0.59,p <0.05 0.54,p <0.05 0.63,p <0.01 -0-14,p <0-001
0.69,p<0.01 0.69,p<0.01 0.6,p<0.05 -0.37, N,S
0.84,p <0.0001 0.J,p <0.01 0.74,p <0.01 -O.5l,p = 0-02
Total fetal weight as Vo
of body weight
Total fetal weight as 7o
of carcass weight
Total placental weight
0.76, p < 0.001 0.64, p < 0.01 0.51, p < 0.05 -0.41, N^S
0.71, p < 0.01 0.58, p < 0.02 0.45, NS
0.79,p <0.001 0.66,p <0.01 0.64,p <0.01 -0.54,p = 0.03
Total placental weight
as Vo of body weight
Total placental weight
as Vo of carcass weight






0.54, p < 0.05
0.64, p < 0.01
0.56, p < 0.05











0.57, p < 0.05 0.44, NS 0.24, NS -0.22, NS
Table 3.25 Associations between hepatic IGF-I mRNA or maternal endocrine IGF axis and fetal and placental weights. Pearson
correlation coefficients r are tabulated and p is significant at p<0.05.
Tissue weight IGF.I/IGFBP-3 IGF-I/IGFBP-1 IGF-I/IGFBP.2 IGF-I/IGFBP.4 IGF-II/IGFBP.1 IGF-IYIGFBP.2
Uterus, g
Uterus as 7o of bodY
weight























0.54, p<0.05 0.54, p<0.05
0.51, p<0.05 0.55, p<0.05
0.53, p<0.05 0.63, p<0.01
0.56, p<0.05












Total fetal weight as Vo of
body weigh
0.51, p<0.05









0.5, p<0.05 0.54, p<0.05 0.61, p<0.02
Total placental weight as
Vo of body weight
0.62, p<0.001
Total placental weight as 0.63, p<0.0i
7o of carcass
Table 3.26 Associations between the ratio of plasma IGFs to plasma IGFBPs and maternal and fetal tissues. Uterine weight (weight of the
uterus, fetus and placenta). Pearsons correlation coefficients r are tabulated and p is significant at p<0.05
Table 3.27 Identification of independent covariates as predictors of fetal and placental




Fetuses per dam IGF-I
+, ô 12 =0.4,p<0.02
Total fetal weight, g IGF-I
+,õ,r2 =O.J2,p<0.001
IGF-I
+, ô 12 = 0.63, p<0.005
IGFBP-2
+, ô 12 = 0.19, p<0.05
IGFBP-4
-,õ? = 0.1, p=0.057
IGF-tr
IGF-I
+, ô 12 = 0.58, p<0.001
IGF-I
+, ô 12 = 0.51, p<0.002
Total placental weight, g IGF-I
Total fetal weight as 7o of
body weight
Total fetal weight as 7o of
carcass weight
Total placental weight as 7o
of body weight
Total placental weight as 7o
of carcass weight
Average fetal weight, g
Average placental weight, g
Average fetal /placental
weight ratio
+,ô 12 = 0.63, p<0.001 +, ô 12 = 0.5, p<0.05
IGF-I
+, ô 12 = 0.38, p<0.02
IGF-I
+, ð 12 = 0.33, p<0.02
IGFBP-3,
+, ô r2 = 0.59, p<0.02
IGF-tr
+, ô 12 = 0.11, p=0.053
IGFBP-2
-, ð r'= 0.55, p<0.001
IGF-I
+, õ 12 - 0.48, p<o.oo5
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Table 3.28 Summary of predictors of fetal and placental tissue weights (dependent variable)
using the ratios of plasma IGFs to plasma IGFBPs as independent variables.
Covariate Analysis










+, ô 12 = 0.13, p<0.05
Ratio of IGF-VIGFBP-2
+, ô r2 = 0.52, p<0.01
Ratio of IGF-IVIGFBP-2
+, õ 12 = 0.I2, P=0.05
Ratio of IGF-VIGFBP-2
+, ô 12 = 0.52, p<0.01
Ratio of IGF-IVIGFBP-2




+, õ 12 = 0.55, p<0.001
Ratio of IGF-I/IGFBP-3
+, ô 12 = 0.14, p<0.05
Ratio of IGF-VIGFBP-I
+, õ 12 = 0.29, p<0.05
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Table 3.29 Identification of independent covariate as predictors of fetal and placental weight
in ad libitumfed and feed restricted pregnant guinea pigs. A combination of eight
independent variables using the ratio of plasma IGFs to plasma IGFBPs as independent
variables.
Pregnant




Total fetal weight, g
Total placental weight, g
Average fetal weight, g
Average placental weight, g
Average fetal /placental
weight ratio
Ratio of IGF-IUIGFBP-4 Ratio of IGF-UIGFBP-I
-, ô ,' = 0.64, p<0.02 +, ô r2 = 0.69, p<0.01
Ratio of IGF-II/IGFBP-4 Ratio of IGF-I/IGFBP-1
-, ô rt = 0.58, p<0.05 +, ô 12 =0.43,P=0.07
Ratio of IGF-VIGFBP-I
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Figure 3.13 Correlations between uterine components and
the ratio of the concentrations of IGF-I and IGFBP-2
in plasma from pregnant guinea pigs.































3.4.1 Endocrine IGF axis in pregnancy
The concentration of plasma IGF-I in guinea pigs in late pregnancy is relatively high
(Sohlstrom et a1.,1998), as seen in pregnant humans (Dwyer and Stickland, I992;Gargosky et
al., 1990a). This contrasts with mice, rats and rabbits where plasma IGF-I levels are high in
mid-pregnancy but are very low late in pregnancy (Fielder et al., l99O;Gargosky et al.,
1990b;Nason et al., 1996). The mechanism of increased plasma IGF-I in human pregnancy
has yet to be defined. In rats, pregnancy-induced changes in plasma IGF-I were not related to
hepatic abundance of IGF-I mRNA (Davenport et al., 1990;Monaco and Donovan,
1997;Travers et al., 1993).
3.4.2 Hepatic expression of IGF-I mRNA
The present study demonstrates that hepatic expression of IGF-I mRNA is increased by late
pregnancy in guinea pigs. This effect was eliminated by feed restriction. As previously
reported, plasma IGF-I follows a similar pattern (Sohlstrom et al., 1998). Plasma IGF-I was
positively correlated (r2 = 0.68) with the relative abundance of IGF-I mRNA in liver. In other
words, 687o of the variation in plasma IGF-I can be accounted for by variation in hepatic
abundance of IGF-I mRNA. This strongly indicates that synthesis by the liver is the major
source of endocrine IGF-I in guinea pigs in late pregnancy. The novel CrelloxP system used
to ablate the IGF-I gene in the murine liver resulted in a 757o reduction of plasma IGF-I,
confirming the liver as the primary source of endocrine IGF-I in nonpregnant mice (Yakar et
a1.,1999).
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3.4.3 Mechanisms of hepatic IGF-I mRNA regulation in pregnancy
PIac ent aI g row th fact o r s
Regulation of expression of hepatic IGF-I mRNA in pregnancy is not completely understood.
Placental hormones have been suggested as potential candidates. Several studies have
suggested placental growth hormone-like peptides, such as placental lactogen and placental
growth hormone may act through hepatic growth hormone receptors (GFIR') stimulating the
expression of hepatic IGF-I thereby increasing endocrine IGF-I. Other candidates include
estrogen, progesterone and cortisol.
Regulation of hepatic IGF-I in pregnancy may follow the original somatomedin hypothesis
where GH or GH-like polypeptides of placental origin stimulate hepatic IGF-I production via
interaction with the transmembrane GHR present on the surface of liver cells (I-e Roith,
2001). Because of the high degree of primary sequence homology between GH, PL and
placental GH it is probable that one of these placental GH-like peptides may interact with the
hepatic GHR. This does not exclude the possibility that these placental peptides act through
distinct alternate receptors.
Placental Lactogen
Mice and rat placentae secrete two forms of placental lactogen (PL). PL-l is secreted early in
pregnancy andPL-2 in the second half of pregnancy in mice (Faria et al., 1990). PL-L and .,
PL-2 mRNA are expressed and the proteins are produced by trophoblast giant cells of mouse
placenta (Faria et al., 1990). Synctiotrophoblast cells of the human placenta synthesise a
single PL (Handwerger, 1991). Maternal plasma concentrations of placental lactogen parallel
the increase in maternal concentrations of plasma IGF-I and they are weakly correlated with
each other from weeks 30 to 31 and weeks 32 to 33 in human pregnancy (Caufriez et al.,
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L993). Placental lactogen has been proposed as a regulator of hepatic IGF-I mRNA through
either the growth hormone receptor or an unidentified placental lactogen receptor. Ovine
placental lactogen and ovine growth hormone were demonstrated to bind a conìmon receptor
in microsomal membranes isolated from pregnant sheep liver (Breier et al., 1994). Ovine
placental lactogen had a lO-fold greater affinity than ovine GH for this receptot. Breiet et al
(1994) suggested that oPL binds to a single subunit of the GHR initiating signal transduction
whereas oGH requires dimerization of two GHR subunits to initiate receptor signalling. Thus
the greater potency of oPL for the receptors isolated from pregnant sheep liver was possibly
achieved by binding one molecule of oPL to one subunit of GHR whereas one molecule of
oGH requires two subunits of GHR (Breier et al., 1994).
PIac ental growth hormone
Human placental growth hormone is expressed by syncytiotrophoblasts of the placenta and
secreted into the maternal circulation from week 15 to 20, progressively increasing to term
(Alsat et al., 1993). Growth hormone receptors are present in the placenta suggesting
placental growth hormone may have an autocrine role (Alsat et al., 1998). Maternal plasma
concentrations of IGF-I are positively correlated with those of placental growth hormone
(Caufriez et al., 1993;Caufri ez et al., 1994;Evain-Brion, 1999;Mclntyre et al., 2000). Mothers
of IUGR babies have lower plasma concentrations of both IGF-I and placental growth
hormone (Mirlesse et a1., 1993). Thus placental growth hormone and/or placental lactogen
may use a mechanism similar to that suggested as the original somatomedin hypothesis of
pituitary growth hormone action on hepatic IGF-I production.
Methylation of placental hormones
A mechanism that potentially may regulate the expression and concentration of placental
growth hormone like peptides is DNA methylation. Methylation of the rat placental lactogen-
1 gene has recently been suggested as a mechanism regulating tissue specific expression of
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placental lactogen (Cho et al., 2001). As the PL and Pl-like genes are co-localizedin a
cluster, DNA methylation may affect gene expression of these Pl-like factors. An inverse
relationship between DNA methylation and tissue expression has been shown for rat prolactin
and growth hormone genes (Ngo et a1.,1996). The degree of DNA methylation can be
influenced by the nutritional status of the animal (Hass et al., 1993). Factors such as folate
and methionine are important precursors of S-adenosylmethionine the major methyl donor in
the body. Thus, caloric deprivation may affect DNA methylation as seen in pancreatic acinar
cells from undernourished rats where genomic methylation of ras DNA was increased
(Slattery et al., 1997). Therefore expression of Pl-like genes can be affected by DNA
methylation, which is potentially dependent on dietary status.
3.4.4 Nutritional regulation of hepatic IGF-I mRNA
Undernutrition in pregnant rats and guinea pigs decreases plasma concentrations of plasma
IGF-I (Muaku et al., 1995a;Muaku et al., l995b;Sohlstrom et al., 1998). This study shows for
the first time that hepatic expression of IGF-I mRNA is reduced by feed restriction in pregnant
guinea pigs. Mechanisms regulating hepatic production of IGF-I in food restricted animals
appear to be independent of growth hormone secretion, but are dependent on energy intake
and availability of essential amino acids (Zhang et al., 1998).
Fasting of pregnant ewes for 72 h was shown to decrease placental lactogen binding to
maternal hepatic microsomal membranesby 707o (Freemark et al., 1992). Infusion of glucose
during this time failed to restore placental lactogen binding. Other studies have shown that
refeeding restored placental lactogen binding, suggesting that nutrients other than glucose,
such as amino acids and fatty acids, regulate abundance of placental lactogen receptors.
Chapter 3-76
Growth hormone resistance produced by undernutrition has been shown to prevent GH
dependent IGF-I stimulation in undernourished nonpregnant steers (Breier, L999). However,
the numbers of growth hormone receptors were minimally decreased by nutritional constraint
suggesting the lack of IGF-I response to GH administration may be due to postreceptor defects
(Thissen et al., 1994). Reduced total energy intake and reduced protein intake correlates with
decreased hepatic expression of IGF-I mRNA. Protein restriction decreases the availability of
essential amino acids, which are required for expression of hepatic IGF-I mRNA. Both
fasting and protein restriction have been demonstrated to reduce transcription and translation
of hepaticIGF-ImRNA(section 1.5.2)(Thissenetal., l99l;Zhangetal., I998;Zhangetal.,
reeT).
3.4.5 Pregnancy changes the relationship between plasma concentrations of IGF'I and
hepatic abundance of IGF-I mRNA
Alternate forms of hepatic IGF-I wRNA transcripts
The second order nature of the relationship between hepatic abundance of IGF-I mRNA and
circulating protein may be a result of altered translation of IGF-I or accumulation of
intermediate RNA transcripts of larger size that are not translated (Hepler et al., 1990).
Protein and caloric restriction have been shown to alter the molecular profile of rat IGF-I
transcripts, as seen on Northern blot analysis (Zhang et al., 1998).
Alternatively placental lactogen and placental growth hormone may differentially regulate
hepatic expression of different forms of IGF-I transcript class 1 and class 2. Class I and2
transcripts are regulated by pituitary GH and nutrition, although class 2 transcripts are more
sensitive to growth hormone and higher dietary intake of protein and energy intake (Pell et al.,
1993;Weller et al., 1993). GH and higher nutrition act synergistically to increase the
expression of IGF-I class 2 transcripts in ovine liver (Pell et al., 1993). This synergistic effect
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appears similar to that observed between pregnancy and higher nutrition in guinea pig liver on
the relative abundance of IGF-I mRNA. Circulating IGF-I protein was more strongly
associated with class 2 transcripts than class 1 in sheep, suggesting this form may be
responsible for changes in circulating IGF-I. Pell et al (1993) proposed that the relative
amount of class 2 to class 1 transcripts act as a switch to determine the endocrine secretion of
IGF-I into blood. In pregnant ad libitum fed guinea pigs, the relative abundance of hepatic
IGF-I mRNA may be equivalent to class 1 plus class 2 transcripts (6 fold increase), while
plasma IGF-I (3 fold increase) may correlate with only class 2 transcripts. The large
discrepancy between the change in plasma IGF-I concentration and hepatic IGF-I mRNA
abundance in ad libitumfed guinea pigs caused by pregnancy may therefore be explained by
pregnancy specific factors increasing IGF-I class 1 transcripts, which do not lead to circulating
IGF-I protein, as well as class 2 transcripts which are translated.
In rodents the IGF-I gene has two leader exons (exon 1 and 2) producing two kinds of
mRNAs, class 1 and class 2, although a third mRNA is present designated class 1 del (mRNA
lacking a segment of exon 1) (Holthuizen,l99I). Mouse ObI77l preadipocyte cells cultured
with growth hormone differentiate to adipocytes and express class I IGF-I mRNA and class 1
del IGF-I mRNA. These preadipocytes when cultured with GH and IGF-I stimulate both
classes of transcripts with class 1 IGF-I mRNA the major form. The class 1 IGF-I mRNA
species was translated more efficiently than the class 1 del IGF-I mRNA. Kamai et al (1996)
hypothesised that GH stimulates the initial synthesis of a less efficiently translated class 1 del
IGF-I 6RNA, which subsequently stimulates class I IGF-I mRNA. Therefore in pregnancy
placental lactogen or placental growth hormone may initially stimulate the expression of the
less stable IGF-I class 1 del mRNA, which does not lead to circulating protein but may also
regulate the expression of IGF-I transcripts that contribute to the concentration of IGF-I in
blood.
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3.4.6 Pregnancy increases the clearance rate of endocrine IGF-I from blood
As discussed above, the relationship between hepatic abundance of IGF-I mRNA and plasma
IGF-I concentrations, while very strong, is not linear. In ad libitum fed guinea pigs,
pregnancy increased plasma IGF-I concentration about 3-fold whereas hepatic abundance of
IGF-I mRNA was increased about 6-fold. As an alternative to the mechanism described above
this discrepancy could be due to proteolytic conversion of a proportion of IGF-I protein to the
des-(l-3) IGF-I variant which is indistinguishable from IGF-I in the RIA and is cleared from
blood more rapidly. Des-(1-3) IGF-I has reduced affinity for IGFBPs and is cleared more
rapidly from the circulation than either IGF-I or IGF-tr in rats (Ballard et al., 1991;Gillespie et
al., 1990). The formation of this variant is thought to be a posttranslational modification of
the mature IGF-L Several studies support this view including the identification of a trypsin-
like acid protease capable of cleaving des-(1-3) IGF-I from the mature IGF-I (Yamamoto and
Murphy, 1994). Hypophysectomized rats have increased activity of a protease that can
convert IGF-I to the des-(1-3) IGF-I in many tissues with the highest being in the liver.
Treatment with growth hormone reversed this (Yamamoto and Murphy, 1995). In human
pregnancy pituitary growth hormone levels in blood decline while a continuous secretion of
placental growth hormone increases. Reduction of pituitary GH in pregnancy may act to
increass protease activity in the liver thus increasing production of des-(l-3) IGF-I. The
activity of the acid protease responsible for generating des-(l-3) IGF-I from IGF-I has been
demonstrated to be inhibited by a growth hormone dependent serine protease inhibitor Spi 2.1
(Maake et a1., L997).
If hepatic synthesis and secretion of IGF-I is directly linearly related to hepatic abundance of
IGF-I mRNA in guinea pigs then a change in the ratio of plasma IGF-I to IGF-I mRNA
indicates that the rate of clearance of IGF-I from the blood of ad libitum fed animals was
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doubled by pregnancy. Pregnancy has been reported to increase clearance of IGF-I from the
circulation in rats (Bastian et al., 1993;Davenport et al., 1990).
A synthetic IGF-I analogue LR3IGF-I, known to have very poor affinity for IGFBPs, is more
rapidly cleared than IGF-I in nonpregnant and pregnant rats. This demonstrates that
association with IGFBPs extends the half-life of circulating IGFs. Radiolabelled IGF-I and
LR3IGF-I were found localised in different tissues after intravenous injection into pregnant
and nonpregnant rats, suggesting transportation by IGFBPs plays a significant role in targeting
IGF-I to tissues (Bastian et al., 1993). Uptake of radiolabelled IGF-I was higher than that of
LR3IGF-I in the placenta, fetus and fetal plasma. Thus the ability of IGF-I to bind IGFBPs in
pregnancy appears important in the uptake or action at the maternal-fetal interface.
Insulinlike growth factor binding proteins play a very significant role in the delivery,
availability and activity of IGFs. In guinea pigs, as in other mammals, plasma IGFBPs were
altered by pregnancy and nutrition. However, unlike most mammals, pregnancy had no
discernible effect on plasma IGFBP-3 in guinea pigs. Also, there was no evidence of IGFBP-
3 proteolytic activity in guinea pig plasma. This contrasts with human and rat where
pregnancy increases plasma IGFBP-3 proteolysis (Binoux et al., 1993;Davenport et al.,
I992;Gargosky et a1.,1992). In feed restricted guinea pigs, however, pregnancy increased
concentrations of IGFBP-I and IGFBP-2 and decreased those of IGFBP-3 in plasma.
3.4.7 Potential actions of endocrine IGF-I in pregnancy
The relative abundance of IGF-I mRNA in liver and the concentration of IGF-I in plasma of
pregnant guinea pigs were both positively correlated with maternal body weight, net body
weight, weight gain, net weight gain and uterine weight, the latter both as a fraction of body
weight and carcass weight, as well as weights of retroperitoneal fat, dorsal fat, spleen and
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thymus. This suggests that IGF-I synthesised and secreted by the liver may have endocrine
actions on maternal tissues during pregnancy. This is supported by the observation that
infusion of IGF-I (350 pglday) into late pregnant rats increased maternal weight gain, but had
no effect on placental or fetal weight (Gargosky et al., 1991). More recently, however,
administration of IGF-I (565 ¡tglday) to ad libitum fed guinea pigs from day 20 to 37 of
pregnancy failed to increase maternal body weight, but increased fetal and placental weight
(Sohlstrom et al., 2001).
In nonpregnant animals the relative abundance of hepatic IGF-I mRNA was not significantly
related to the weight of any tissue except liver. This suggests that IGF-I may have autocrine
or paracrine actions on the liver and somatic growth of nonpregnant guinea pigs is not
dependent on endocrine actions of hepatic IGF-I. Somatic growth of nonpregnant guinea pigs
is reported to be independent of pituitary GH (Keightley and Fuller, 1996). Passive
immunoneutralization of endocrine IGF-I in male guinea pigs had no effect on growth rate or
weight of tissues (Kerr et al., 1990).
In the nonpregnant guinea pig, plasma IGF-I positively correlated with the weights of
retroperitoneal fat, dorsal fat, spleen, thymus and soleus muscle. However plasma IGF-tr was
a better correlate with almost all tissue and organ weights in nonpregnant guinea pigs,
suggesting IGF-tr is normally a more important endocrine growth factor than IGF-I in this
species.
In this present study covariate analysis was performed with six independent variables, the
plasma concentrations of IGF-I, IGF-tr and IGFBP -I, -2, -3 and 4, to determine if any of
these factors were independently related to tissue and organ weights. In pregnant guinea pigs,
IGF-tr (n = 10, where n is the number of variables that correlated with an independent IGF
endocrine factor) or IGFBP-3 (n = 2) concentrations in plasma were the main independent
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covariates of organ and tissue weights. This contrasts with the situation in pregnancy, where
the plasma concentrations of IGF-I (n = 12) or IGFBP-3 (n = 8) were the most frequently
observed independent covariates of tissue and organ weights.
In pregnant animals, the concentration of either IGF-I or IGFBP-3 was found to be a better
independent covariate of all organ and tissue weights than the concentration of IGF-tr or any
other IGFBP in blood (Table 3.I8,3.19,3.27). The only exception is that the concentration of
IGFBP-2 in plasma is the strongest correlate of fractional carcass weight in pregnancy.
Correlations between tissue weights and the concentrations of IGFBP-I, -2 and -4 in pregnant
guinea pigs were generally weak and negative except for average placental weight where the
concentration of IGFBP-2 is a major independent covariate (Table 3.27).
Plasma concentration of IGFBP-3 was a strong and positive independent predictor of spleen
and thymus weight in pregnant guinea pigs, suggesting IGFs associated with IGFBP-3 may be
important in regulating the immune system. IGF-I stimulates lymphocyte maturation through
the type 1 IGF receptor (Kooijman et al., 1995). IGF-I has also been demonstrated to alter the
ratio of CD4 to CD8 lymphocytes in the thymus, which may be important in the development
of immune tolerance in pregnancy. In pregnant mice the thymus shrinks and rearrangement of
the internal structure occurs which may be involved with the development of maternal
tolerance of paternal and fetal antigens (Clark, 1991). Administration of IGF-I to the fetal
rhesus monkey increased thymus, spleen, kidney and small intestine weights as well as the
number of red blood cells, lymphocytes and neutrophils in the third trimester. The ratio of
CD4 to CD8 lymphocytes was also increased by IGF-I in fetal lymph nodes (Tarantal et al.,
1991). Total gastrointestinal weight in pregnant guinea pigs was negatively related to plasma
IGF-I, suggesting the anabolic action of endocrine IGF-I was inhibited possibly by circulating
IGFBPs in plasma. Findings of this current study imply IGF-I and/or IGFBP-3, either in
combination or independently, may play an important role in the immune system.
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The concentration of plasma IGFBP-3 \ryas a major independent covariate of the weights of
retroperitoneal and dorsal fat in pregnant animals. In nonpregnant guinea pigs IGFBP-3 was a
major independent predictor of retroperitoneal fat and soleus muscle weight. These strong
positive correlations suggest IGFBP-3 may deliver IGFs to these tissues. However some
IGFBP-3 actions are known to be independent of either IGF-I or IGF-tr (Baxter,
2000;Wetterau et al., 1999).
3.4.8 Nutritional regulation of endocrine IGF axis in pregnant and nonpregnant
gurnea plgs
In ad libitum fed animals the plasma concentration of IGF-I was a major independent
covariate of total body weight, weight gain and uterine weight. Correlation between thymus
weight and the concentration of IGF-I in ad libitumfed animals was strong and negative with
IGF-tr, IGFBP-3 and IGFBP-4 as minor independent covariates. Soleus muscle weight
correlated positively with the concentration of IGF-I and negatively with the concentration of
IGFBP-1 in ad libitumfed guinea pigs. The positive association of soleus muscle weight with
IGF-I and negative association with IGFBP-1 suggest they may interact to maintain
homeostatic balance between synthesis and degradation of protein in muscle (Oddy and
Owens, 1996).
In feed restricted animals the plasma concentration of IGFBP-I, IGFBP-2, IGFBP-3 and
IGFBP-4 were found to be weak independent positive covariates of tissue and organ weights,
except for thymus weight where the relationship was negative (Table 3.18, 3.20). The
concentration of IGF-tr and IGFBP-I were equal positive independent covariates of net body
weight. The concentration of IGF-I was a weak independent covariate of liver weight in
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underfed animals. These associations may indicate that all IGFBPs may act to increase the
bioavailability of limited circulating IGF-I and tr to target tissues promoting their growth.
In nutritionally restricted dams the concentrations of IGF-I and IGF-tr in blood were found to
be major independent covariates of number of fetuses per dam and total placental weight
respectively (Table 3.27).
Nutritional restriction decreases plasma IGF-I, which may limit the number of fetuses
supported in pregnancy. IGF-tr has been suggested to have an important role in determining
placental size by promoting trophoblast invasion into maternal decidua (Hamilton et al.,
1ee8).
3.4.9 Potential function of circulating complexes between IGFs and IGFBPs
In pregnant guinea pigs undernutrition increased plasma concentrations of IGFBP-I and -2
and decreased those of IGFBP-3, IGF-I and IGF-tr, suggesting that changes in the
concentrations of IGFBPs and IGFs may contribute significantly to both fetal and placental
growth (Sohlstrom et al., 1998) because the bioavailability of IGFs is dependent on plasma
concentrations of IGFBPs and IGFs.
The ratios of the concentrations of IGF-I and IGF-tr to that of IGFBP-1, -2, -3 and -4 in
plasma are indicators of potential amounts of circulating complexes in blood. The theoretical
interpretation of the relationships between tissue weights and the ratios of the concentrations
of IGFs to IGFBPs are as depicted in Figure 3.I4. Arelatively high ratio of the concentrations
of IGF-I or IGF-tr to those of a particular binding protein, indicate that a relatively large
amount of the IGF is not complexed to that particular binding protein. A positive relationship
between tissue weight and the ratio of plasma IGF to IGFBP concentrations therefore means
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that particular binding protein inhibits growth promoting endocrine actions of IGF (-1 or -tr)








Figure 3.14 Theoretical model showing the two possible relationships between the ratio of the concentration of
IGFs to IGFBPs and tissue weights. A positive relationship indicates IGFBP restricts IGF actions on tissue
growth. While a negative relationship indicates tissue growth is greatest when IGF is complexed with IGF
binding proteins.
A negative relationship between weight of a tissue and the ratio of the concentrations of IGF
(-I or -tr) to those of a particular binding protein means that tissue growth is greatest when
there is a high percentage of these particular IGF/IGFBP complexes. This suggests that
complexes between IGF (-I or -tr) and this particular binding protein promote growth of this
particular tissue.
All potential measures of circulating complexes of IGF-I or IGF-tr to IGFBP-1 , -2, -3 and -4
were investigated by forward stepwise regression. In pregnancy almost all the significant
correlations between tissue weights and ratio of concentrations of IGFs to IGFBPs in plasma
involve either IGFBP-I (n = 8) or IGFBP-2 (n=11) as major independent covariates. In








measures of potential IGF to IGFBP complexes involve the ratio of concentration of IGF-tr to
IGFBP-2 (n = 11) as a major covariate.
Fifty to eighty percent of the variation in weights of tissues and organs in nonpregnant guinea
pigs was determined independently by the ratio of the concentration of IIGF-tr] to [IGFBP-2]
in plasma. IGF-tr was a more dominant factor than IGF-I in covariate analyses of IGF
endocrine determinants of weights of tissues and organs in nonpregnant animals suggesting
that IGF-tr may have a gteater endocrine role than IGF-I in nonpregnant guinea pigs.
Treatment of normal nonpregnant rats with IGF-tr (650 t"tg/dÐ increased gut weight, kidneys,
spleen, stomach and small intestine (Conlon et al.,I995a). However in guinea pigs
administration of IGF-tr (360 pglday) over 7 days failed to increase any tissue weights,
although plasma IGF-tr was significantly increased (Conlon et al.,1995b). In contrast ad
libitum fed pregnant guinea pigs treated with IGF-tr (565 pg/day) had higher interscapular fat
weight as a7o of body weight as well as greater fetal and placental weights (Sohlstrom et al.,
2001). Undernourished pregnant guinea pigs similarly treated with IGF-tr had higher spleen
weight only. In general administration of IGF-tr to either pregnant or nonpregnant guinea pigs
had little effect on adult tissue growth, although in pregnancy growth of both the placenta and
fetus was observed. Simultaneous infusion of IGF-I (15 ¡rglkg.hr) and IGF-tr (50 ¡rglkg.hr)
into 4 month old lambs prevented the decrease in net protein catabolism seen with IGF-I (15
¡rglkg.hr) only (Koea et al., 1992). It has been proposed that IGF-tr may modulate IGF-I
anabolic effects either by inhibition at the receptor site or by downregulation of the type I IGF
receptor (Rosenthal et a1.,1991). Also, unlike endogenous endocrine IGF production,
administration of IGF-I (or IGF-tr) reduces circulating levels of insulin and IGF-tr (or IGF-I).
Furthermore, IGF administration alters amounts of IGFBPs in blood in ways that are different
from those produced by environmental regulation of endogenous production of IGFs.
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The ratios of the concentrations of IGF-I to those of either IGFBP-I (IIGF-II/[IGFBP-1]) or -2
are better independent correlates than the ratios of the concentrations of IGF-tr to those of any
IGFBP for all tissue and organ weights measured in pregnancy (Table 3.2I,3.22,3.28). This
suggests that in general, IGF-I promotes growth of maternal organs in pregnancy and that
IGFBP-I and -2 inhibit this action. The only exception is that the ratio of plasma IGF-tr to
IGFBP-3 concentrations was the strongest correlate of net maternal weight gain during
pregnancy. Net weight gain during pregnancy was negatively correlated with [IGF-
trl/[IGFBP-3]. The IIGF-tr1/UGFBP-11 was a minor independent covariate of net weight gain
during pregnancy (Table 3.2I).
The negative relationship between net weight gain and the ratio of plasma IIGF-tr] to IIGFBP-
3l raise the possibility that IGF-tr actions on maternal weight gain in pregnancy are dependent
on formation of complexes with IGFBP-3. The positive association between net weight gain
and the rario of the [IGF-tr] to IIGFBP-I] suggests IGFBP-I inhibits these anabolic actions of
IGF-tr.
The above correlations between the ratio of [IGF-I] to either [IGFBP-l], l-21and tissue
weights in pregnancy are all positive except for the ratio of the [IGF-I] to [IGFBP-2] and
weight of total gastrointestinal tract. This negative relationship between the ratio of the [IGF-
Il to [IGFBP-2] and total weight of gastrointestinal tract may suggest that IGFBP-2 may
preferentially deliver IGF-I to this organ possibly regulating the gut immune system to protect
the mother from infection across the gut (Clark, 1997).
The ratio of [IGF-I] to [IGFBP-2] in plasma was an independent positive covariate of
pregnant body weight, total weight gain during pregnancy, the weights of retroperitoneal fat,
uterus, average and total fetal weight and average and total placental weight. The ratio of
tIGF-Il to [IGFBP-I] was a positive correlate of pregnant net body weight at the end of
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pregnancy and the weight of dorsal fat, spleen, soleus muscle, thymus and liver, as well as the
average fetal to placental weight ratio (Table3.21,3.22,3.28). This suggests endocrine IGF-I
promotes growth of these tissues in pregnancy and that IGFBP-2 and IGFBP-I inhibit these
actions.
For example, dorsal fat weight in pregnancy was positively correlated with the ratio of [IGF-I]
to [IGFBP-I]. This may indicate that the lipolytic effects of IGF-I are inhibited by IGFBP-I.
Different fat depots are metabolically different and are differentially regulated (Wajchenberg,
2000). Visceral fat has higher lipolytic activity than subcutaneous fat and thus mobilises fatty
acids more quickly (Wajchenberg, 2000). Visceral fat is highly sensitive to catecholamines
and poorly sensitive to insulin's antilipolytic effect, whereas in subcutaneous fat the opposite
is observed. There are more p-adrenoreceptors and fewer insulin receptors in visceral fat than
in subcutaneous fat. High concentrations of IGFs can be antilipolytic when acting via the
insulin receptor or lipolytic at low concentrations acting via the type I IGF receptor (Zapf,
1999). Undernutrition decreased the size of retroperitoneal and dorsal fat depots but
pregnancy attenuated this effect in dorsal fat, suggesting that pregnancy may change the
metabolic regulation of specific fat depots.
In pregnancy a strong positive association between soleus muscle weight and the ratio of the
tIGF-Il to [IGFBP-1] in plasma was found, but this was not observed in nonpregnant animals.
Thus, in pregnancy, the ratio of concentration of IGF-I to IGFBP-1 in plasma may potentially
regulate muscle protein metabolism. IGFBP-1 inhibits IGF-I stimulated protein synthesis and
glucose uptake in human skeletal muscle cells (Frost and Lang, 1999). IGFBP-1 also acts
independently of IGFs by binding to B1 integrin in human skeletal muscle cells inhibiting
protein degradation (Frost and Lang, 1999). This mechanism may be important in partially
controlling partitioning of nutrients between maternal tissues and the conceptus.
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Correlations between maternal tissue weights and ratios of [IGF-I] or [IGF-tr] to [IGFBP-3] in
pregnancy were much less frequently observed than those involving [IGFBP-1] or [IGFBP-2].
They are also generally weak and negative.
Analysis of the dependence of fetal and placental tissue weights on the ratio of concentrations
of IGF to IGFBP identified the ratio of [IGF-I] to [IGFBP-2] as a major independent covariate
and the ratio of tIGF-tr1 to [IGFBP-2] as aminor independent covariate (Table 3.28). These
relationships suggest that the ratio of the concentrations of IGF-I to IGFBP-2 in maternal
plasma may have an important role in fetal and placental growth. The exceptions to this were
average fetal to placental weight ratio where tIGF-Il to [IGFBP-I] was a minor independent
covariate and average placental weight where the [IGF-I] to [IGFBP-3] was a minor
independent covariate. The strong positive dependence of fetal and placental weights on the
ratio of UGF-II to [IGFBP-2] in maternal plasma suggests the pregnant uterus, fetus and
placenta are target tissues for IGF-I, while IGFBP-2 inhibits this action. The ratio of [IGF-I]
to [IGFBP-1] was a major independent covariate of number of fetuses per dam and total fetal
and placental weight in feed restricted animals. None of these correlations contained plasma
IGF-tr suggesting endocrine IGF-tr does not contribute to fetal and placental growth late in
gestation.
In ad libitumfedpregnant animals the ratio of IIGF-tr] to [IGFBP-4] in plasma was a major
independent covariate of number of fetuses per dam and total fetal weight. The ratio of [IGF-
Il to [IGFBP-3] in ad libitum fed pregnant and nonpregnant animals is a major independent
covariate of body weight, weight gain, uterine weight, thymus weight while [IGF-I] to
TIGFBP-l1 was a major independent covariate of soleus muscle weight (Table 3.23,3'24).
Administration of an equimolar mixture of IGF-I and IGFBP-3 (5 þglg of body weight) is
reported to be more effective in increasing muscle protein synthesis in chronically semi-
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starved rats than IGF-I alone (Svanberg et al., 2000). Improved bioavailability of IGF-I was
also claimed when a combination of IGF-I and IGFBP-3 was administered to
hypophysectomized rats (Adams et al., 1995;Zapf et al., 1995). Affinity between IGF-I to
IGFBP-3 is reduced when the complex becomes cell surface-associated thereby increasing the
release of IGF-I for binding to the type-I IGF receptor or insulin receptor for pericellular
localisation or for trans-pericellular transport (Wetterau et a1.,1999). However the formation
of the complex between IGF-I and IGFBP-3 inhibited cell surface binding of IGFBP-3 to
Hs578T human breast cancer cells (Oh et al., 1993). These studies highlight the diverse
functional role of IGFBP-3 to either promote or inhibit the bioactivity of IGFs and
independent actions of IGFBP-3 mediated by cell surface proteins or an unidentified IGFBP-3
receptor.
In ad libitum fed guinea pigs most of the variation in organ and tissue weights can be
accounted for by the combination of two or three independent covariates. The combination of
the ratio of [IGF-I] to [IGFBP-3] and [IGF-tr] to [IGFBP-3] plasma concentrations as
independent covariates accounts for 737o of the variation in body weight, 807o of the variation
in weight gain and 89Vo of the variation in total uterine weight in ad libitum fed guinea pigs
(Table 3.23,3.24).
In feed restricted animals almost all endocrine IGF/IGFBP concentration ratios examined as
covariates of tissue and organ weights identified the ratio of [IGF-tr] to either [IGFBP-l], [-2]
or [-3]. These relationships are weak except for that between [IGF-tr] to [IGFBP-I] and
weight gain, which is strong (Table 3.23,3.24). In underfed guinea pigs 73 7o of the variation
in total uterine weight is accounted for equally by the combination of the independent
covariates ratio of tIGF-tr1 to [IGFBP-Z],ntio of IIGF-tr] to [IGFBP-I] and ratio of [IGF-I] to
IIGFBP-31 in plasma (Table 3.24).
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Plasma IGF-tr was identified as an independent covariate of placental weight in feed restricted
pregnant animals (Table 3.27). As the above relationships between uterine weight and the
ratio of the [IGF-tr] to either UGFBP-11 or [IGFBP-2]in plasma are negative, this suggests
that high levels of IGFBP-I and-2, relative to IGF-tr, are delivering IGF-tr to the placenta to
promote its growth. The positive correlation between uterine weight and the ratio of [IGF-I]
to [IGFBP-3] in feed restricted animals suggest IGFBP-3 inhibits the access of IGF-I to
uterine tissues at this level of nutrition.
The combination of the ratio of tIGF-Il to [IGFBP-l],1-21and [-3] can accountfor 897o of the
variation in soleus muscle weight in ad libitumfed animals (Table 3.24). The ratio of [IGF-I]
to either TIGFBP-31 or [IGFBP-4] in combination with the ratio of IIGF-tr] to UGFBP-21in ad
Iibitum fed animals can account for 93Vo of the variation in thymus weight.
3.4.10 Delivery and actions of endocrine IGFs in pregnancy
IGFBP-3 and IGFBP-Zhave a characteristic heparin binding site which could localise
associated IGF-I or -II to cells. IGFBP-2 when complexed to.either IGF-I or IGF-tr has been
suggested to undergo a conformational change exposing a glycosaminoglycan-binding domain
that can then bind proteoglycans on the cell surface or within the extra-cellular matrix (Arai et
a1.,1996). Cultured porcine aortic smooth muscle cells secrete a serine protease for IGFBP-2.
Coincubation of IGFBP-2 and either IGF-I or IGF-tr with media conditioned by porcine aortic
smooth muscle cells increased the proteolytic degradation of IGFBP-2 (Gockerman and
Clemmons, 1995). Proteolytic activity was more effective when IGFBP-2 was coincubated
with IGF-tr. In pregnancy IGFBP-2, -3 and -4 arc also proteolytrcally modified. The RGD
binding motif in IGFBP-2 may bind to integrin øsÊr (Rauschnabel et a1., 1999). IGFBP-2
interaction with this integrin may stimulate secretion of tissue specific proteases ultimately
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affecting the affinity of IGFBP-2 for IGFs. This mechanism may be a means of releasing IGF-
I from IGFBPs after delivery to tissue making it available to receptors. Epithelial basement
membranes such as those present in trophoblasts cells in the placenta are rich in heparan
sulfate proteoglycans which can readily concentrate IGFBP-2 and associated IGF-I and -tr to
these sites (Kreis, 1993).
Delivery of IGF-I to the fetal-maternal interface may have different functions at different
stages of pregnancy. Early in pregnancy interactions between IGF-I, IGFBP-I and/or IGFBP-
2, integin and extra-cellular matrix appear to be involved with cytotrophoblast proliferation
and migration (Gibson et al., 2001).
Later in pregnancy when fetal growth places a significant demand on maternal energy
resources, IGF-I, IGFBP-1 and IGFBP-2 may act together or independently, increasing
maternal supply of glucose and amino acids and/or by altering placental metabolism to
provide these substrates for the fetus. Infusion of IGF-I into pregnant sheep at 129-133 days
gestation increased placental production and fetal uptake of lactate, while decreasing blood
amino nitrogen in both mother and fetus (Liu et a1.,1994). Maternal endocrine IGF-I has
been suggested to increase carbohydrate availability and affect amino acid metabolism,
although increased uptake by the fetus or placenta of those substrates remains to be
determined (Harding et al., 1994). Increased circulating levels of IGF-I in pregnancy has also
been suggested to regulate glucose transporters GLUT 1 and GLUT 3, which have been
identified in the placenta. GLUT 1 is located on the microvillous and basal membrane of the
human syncytiotrophoblast whereas GLUT 3 is localized in the vascular epithelium of the
placenta and is proposed to be a scavenger removing glucose from blood already partially
depleted by GLUT 1 (Illsley, 2000). IGF-I, IGF-tr and insulin have been shown to increase 2-
deoxyglucose uptake (Kniss et al., 1994) suggesting a mechanism of increasing glucose
transport to the placenta and fetus.
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3.5 ST]MMARY
This study has shown that hepatic IGF-I mRNA is the major source of endocrine IGF-I in
pregnancy in guinea pigs. The relationship between hepatic IGF-I mRNA and circulating
levels of IGF-I is altered by pregnancy. The abundance of IGF-I mRNA is increased 6 fold
and plasma IGF-I is increased 3 fold by pregnancy in ad libitum fed guinea pigs. This
strongly suggests that pregnancy also increases clearance of IGF-I from blood or alters RNA
processing.
The concentrations of IGF-I and./or IGFBP-3 in plasma were major independent covariates of
maternal tissue and organ weights including those of the placenta and fetus. This is consistent
with the suggestion that endocrine IGF-I has anabolic effects on both maternal and conceptus
tissues as well as facilitating the supply of nutrients and substrates required by the growing
placenta and fetus and that IGFBP-3 inhibits these actions. IGF-I is the dominant endocrine
IGF in pregnancy in the guinea pig while IGF-tr is the dominant endocrine IGF in
nonpregnant guinea pigs.
The ratio of the [IGFs] to IIGFBPs] in plasma suggested that in pregnant guinea pigs
complexes between IGF-I and either IGFBP-2 or IGFBP-1 were major independent
determinants of maternal tissue and organ weights while almost all fetal and placental weights
were predicted by the ratio of [IGF-I] to [IGFBP-2] in plasma.
These studies suggest that IGFBPs transport and deliver IGF-I to specific target tissues and
regulation of both IGF-I and the IGFBPs are important in maternal adaptation for support of
the developing conceptus. Because IGF-I regulates IGFBP synthesis and degradation, the
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4.1 Effect of pregnancy on IGF-I production
In the present study the relative abundance of IGF-I mRNA in liver was found to be greater
than that in parametrial fat, interscapular fat and retroperitoneal fat of guinea pigs. Previous
studies (Gosiewska et al., 1994) also found that IGF-I mRNA was expressed more abundantly
in liver than bone and cartilage in guinea pigs. In rats IGF-I mRNA is most abundant in liver
(Hoyt et al., 1988) whereas in pigs, adipose tissue has the greatest abundance of GH-
dependent IGF-I mRNA (Coleman et al., 1994). Liver appears to be the major source of IGF-
I in the guinea pig (section 2.3.2).
Specific assays for the measurement of guinea pig IGF-I mRNA and the reference gene
guinea pig B-actin were developed and validated for the present study and used to determine
the effects of pregnancy and nutrition on hepatic expression of IGF-I. Pregnancy increased
the relative abundance of hepatic IGF-I mRNA in ad libitumfed guinea pigs. Undernutrition
abolished this effect. Most of the variation in the concentration of IGF-I in blood of guinea
pigs could be explained by variation in the relative abundance of IGF-I mRNA in liver. This
strongly indicates that liver is the primary source of endocrine IGF-I in guinea pigs.
4.2 Regulation of hepatic IGF-I production in pregnancy
Hepatic IGF-I expression in pregnancy is proposed to be regulated by placental hormones
such as placental growth hormone and placental lactogen (Caufnez et al., 1990). These
polypeptides are structurally similar to pituitary growth hormone, which positively regulates
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IGF-I gene expression in well fed nonpregnant adolescent and adult mammals. However
nonpregnant guinea pigs continue to grow after hypophysectomy suggesting IGF-I may not be
pituitary GH dependent in this species although this remains to be proven directly by
treatment with guinea pig GH (Gabrielsson et al., 1990). Keightley et al (1996) suggested
that the failure of IGF-I to increase in hypophysectomized guinea pigs after treatment with
bovine GH or human GH may be related to lack of guinea pig GH receptor recognition by the
heterologous hormones used, the impurity of the growth hormone preparations used, the dose
and time of administration and/or the age at which GH was given. In the pregnant guinea pig
placental growth hormone may be synthesised by the placenta and bind to liver GH receptors
to promote IGF-I synthesis. Treatment of guinea pigs with homologous placental lactogen
has not been reported.
In nonpregnant guinea pigs all correlations between tissue weights and concentrations of
molecular components of the IGF endocrine system contained UGF-III alone or as a major
component. None of these correlations in nonpregnant guinea pigs contained IGF-I.
Therefore somatic growth of the nonpregnant guinea pig appears to be dominated by IGF-II
while pregnancy changes this to IGF-I. This finding is unique as in other species the main
endocrine IGF covariate of somatic growth is IGF-L
4.3 Source of endocrine IGF-I in pregnant guinea pigs
The concentration of IGF-I protein in blood plasma was found to be strongly positively
correlated with the relative abundance of IGF-I mRNA in liver in the guinea pig. Sixty-eight
percent of the variation in plasma IGF-I concentration can be accounted for by the variation in
relative abundance of hepatic IGF-I mRNA. Liver therefore appears to be the major source of
endocrine IGF-I in guinea pigs. Variation in hepatic abundance of IGF-I mRNA was not
associated with variation in plasma IGF-I at concentrations higher than -850 nglml. Viewed
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another way, pregnancy increases the abundance of hepatic IGF-I mRNA by 6 fold but
increased plasma IGF-I by only 3 fold. This could be explained if the rate of clearance of
IGF-I from the circulation in guinea pigs was doubled by pregnancy. Pregnancy has been
shown to increase IGF-I clearance in rats (Bastian et al., 1993).
4.4 Potential actions of liver derived endocrine IGF'I in pregnancy
The relative abundance IGF-I mRNA in liver and the concentration of IGF-I in plasma were
positively correlated with net body weight, net weight gain, and the weights of retroperitoneal
fat, dorsal fat, spleen, thymus, uterus, total fetuses and placentae. Covariate analysis
identified maternal plasma IGF-I concentrations as independent covariates of total maternal
body weight and weights of liver, uterus, total fetuses and placentae. This indicates that
endocrine IGF-I of hepatic origin in pregnancy may have anabolic actions on uterus, fetus and
placenta as well as selective tissues in the mother. This view is partly supported by a recent
study in which IGF-I treatment of ad libitum fed guinea pigs from day 20 to 37 of pregnancy
increased fetal and placental weights but not weights of maternal tissues by day 40 of
pregnancy lSohlstrom, 2O0l #17 2
In nonpregnant guinea pigs the abundance of IGF-I mRNA in liver was positively correlated
to liver weight only while plasma IGF-I concentration was not related to weight of any tissue
suggesting somatic growth of nonpregnant guinea pigs is not dependcnt on endocrine IGF-I.
This is supported by a previous study in which treatment of nonpregnant guinea pigs with
IGF-I increased adrenal weight but not that of other tissues (Conlon et a\.,1995).
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4.5 The effect of pregnancy on the endocrine IGF system in guinea pigs
The concentrations of IGF-I and IGF-II in plasma were positively correlated with almost the
same tissue and organ weights in pregnancy except for liver weight as a 7o of body weight
and uterine weight as a 7o of carcass weight, which were positively correlated to IGF-I only.
Covariate analysis showed that plasma IGF-I in pregnancy was a determinant of maternal
body weight, maternal weight gain during pregnancy, liver weight, pregnant uterine weight,
fetal weight and placental weight. In nonpregnant animals however, IGF-II and not IGF-I
was the major determinant of weights of tissues and organs. Pregnancy appears to change the
dependence of somatic and organ growth from endocrine IGF-II to IGF-I in the guinea pig'
This may also partly explain the lack of growth response of guinea pigs to hypophysectomy,
since IGF-II is not directly GH-dependent.
4.6 Role of circulating IGFBP-3 in pregnancy
The concentrations of IGFBP-3 in plasma were unaltered by pregnancy in guinea pigs as
detected by western ligand blotting and pregnancy associated IGFBP-3 proteases were not
evident in plasma in this species. Plasma IGFBP-3 concentration was positively correlated
with the relative abundance of hepatic IGF-I mRNA and the concentrations of IGF-I protein
in plasma. Therefore it is possible that hepatic IGFBP-3 expression may be regulated by IGF-
I as in other species liver is a major source of endocrine IGFBP-3 (Clemmons, 1991). The
concentrations of plasma IGF-I and IGFBP-3 in day 60 pregnant guinea pigs were positively
related to total fetal weight, total placental weight and the avera1e weights of fetuses and
placentae, suggesting IGFBP-3 might potentially enhance the actions of IGF-I on the placenta
and /or fetus. In recent studies, the concentrations of IGF-I and IGFBP-3 in blood of pregnant
guinea pigs were found to be positively correlated with placental vascularity, structural
maturation and syncytiotrophoblast surface area and thickness (Roberts, 2002). Since
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treatment of pregnant guinea pigs with IGF-I increases placental weight (Sohlstrom et al.,
2O0I), cell surface-associated binding of IGFBP-3 may potentiate endocrine IGF-I action by
facilitating the delivery of IGF-I to placental type I IGF receptors (Firth et aI.,1998;'Wetterau
et al., 1999).
The concentration of IGFBP-3 in blood plasma in pregnancy was identified as an independent
covariate of net body weight, weight gain and the weights of carcass, retroperitoneal fat,
dorsal fat, spleen and thymus suggesting IGFBP-3 may have actions independent of those of
IGF-I mediated by adherence of IGFBP-3 to cell surface proteins and./or an unidentified
IGFBP-3 receptor (Figure 4.1). The correlations between weights of these tissues and
TIGFBP-3] alone was much stronger than the corresponding correlations with the ratio of
tIGF-Il to [IGFBP-3]. All associations between maternal tissue weights and the ratio of [IGF-
Il or [IGF-II] to [IGFBP-3] were very minor and negative. The associations between
maternal tissue weights and [IGFBP-3] was equally as strong as that seen with [IGF-I]. In
this study a comparison between the concentrations in blood of the independent components
of the IGF endocrine system as well as the ratio of the concentrations of IGFs to IGFBPs were
evaluated as covariates of the weights of maternal organs. This comparison suggested that
growth of retroperitoneal fat, spleen, net body weight, maternal weight gain and carcass
weight are determined principally by the concentration of IGFBP-3 in plasma. For some
maternal tissues the concentrations of two or more components of the IGF endocrine system
were independent covariates which when combincd accounted for a greater amount of
variation of tissue weights. For example the weight of the spleen is best explained by
combination of independent contributions of the concentration of IGFBP-3 and that of IGF-II
in plasma.
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4.7 fmportance of IGFs associated with IGFBPs in the circulation
In this study the ratio of the concentration of IGF-I or IGF-II to that of IGFBP-I , -2,'3 or -4 in
plasma were calculated as indicators of the concentrations of binary molecular complexes in
blood. In pregnant animals the ratio of [IGF-I] to [GFBP-2] in plasma was identified as the
major independent covariate of maternal body weight, weight gain and weights of carcass,
uterine, retroperitoneal fat, gastrointestinal tract, fetuses and placentae. These associations
are stronger than those with IGFBP-2 alone and are equally as strong as those with IGF-I
alone. This suggests that any actions of IGFBP-2 on these tissues are IGF-I dependent (Figure
4,1).
Weights of other maternal tissues are determined by the ratio of [IGF-I] to [IGFBP-I] in
plasma including net body weight, dorsal fat weight, spleen weight, soleus muscle weight,
thymus weight, liver weight and average ratio of fetal weight to placental weight. These
conelations between the ratio of [GF-I] to [IGFBP-U with maternal tissue weights are much
stronger than those observed with fGFBP-1 alone and are equally as strong as those for IGF-I
alone suggesting any actions of IGFBP-I on those tissues are also IGF-I dependent.




































Figure 4.l Proposed IGFBP-I and IGFBP-2IGF dependent and IGFBP-3
independent actions in pregnancy
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In the present study the ratio of [IGF-I] to [IGFBP-2] is in plasma a better independent
covariate of pregnant uterus weight, total fetal weight and total placental weight at day 60
than that seen with TIGFBP-21 alone. tIGF-Il alone is a better independent correlate of total
fetal weight than the ratio of [IGF-I] to [IGFBP-2] or the combination of the ratio of [IGF-I]
to [IGFBP-2] andthat of IIGF-III to [IGFBP-2]. [IGF-I] alone and the combination of the
ratios of the concentration of [IGF-I] to [IGFBP -2] and UGF-III to [IGFBP -2] are similar
independent covariates of total placental weight.
The positive relationship between the ratio [IGF-I] to [IGFBP-2) and pregnant uterine weight,
total fetal weight and total placental weight suggests IGFBP-2 may inhibit endocrine growth
promoting effects of IGF-I on the conceptus in late pregnancy. The increase in IGFBP-2 in
feed restricted pregnant guinea pigs may prevent IGF-I from interacting with type I IGF
receptor and"/or the insulin receptor at the maternal fetal interface. Type I IGF receptors have
been identified in the second and third trimester of human pregnancy in the chorionic villi,
chorionic plate, basal plate and fetal membranes (Han et al., 1996). Location of the type I
IGF receptors have not been reported in the guinea pig placenta as yet.
Alternatively an increase in the ratio of [IGF-I] to [IGFBP-2] inpregnant guinea pigs, an
indicator of the concentration of this binary complex, may reflect a potential increase in this
circulating reservoir of endocrine IGF-I. Studies have demonstrated that binding of IGF-I to
IGFBP-2 facilitates proteolysis of IGFBP-2 by exposing a proteolytic cleavage site
(Gockerman and Clemmons, 1995), potentially increasing the availability of IGF-I to tissue
receptors. Binding of IGF-II to IGFBP-2 also increases proteolysis of IGFBP-2.
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4.8 Nutrition and circulating IGFBP-I in pregnancy
In this study the ratio of the concentration of IGF-I to IGFBP-1 in the maternal circulation is
an independent covariate of the weights of dorsal fat, spleen, thymus, soleus muscle, liver and
net maternal body weight and these associations are stronger than that of IGFBP-I alone. In
contrast in feed restricted mothers the ratio of [IGF-II] to either IIGFBP-I] or [IGFBP-2] ate
associated with weights of maternal tissues and none of these associations contain IGF-I as a
covariate. The positive associations seen for the weights of these tissues suggest IGFBP-1
and/or IGFBP-2 inhibits growth promoting actions of IGF-I or -II on these maternal tissues
depending on nutritional status.
IGFBP-1 has been suggested to have a potential role at the maternal-fetal interface regulating
placental and fetal growth (Gibson et al., 2001). This is a complex interaction where IGFBP-
1 either inhibits the bioavailability of IGF-I or IGF-II or conversely increases the potency of
the growth factor by facilitated interaction with type I IGF receptor and/or type II IGF
receptor by IGFBP-I interactions with cr5Bl integrin. In this study in feed restricted animals
the ratio of [IGF-I] to [IGFBP-I] in plasma was found to be a positive covariate of the
number of fetuses per dam, total fetal weight and total placental weight. This therefore
suggests that IGFBP-I in the undernourished guineaptg at day 60 of pregnancy may inhibit
growth promoting properties of endocrine IGF-I on dorsal fat, soleus muscle, fetuses and
placentae. A proposed inhibitory action of IGFBP-1 on fetal and placental tissues in pregnant
guinea pigs is supported by observations in human pregnancy where maternal plasma IGFBP-
1 levels are negatively related to birth weight (Iwashita et al., 1992), placental weight and
maternal weight (Hills et al., 1996). Also, intrauterine growth retardation is associated with
increased maternal and fetal plasma concentrations of IGFBP-1 in humans (Hills et al., 1996)
and mothers of small for gestational age babies have higher plasma levels of IGFBP-1 than
those with average for gestational age babies. Furthermore maternal IGFBP-I are 5-fo1d
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higher and plasma IGF-I is 2-fold lower in preeclamptic subjects with growth retarded fetuses
(Giudice et al., 1997).
4.9 Summary of independent covariates of tissue weights
Individual components of the IGF endocrine system were identified as major positive
correlates of pregnant tissue weights (Table 4.1). Plasma concentration of IGF-I was
positively correlated with weights of fetuses, placentae and some maternal tissues while the
concentration of IGFBP-3 was positively correlated with another group of tissues, which are
different from those whose weights are related to endocrine IGF-I concentration. Soleus
muscle was the only tissue whose weight was positively correlated with endocrine IGF-II
concentration. The ratio of the concentration of IGF-I to that of IGFBP-2 was a positive
correlate of weights of several maternal tissues. This suggests that complexes formed
between IGF-I and IGFBP -2 may have different biological roles at different tissue sites. The
ratio [IGF-I]/[IGFBP-11 was also correlated with weights of certain tissues in pregnancy but
these are different tissues from those whose weights are correlated with [IGF-I]/[IGFBP-2].
For example, weight of retroperitoneal fat is positively correlated with [IGF-I]/[IGFBP-2]
whereas, weight of dorsal fat is positively correlated with [IGF-I]/[IGFBP-1]. These results
suggest that different fat sites are differentially regulated in pregnancy and this is IGFBP
dependent. Alternatively pregnancy may alter the expression of different IGFBPs in different
tissues. All of the IGF endocrine concentration ratios that correlate with weights of tissues in
pregnancy contain the concentration of IGF-I while none contain that of IGF-II. When
comparing the concentration of individual components of the IGF system to those of the ratios
of [IGFs]/IIGFBPs] that were identified as independent covariates of tissue weights many of
the correlations are IGF-I dependent although some coffelations have suggested IGFBP-3 has
independent actions on some maternal tissues. This suggests there may be actions of IGFBP-
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3 mediated through putative IGFBP-3 receptors, or by IGFBP-3 cell surface-association,
which may potentiate the actions of endocrine IGF-I.
Table 4.1 Covariates of tissue weights in pregnant guinea pigs.





















the IGF system as
independent covariates
In nonpregnant guinea pigs plasma IGF-II concentrationwas identified as an individual
corelate of almost all tissues studied (Table 4.2). The concentration of IGFBP-3 was
identified as an independent correlate of weights of retroperitoneal fat and soleus muscle in
nonpregnant guinea pigs and these tissues are different from those whose weights in pregnant
animals are related to concentration of endocrine IGFBP-3. In contrast to the correlations
with tissue weights seen in the pregnant guinea pig all ratios contained [IGF-II] and none
contained tIGF-Il in the nonpregnant animal. In nonpregnant guinea pigs the ratio of [IGF-
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III/[IGFBP-2] was a positive correlate of the majority of tissues studied. When comparing the
individual IGF pndocrine component concentrations with those of the ratio of
IIGFsU[IGFBPsI that were identified as independent covariates, IGFBP-3 may have
independent actions on both retroperitoneal fat and soleus muscle. The actions of IGF-
II:IGFBP complexes on other tissues appear to be IGF-II dependent'
Table 4.2 Covariates of tissue weights in nonpregnant guinea pigs.
4.10 Future Directions
The studies in this thesis has established the liver as the major source of increased circulating
IGF-I in pregnancy in guinea pigs. Hepatic abundance of IGF-I mRNA was increased by
pregnancy in ad libitum fed animals. The quantitative relationship between relative
abundance of hepatic IGF-I mRNA and plasma concentrations of IGF-I is positive although
not linear. Future studies need to identify the mechanism by which pregnancy increases
expression of IGF-I in liver, and identify specific IGF-I mRNA transcripts that are primarily
















The ratio of [IGFs]/[IGFBPS]
as independent covariates
Individual components of
the IGF system as
covariates
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In this study many of the associations between plasma IGF-I concentration with maternal,
fetal and placental tissue weights and organ weights in pregnancy are strong and positive
suggesting a major role for endocrine IGF-I in promoting growth. The concentration of IGFs
in pregnancy and relationships with specific tissue weights suggest IGF-I may be a dominant
growth factor and is important for maternal adaptation to pregnancy. Estimation of the
interactions between IGFs and IGFBPs suggests pregnancy alters the binary molecular
complexes and they are tissue specific in their actions. IGFBPs may deliver IGF-I to some
tissues and prevent their action on others. The development of diagnostic assays for the
measurement of circulating complexes between IGFs and IGFBP-I, IGFBP-2 and IGFBP-3
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